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ABSTRACT 
 
Clostridium difficile is a Gram positive pathogen of significant importance in the 
UK, Europe and the USA. No vaccine has been developed and current treatments are 
focused on hospital management and the use of antibiotics. The disease is spread in 
hospitals in the spore form and the role of spores in C. difficile infecton is poorly 
understood. In this project spores of C. difficile have been characterised. The proteins 
from the outermost layers of the spore were identified and the genes cloned. Three of 
these surface proteins have unique enzymatic properties that maybe important for 
symptoms of disease. The ability of C. difficile spores to adhere to intestinal cells 
was found to be far greater than with live cells and through this we have identified 
that the spore may play an important role in colonisation. The regulation of spore 
coat gene expression during sporulation was also examined and temporal phases of 
genes expression identified. A major part of this project was to develop a mucosal 
vaccine to C. difficile. The approach used was to clone the C-terminus of toxin A 
onto the surface of Bacillus subtilis spores and use these recombinant spores to 
immunise mice and hamsters. We found that oral delivery of these spores conferred 
75% protection to C. difficile infection in a hamster model of infection. Further, 
parenteral immunisation of the same antigens (toxin A and B) failed to generate 
mucosal responses and this showed that mucosal immunisation is critical for good 
protection. Finally, we found that antibodies to the C-terminus of toxin A were cross 
reactive to the C-terminus of toxin B. This showed that mucosal delivery of just the 
C-terminus of toxin A is sufficient to confer protection in an animal model of 
infection. The outcome of this work is that we have shown the parameters for 
successful immunisation and vaccination against C. difficile. 
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CHAPTER 1 
INTRODUCTION 
 
 
1.1 Clostridium difficile and its Impact as a Human Pathogen 
C. difficile is an example of a pathogen that until recently was considered of minor 
importance to public health. As a nosocomial pathogen morbidity and mortality rates 
fell far below those of other hospital-acquired diseases. With the advent of vaccines 
and antibiotics other diseases have been controlled and managed which, in turn, has 
exposed this organism as a growing problem in the UK, Europe and USA. 
 
C. difficile is a Gram-positive anaerobic bacterium  that is able to form spores. It is 
the most common cause of nosocomial diarrhoea (C. difficile-associated diarrhoea, 
CDAD) and can cause a condition known as pseudomembranous colitis. Between 
1990-2004 rates of C. difficile infection (CDI) increased significantly in the UK with 
the greatest changes in the elderly (age 60-64 years). Over 50,000 cases of CDI were 
reported in 2007, which included 20% in the younger age groups (<30 years) (see 
Figures 1.1 and 1.2). In 2007 alone 4,056 deaths were assigned to CDI (HPA, 2009). 
 
The increase in CDI has become a national as well as international issue and 
attention is now focusing on the cause. Two principle factors appear to be important; 
Chapter 1                                                                                                                                Introduction !!
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1. The appearance of hypervirulent strains of C. difficile that have increased 
toxin production referred to as hypervirulent strains (e.g. the 027 ribotype), 
and 
2. The failure to diagnose and control the transmission of spores of C. difficile 
in hospitals. 
The latter issue is particularly important and of a sensitive nature to national 
governments, especially the UK, where a potential link can be made between 
hospital cleanliness and transmission of disease. 
 
 
Figure 1.1 C. difficile infection rates in UK hospitals (modified from HPA, 2009). 
 
The current situation with CDI in the UK is that the disease is controlled primarily 
by antibiotic therapy, which is universally considered unsuitable in the long-term 
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because of the associated risks of the development of antibiotic drug resistance. No 
vaccine is currently available and diagnosis of CDI remains ineffective. 
Improvements in the incidence of CDI have been achieved but mostly from strict 
management regimes in hospitals (HPA, 2009). 
 
 
Figure 1.2 CDI cases in 2000-2007 by patient group (modified from HPA, 2009). 
CDI cases are reported in two age groups, 2-65 and 65+. Mandatory reporting of 
cases in over 65s was introduced in 2004, followed by mandatory reporting of all 
cases in 2007. Mandatory reporting of cases was introduced in 2004 as part of 
control measures to reduce C. difficile incidence. 
 
1.2 C. difficile Infection 
1.2.1 The disease 
Spores of C. difficile exist in the environment but also in the human and animal GI-
tract and most healthy adults are expected to carry C. difficile spores. The primary 
cause of CDI and its resulting illnesses (CDAD) result from antibiotic use and/or 
prolonged stays in hospitals (Kuipers & Surawicz, 2008). It is assumed that antibiotic 
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treatment disturbs the resident gut microbiota enabling spores of C. difficile to 
germinate, outgrow and proliferate. Illness nearly always results from the production 
of secreted toxins, toxin A and toxin B (Lyerly et al., 1988, Rupnik et al., 2009) 
(Figure 1.3). Patients will most probably become infected with C. difficile acquired 
from the hospital environment although resident strains may also account for primary 
infection. Whether a person then goes on to experience illness will depend on a 
number of factors, for example, if the host immune response is impaired illness is 
more likely. Another prerequisite is whether the C. difficile strain is a toxin 
producing strain since not all strains of C. difficile produce toxins. Transmission of 
C. difficile spores is also considered a growing problem and the emergence of 
hypervirulent strains of C. difficile that have increased levels of toxin production 
have been associated with recent outbreaks or epidemics in the USA, Canada, 
Europe and Japan (Kuijper et al., 2007, Hubert et al., 2007, Warny et al., 2005). 
 
CDAD can manifest itself in levels of severity ranging from mild diarrhoea to 
fulminant pseudomembranous colitis, sepsis, organ failure and potentially death. One 
of the major problems with CDAD is in diagnosis where early indicators such as 
fever and inflammation are confused with other illnesses. Ultimately, as the disease 
progresses severe colitis develops and at this point aggressive antibiotic therapy to 
prevent the most severe forms of the disease which can lead to toxic megacolon, 
perforation of the colon and progressive multi-organ failure leading to death. 
Mortality in CDAD patients is typically 3-30% mostly in the elderly (Kuijper et al., 
2007, Loo et al., 2005, HPA, 2009). 
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Figure 1.3 CDI in response to antibiotic. This figure shows the effects of 
antibiotics on the human microflora resident in the GI-tract. In the presence of 
antibiotics (b) the gut flora declines and C. difficile that is resistant to the antibiotic 
can proliferate. As soon as antibiotic treatment stops (c), the normal gut microflora 
recovers but there is a delay depending upon the antibiotic used. It is at this point (c) 
that there is a risk of CDI, whether by resistant or susceptible strains of C. difficile 
(modified from Rupnik et al, 2009).  
 
 
1.2.2 Recurrence 
Possibly one of the most serious aspects of CDI is that the illness can reappear, a 
condition known as relapse where the original infecting strain causes a second bout 
of illness, or re-infection, where a different strain is responsible for the illness. 
Recurrence can affect up to 30% of patients experiencing CDAD (Lyerly et al., 
1988, Williams & Spencer, 2009). Typically diarrhoea returns after 10-14 days but 
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this can be delayed by up to 1 month. What causes relapse is unclear but presumably 
the antibiotic treatment used to control CDAD may actually precipitate further 
rounds of germination and proliferation of C. difficile in the GI-tract, either of the 
original strain or alternatively, with a second, un-related strain of C. difficile acquired 
from the hospital environment. 
 
1.2.3 Virulence Factors 
Toxins 
C. difficile strains produce three toxins, two glucosyltransferase toxins referred to as 
toxin A (TcdA) and toxin B (TcdB) and a binary toxin known as CDT (Figure 1.4). 
The toxin A and B genes are contained within a 19.6 kb chromosomal pathogenicity 
locus (PaLoc) (Lyerly et al., 1988, Rupnik et al., 2009). PaLoc carries the two toxin 
genes, tcdA and tcdB, a putative holin (TcdE) and two regulators, TcdC (a negative 
regulator) and TcdR (activator/sigma factor). Both of which regulate toxin gene 
expression. In non-toxigenic (TcdA- TcdB-) strains of C. difficile the PaLoc sequence 
is replaced by an 115 bp  non-coding sequence. Both toxins are produced during the 
late log and stationary phases of growth (Hundsberger et al., 1997). 
 
Substantial evidence shows that the toxins A and B are the primary determinants of 
virulence and pathogenicity and produce the classical symptoms of CDI (diarrhoea 
and inflammation) (Thelestam & Chaves-Olarte, 2000, Jank et al., 2007). Most 
importantly, genetic inactivation of the tcdA and tcdB genes shows that in the 
absence of toxins A and B no symptoms of disease occur in a hamster model of 
infection (Kuehne et al., 2010). TcdA and TcdB are both cytotoxic and will disrupt 
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the actin cytoskeleton and tight junctions which lead to decreased transepithelial 
resistance, fluid accumulation and destruction of the intestinal epithelium (Thelestam 
& Chaves-Olarte, 2000, Riegler et al., 1995). A further consequence of the secretion 
of both toxins is that they cause the release of inflammatory cytokines from the 
intestinal epithelial cells, mast cells and macrophages. The consequence of these 
signalling molecules is an influx of inflammatory cells which further amplifies the 
inflammatory response (Figure 1.4). 
 
 
Figure 1.4 C. difficile pathogenesis. C. difficile colonises the intestine (colon) 
following disruption of the host gut microflora. Spores or vegetative cells of C. 
difficile adhere to the gut mucosa and toxigenic strains of C. difficile secrete toxins. 
The toxins initially insert into the membrane and then self-cleave releasing the 
catalytic (enzymatic) amino-terminal portion of each toxin into the cytoplasm. The 
toxins cause disruption of the tight junctions and loosening of the epithelial barrier 
ultimately leading to cell death or the production of inflammatory mediators that 
attract neutrophils. In animal models it has been shown that TcdB can enter the 
bloodstream (modified from Rupnik et al, 2009). 
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TcdA (308 kDa) and TcdB (269 kDa) are similar to a family of large clostridial 
toxins (LCTs) that all carry three functional domains (von Eichel-Streiber et al., 
1996, Amimoto et al., 2007). An amino-terminal catalytic domain, a central 
translocation domain and a carboxy-terminal cell-binding domain. The catalytic 
domain is responsible for glycosylating small GTPases of the Rho and Ras families 
in host cells, this leads to their inactivation and causes cytoskeletal changes that 
initiate symptoms of CDI (Thelestam & Chaves-Olarte, 2000, Jank et al., 2007, Just 
et al., 1995). The binding domain interacts with putative cell-surface carbohydrate 
receptors where seven potential carbohydrate binding sites have been identified for 
TcdA (Greco et al., 2006, Ho et al., 2005). In animals the TcdA receptor carries the 
trisaccharide Gal1(!1-3)Gal("1-4)GlcNac (Krivan et al., 1986) but it is thought that 
this receptor sequence is not found in humans where the glycoprotein gp26 is 
thought to act as a co-receptor (Na et al., 2008). No receptor has yet been identified 
for TcdB.  
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Figure 1.5 (see previous page) Toxins produced by C. difficile. 
a) The PaLoc chromosomal locus encodes toxins A (308 kDa) and toxin B (269 
kDa) in pathogenic (ToxA+ ToxB+) strains. In non-toxigenic strains this is 
replaced by a 115 bp segment of non-coding DNA. Both toxins are single 
chain polypeptides with distinct functional domains.  
b) b) The CdtLoc pathogenicity locus encodes the binary toxin CDT comprised 
of two proteins, CdtA and CdtB. CdtB binds to cells while CdtA carries 
enzymatic activity. Figure taken from Rupnik et al., 2009. 
 
 
A particularly interesting feature of the carboxy-terminal cell binding domains of 
TcdA and TcdB is that they carry multiple repetitive sequences referred to as CRD 
(C-terminal repetitive domain) (Figure 1.5).  Different sequences have 21, 30 or 50 
amino acids and repeated multiple times in the CRD of both toxins (von Eichel-
Streiber et al., 1992a, Dove et al., 1990, von Eichel-Streiber et al., 1992b). TcdA for 
example, carries 3- to 38 of these repeated sequences. Note that the number of 
repeated motifs depends upon how the motifs are defined. These sequences have 
some similarity with a number of bacterial proteins that bind to cell walls 
(Fernandez-Tornero et al., 2001). It has been proposed that the multiple repeats may 
serve to amplify the affinity and avidity of receptor binding (von Eichel-Streiber et 
al., 1992b, Weis & Drickamer, 1996).  
 
The crystal structure of TcdA has been resolved and shows that the CRD contains a 
"-solenoid fold containing five repeats. Each repeat is further defined as consisting 
of a "-hairpin followed by a loop of 7-10 residues in short repeats or long repeats of 
18 residues (Ho et al., 2005).  For TcdB only the amino-terminal catalytic domain 
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has been resolved demonstrating a classical glycosyltransferase with an interface for 
substrate binding (Wright et al., 2008). 
 
After cell binding and subsequent endocytosis the decrease in endosomal pH induces 
a conformational change in the toxin which results in exposure of the hydrophobic 
membrane insertion (MI) domain within the central translocation segment (Figure 
1.4). This enables the amino-terminus to insert into the endosomal membrane via the 
formation of a pore (Jank & Aktories, 2008). The host cell is able to initiate 
autocatalytic cleavage of the amino-terminal region proximal to the cysteine protease 
(CP) site which releases the amino–terminal glucosyltransferase  (GT) into the 
cytoplasm leaving the remainder of the toxin polypeptide attached to the membrane 
(Reineke et al., 2007). GT is then, after a cascade of events, to inhibit Rho-GTPases 
that ultimately cause increased membrane permeability and loss of barrier function 
(Hecht et al., 1992). 
 
The binary toxin is least well understood although common with other clostridia is 
otherwise unrelated to TcdA and TcdB. In hamsters C. difficile strains that are tcdA- 
tcdB- cdt+ produce no symptoms if CDI and it has been assumed that this toxin is not 
associated with disease (Perelle et al., 1997). The binary toxin comprises two toxins, 
CdtA and CdtB. CdtB binds to host cells and translocates CdtA which is the catalytic 
component where it can ribosylate (ADP dependant) actin molecules. The cdt genes 
are located in the binary toxin locus known as CdtLoc which includes cdtR, encoding 
a regulator of toxin synthesis (Perelle et al., 1997). 
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S-layer proteins 
Vegetative cells of C. difficile carry an exterior coat of proteins that are referred to as 
the S-layer (Calabi et al., 2001). The S-layer lies above the peptidoglycan layer of 
the Gram-positive cell wall and is common in many Gram-positive and Gram-
negative bacteria. The layer is comprised of two S-layer proteins (Slp) that arise from 
post-translational cleavage of a single precursor, SlpA (Eidhin et al., 2006). The two 
forms exists as low and high molecular weights which self-assemble in an organised 
process and has been shown to mediate adhesion to enteric cells (Calabi et al., 2002). 
Other functions have been proposed for the S-layer including protecting the cell from 
phagocytic attack or to avoid the immune system (Sara & Sleytr, 2000). SlpA is the 
predominant surface antigen and has been considered as a potential vaccine 
candidate (see 1.4.2). Interestingly, different variants of the slpA gene have been 
identified in C. difficile including the hypervirulent 027 strains (Fagan et al., 2009, 
Eidhin et al., 2006). 
 
Spores 
The spore is the dormant form of C. difficile and like other Gram-positive spore 
formers is metabolically inactive and can remain in this state for long periods of 
time. Relatively little has been known about the spore until fairly recently. This has 
resulted from difficulties in preparing pure crops of spores. What is clear is that the 
spore is the most important agent of transmission since vegetative cells, being 
anaerobic, can not survive outside of the host. Person-to-person transmission of C. 
difficile is directly linked with the excretion of spores in the faeces of infected 
patients which creates a reservoir of C. difficile that has proven difficult to control 
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(Riggs et al., 2007, Vonberg et al., 2008). Germination studies on C. difficile spores 
has shown that they show increased levels of germination in response to cholate 
derivatives found in bile which demonstrates that they are adapted for life in the GI-
tract (Sorg & Sonenshein, 2008, Sorg & Sonenshein, 2009). Hypervirulent strains of 
C. difficile, notably the 027 ribotype, show increased levels of sporulation which be 
associated with their increased virulence (Merrigan et al., 2010). C. difficile spores 
resemble other spores from other Bacilli and Clostridia and carry a core containing 
the germ-line chromosome, a cortical layer of peptidoglycan and a proteinaceous 
spore coat. In addition, spores carry an exosporium which is a loose-fitting layer that 
encases the spore. The exosporium is found in some but not all spore formers and its 
role has yet to be defined, moreover, this layer is particular fragile and is easily lost 
during spore preparation (Panessa-Warren et al., 1997, Henriques & Moran, 2000). 
Bioinformatic analysis based on the genome sequence of C. difficile has shown the 
presence of orthologues of many of the regulatory genes found in Bacillus subtilis 
(Paredes et al., 2005). For example, SpoOA, a regulatory protein that initiates spore 
formation and several sigma factors, #E, #F that control sporulation gene expression. 
This suggests that spore formation is likely to be similar in design to that of B. 
subtilis and other spore formers. 
 
The most important study to date has been a proteomic analysis of C. difficile spores 
(Lawley et al., 2009b). Here, pure spores of strain 630 (tcdA+ tcdB+) were prepared 
and total spore proteins solubilised and analysed using mass-spectrometry. Using the 
genome sequence of 630 (Sebaihia et al., 2006) for comparison 336 spore-associated 
polypeptides were identified. Of particular interest as a potential vaccine candidate 
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was the BclA1 protein which has orthologues in Bacillus anthracis and Bacillus 
cereus (Sylvestre et al., 2002, Henriques & Moran, 2000, Charlton et al., 1999). 
BclA1 is found in the exosporium of other spore formers and is a collagen-like 
protein that is found in hair-like appendages that protrude from the exosporial layer 
(Henriques & Moran, 2000). C. difficile spores carry a fragile exosporium that 
encases the spore in a loose-fitting sac. The role of BclA1 in B. anthracis is that of 
increasing opsonophagocytic uptake by host cells and increasing spore germination 
(Brahmbhatt et al., 2007, Hahn et al., 2006). It may also be involved in adhesion or 
spore clumping at the mucosa (Bozue et al., 2007). 
 
1.2.4 Hypervirulent (HV) strains 
Starting in the year 2000 highly virulent strains of C. difficile have emerged resulting 
in epidemics typically of a higher incidence, greater severity and increased 
mortalities (Loo et al., 2005, McDonald et al., 2005, Eggertson & Sibbald, 2004). 
The strains responsible are referred to as hypervirulent and cluster into a distinct 
phylogenetic group (Killgore et al., 2008). HV strains can be typed by a number of 
different methods include PCR ribotyping where the HV strains are referred to as 
027 (Warny et al., 2005). Currently 20 sub-types of the ribotype 027 have been 
identified using an enhanced DNA fingerprinting method known as multilocus 
variable repeat analysis (MVLA) (Fawley et al., 2008). What has become clear is 
that the 027 strains have spread widely and have been responsible for a large number 
of C. difficile epidemics worldwide. Interestingly, in the UK at least, MVLA analysis 
of C. difficile specimens isolated from faecal samples showed a gradual decline in 
2010 compared to samples taken over the previous 24 months. The explanation for 
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this is not clear and it should be noted that there has been a compensatory increase in 
other ribotypes, for example, 078, 005, 023 and 002 (HPA, 2011). 027 strains have 
been characterised and shown to produce higher levels of sporulation (and therefore 
spores) and toxin production. The precise reason why toxin production and 
sporulation is more robust in 027 strains is unclear but one hypothesis involves 
TcdC, the negative regulator of toxin production, which is absent in 027 strains, and 
this may enable higher levels of sporulation and toxin production (Merrigan et al., 
2010).  
 
1.3 Control and Prevention of CDI 
1.3.1 Antibiotic therapy 
For patients showing symptoms of CDAD existing antibiotics being used are 
terminated (as these may have precipitated the disease) and oral treatment with 
vancomycin or metronidazole is initiated. Currently, resistance to these drugs is rare 
and metronidazole is preferred for initial treatment of CDAD and vancomycin 
reserved for the more severe cases (Nelson, 2007). For relapse prolonged treatments 
with vancomycin are prescribed although metronidazole is not used due to the risk of 
neuropathy. The use of live probiotic organisms as an adjunct to antibiotic treatment 
has been shown to have value based on human trials (see 1.4.2). 
 
1.3.2 Diagnosis 
The primary method for diagnosing C. difficile infection is by bacterial culture or by 
detection of the toxins in faeces (HPA, 2009, Kuipers & Surawicz, 2008, Williams & 
Spencer, 2009). In the case of the latter, methods are based either on tissue culture 
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where cytotoxicity is measured or immunodiagnostics where an ELISA-based 
method is used to detect the toxin. There are many problems with current strategies 
for diagnosis. First, culture-based methods do not discriminate between non-
toxigenic/toxigenic strains. Second, methods for working with faecal samples are 
problematic and sensitivity can be low. Third, tissue culture based methods are 
expensive and there is an error of subjectiveness that can impede diagnosis. Fourth, 
some immune-based methods only detect toxin A and therefore can miss virulent 
strains that produce only toxin B. Fifth, the sensitivity of immune-based methods is 
low (60-85% compared to tissue culture based methods). Finally, the detection 
methods are all focused on detection of the live vegetative cell of C. difficile that 
produces the toxin and not the spore form. As mentioned below (1.3.3) during CDI 
the number of spores increases exponentially and a method to detect the spore rather 
than the live cell may prove to be a better indicator of the disease state. 
 
1.3.3 Hospital management 
Considerable effort has now been focused on improving the control of C. difficile in 
a hospital environment (Williams & Spencer, 2009). This ranges from standardised 
regimens of hand washing, use of gloves, disinfection and education (HPA, 2009). 
Studies in animals have shown some alarming insights to how C. difficile may spread 
in a hospital environment (Lawley et al., 2009a). In mice virulent C. difficile can 
colonise the GI-tract and establish a carrier state that persists for many months. 
Spores of C. difficile are shed in the faeces but do not transmit to other mice. Upon 
antibiotic treatment though spores become able to transmit easily to other mice. C. 
difficile proliferates in the GI-tract and accompanies a drastic reduction in the normal 
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microflora of the GI tract. In this ‘supershedder’ state large numbers of C. difficile 
spores are shed in the faeces and infect other mice. If the other mice are 
immunocompromised (e.g., are Myd88-) they suffer severe intestinal disease that can 
be fatal. This study demonstrates that in a hospital environment the use of antibiotics 
may lead to a supershedder state of virulent C. difficile and under these 
circumstances transmission from person to person is highly probable and would 
require a rigorous program of containment to prevent an outbreak. Because of this 
methods need to be developed that facilitate destruction of the spore since this is the 
principal agent of transmission (Lawley et al., 2010). 
 
1.4 Prophylaxis 
1.4.1 Correlates of protection 
Compelling evidence suggests that the primary agent of pathogenesis and disease is 
the action of toxins A and B (Lyerly et al., 1985, Kim et al., 1987, Du & Alfa, 2004). 
The CDT binary toxin as mentioned earlier is not implicated in CDI. Toxigenic 
strains of C. difficile have been identified from patients that are ToxA+ ToxB+ and 
ToxA- ToxB+ but to date no naturally occurring ToxA+ ToxB- strains have been 
isolated (Drudy et al., 2007a, Drudy et al., 2007b). Despite this, insertional 
mutagenesis of the PaLoc locus in isogenic strains of strain 630 has shown that both 
ToxA+ ToxB- and ToxA- ToxB+ are virulent and can cause fulminant disease in a 
hamster model of infection (Kuehne et al., 2010). 
 
In humans anti-toxin A and anti-toxin B antibodies have been shown to correlate 
with protection. For example, using a parenteral injection of toxoid A in 30 
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recipients, high level IgG responses specific to toxin A were reported (Aboudola et 
al., 2003). In another study of 63 patients serum IgG specific to toxin A was 
associated with protection against recurrence (relapse) (Kyne et al., 2001). Similarly, 
antibodies to both toxin A and toxin B correlated with protection to relapse in 29 
subjects in a trial evaluating a mAb to toxin A (Leav et al., 2010). Systemic antibody 
responses to toxin A or B develop in approx. 50-70% of patients who develop 
CDAD (Viscidi et al., 1983, Johnson et al., 1992, Aronsson et al., 1985, Bacon & 
Fekety, 1994) with responses to toxin B being more common than to toxin A 
(Viscidi et al., 1983, Aronsson et al., 1985, Bacon & Fekety, 1994). Levels of serum 
IgA specific to the toxin have been shown to be higher than specific IgG (Johnson et 
al., 1992). For example, in one human study serum monomeric IgA has been shown 
to be important for neutralisation and is possibly more important than serum IgG 
(Johnson et al., 1995). A later study based only on in vitro methods that suggests that 
polymeric IgA (i.e., secretory IgA) may play the most critical role in protection 
suggesting that to protect against CDI, mucosal, rather than systemic vaccination is a 
requirement (Stubbe et al., 2000). Systemic IgG responses may reflect systemic 
infection brought about if the toxins have entered the bloodstream and arising during 
severe infections. Mucosal responses on the other hand may provide the primary 
response to CDI. Most studies in humans have shown mucosal IgA responses 
underlying the importance of mucosal immunity (Kelly et al., 1992, Johnson, 1997). 
Interestingly, the role of antibodies in the prevention of relapse has not been resolved 
with limited studies and with different conclusions. (Johnson, 1997). In one study 
toxin A-specific IgG and IgA in serum were lower in patients recovering than those 
who went in to relapse (Johnson et al., 1992). In a second study, levels of serum IgG 
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and faecal IgA were lower in patients who relapsed (Warny et al., 1994). There is 
currently no clear picture of what is required for protection and it is possible that 
protection requires other host responses, i.e., in addition to anti-toxin responses. An 
example might be decolonisation antibodies, i.e., antibodies directed against 
components of the live cell or spore that prevent C. difficile from colonising the GI-
tract. 
 
Antibodies specific to the cell-binding domain of toxin A can protect against CDI. 
Specifically, a defined region of the carboxy-terminal cell-binding domain of toxin A 
known as 14CDTA when expressed in a recombinant Salmonella vaccine (delivered 
nasally) generated mucosal and systemic antibodies against 14CDTA and toxin A 
neutralising activity (Ward et al., 1999). This particular study is interesting because 
it shows that for vaccination just a small region of toxin A can be cloned and 
displayed and antibodies directed against it are sufficient to confer protection. This is 
supported by studies using 14CDTA-specific mAbs that abolish toxin A-mediated 
cytotoxicity (Sauerborn et al., 1997). In hamsters immunized with IgY antibodies to 
toxin A or toxin B (i.e., passive immunisation) that had been raised in chickens 
protection against morbidity and mortality was observed (Kink & Williams, 1998). 
Interestingly, these studies showed that antibodies raised against the carboxy-termini 
of each toxin were most effective at generating toxin-neutralising antibodies 
suggesting these regions to be highly immunogenic. Formalin-inactivated toxoids 
have been evaluated as protective antigens by a variety of systemic and mucosal 
(oral, nasal and rectal in combination with cholera toxin as a mucosal adjuvant) 
routes using the hamster model of infection (Torres et al., 1995). In all cases varying 
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levels of protection could be observed supporting the notion that antibodies to toxin 
A and toxin B are required for protection. What is particularly interesting is that 
delivery of either toxoid A or only toxoid B can generate protection, an observation 
best explained if the carboxy-terminal domains of each toxoid generate cross-
reactive and cross-neutralising antibodies. 
 
In patients with CDAD IgG responses to the S-layer proteins has been observed 
using immunoblotting of patient’s sera (Pantosti et al., 1989) or by mass-
spectrometry (Wright et al., 2008). The conclusion of both studies was that the S-
layer proteins were the immunodominant antigens present in vegetative cells of C. 
difficile. In addition, the S-layer proteins have been shown to induce inflammatory 
and regulatory cytokines in human monocytes and dendritic cells using in vitro 
studies (Ausiello et al., 2006). Taken together, this suggests that these surface 
proteins are both immunogenic and inflammatory and antibodies directed against the 
S-layer proteins could be considered in a vaccine formulation. It is probable that 
other spore-associated proteins may be implicated in virulence and these together 
with the S-layer proteins might be important for protection against relapse.  The S-
layer proteins have been evaluated as vaccine candidates in a hamster model of 
infection. When administered in combination with cholera toxin (CT) as a mucosal 
adjuvant limited anti-Slp responses (IgG and IgA) were obtained suggesting that Slp 
should not be considered as a vaccine candidate unless better mucosal adjuvants can 
be developed (Ni Eidhin et al., 2008). 
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1.4.2 Vaccines under commercial development 
The principle approach considered for prevention of CDAD is by vaccination. In one 
documented phase I clinical study 30 healthy adults were injected (intra-muscular) 
with four spaced doses of formalin-inactivated toxoids A and B. 90% of subjects 
developed serum IgG responses and 50% faecal sIgA (Kotloff et al., 2001). Current 
vaccination programmes under development all rely on the delivery of the toxoids by 
a parenteral route. Sanofi-Pasteur have entered phase II trials with a parenteral 
vaccine (3 doses) consisting of inactivated toxins A and toxin B. Although antibodies 
to toxin A and B are protective it is unclear whether this vaccine will be able to 
prevent CDI in the field. To be fully effective the vaccine must protect against 
hypervirulent strains of C. difficile as well as relapse and it is unclear that the phase 
II trials will demonstrate this. Other major vaccine manufacturers are all pursuing 
vaccine approaches using a parenteral approach based on the use of toxoids but these 
are all at the preclinical stage. 
 
1.4.3 Probiotics 
Probiotics are live bacteria that when ingested are able to confer health benefits to 
the host. Used extensively in humans these products often are comprised of just one 
bacterium, either as a dried formulation in a tablet or capsule, or as a fermented dairy 
product (e.g., Yakult, live yoghurt etc.). The rationale for using probiotics is 
confusing yet following antibiotic treatment there seems to be a compelling case for 
their use. The gut microflora consists of about 1012 bacteria per gram of intestinal 
content in a healthy adult and as many as 1000 different species. This population is 
stable yet antibiotic therapy can reduce the gut population by as much as 1-log and 
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this in turn can lead to classic symptoms associated with antibiotic treatment, for 
example, cramps, constipation and diarrhoea. Since CDAD is a result of antibiotic 
treatment that precipitates the growth and proliferation of C. difficile it might be 
possible that repeated doses of a probiotic bacterium could replenish the gut 
microflora. For CDAD there appears to be data to show that probiotic treatment can 
reduce the symptoms or occurrence of CDAD (reviewed in (Gougoulias et al., 2007, 
Sleator & Hill, 2008)). Numerous animal studies have shown efficacy in reducing the 
incidence and severity of CDI in mice and hamsters. Various mechanisms have been 
put forward, for example, the production of certain antimicrobials (e.g., Abp118 and 
Lactican 3147 produced by Lactobacillus salivarius and Lactococcus lactis 
respectively (Corr et al., 2007, Rea et al., 2007)) that inhibit proliferation of C. 
difficile. While attractive this type of ‘probiotic model’ is not convincing since it is 
species and strain specific and a more universal solution is preferable (perhaps by 
prevention of colonisation or interference with toxin targeting). Despite this, human 
trials have been conducted, including studies with Lactobacillus rhamnosus GG 
(Pochapin, 2000), Lactobacillus plantarum 299v (Wullt et al., 2003), Lactobacillus 
acidophilus + Bifidobacterium bifidum (Plummer et al., 2004) and the yeast 
Saccharomyces boulardii (Surawicz et al., 1989, Surawicz et al., 2000a). The 
conclusions from these human studies as well as others reviewed by Gougoulias et al 
(Gougoulias et al., 2007) show a significant effect on the incidence of CDAD as well 
as relapse when used as an adjunct to antibiotic therapy (Surawicz et al., 2000b). S. 
boulardii has also been shown to significantly enhance sIgA responses to toxin A in 
mice pre-fed with S. boulardii and then orally administered toxoid A (Qamar et al., 
2001). These studies suggest that this yeast may prime the immune mucosal immune 
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response and supports the use of probiotics as dietary supplements and/or mucosal 
adjuvants. As with many studies involving probiotics there are some issues that 
relate to study design and administration yet there seems to be a consensus, that in 
the absence of an alternative treatment, the use of probiotic bacteria could have a 
useful role as an adjunct or alternative treatment to the more conventional antibiotic 
therapies used to control the disease. 
 
1.4.4 Faecal therapy  
One of the most unusual methods shown to work against CDAD is referred to as a 
‘faecal transplant’ or ‘faecal therapy’. The treatment has been performed with 42 
patients to date at Gartnavel General Hospital in Glasgow and in 92% of cases 
patients go on to show a full recovery (MacConnachie et al., 2009). The method 
requires a stool sample (approx. 30 g) from a close relative which is then 
homogenized and solid matter removed by filtration. The faecal extract is then 
administered to the patient using a tube through the patients nose (nasogastric). To 
explain how this treatment works it is assumed that faecal therapy repopulates the 
GI-tract with gut commensals and thus this strategy shares some similarities with the 
use of probiotics. Clearly, there are some concerns over this treatment mostly 
relating to the use of faecal material and this is considered only a suitable and 
realistic option for patients who do not respond to vancomycin therapy. 
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1.4.5 Pre-colonisation with non-toxigenic C. difficile 
A second strategy relates to reducing colonisation of C. difficile in the GI-tract. 
Studies in neonatal pigs (Songer et al., 2007) and hamsters (Sambol et al., 2002) has 
shown that when animals were administered oral doses of a strain of C. difficile 
unable to produce either toxin A or toxin B that, following infection with a toxigenic 
strain of C. difficile significant levels of protection were observed. In the hamster 
model three different non-toxigenic strains of C. difficile were used and 87-97% was 
observed following challenge doses of 106 spores (following clindamycin treatment) 
of each of the respective C. difficile strains (Sambol et al., 2002). These studies are 
interesting since they show that pre-colonisation of animals (and presumably 
humans) with non-toxigenic C. difficile can provide protection to CDI. The basis for 
how this works is not understood but several mechanisms can be proposed including, 
preventing the colonisation of toxin producing strains or possibly by a probiotic 
based mechanism. The strategy has been adopted by one pharmaceutical company, 
Viropharma (Exton, USA) who are completing phase II clinical trials in humans. 
 
1.4.6 Passive immunisation: 
Antibodies specific to toxin A and toxin B are required for protection against CDI. 
Patients with mild cases of CDAD carry high levels of anti-toxin IgG (Kyne et al., 
2001, Warny et al., 1994, Viscidi et al., 1983) while patients who experience relapse 
have low anti-toxin Ig titres (Kyne et al., 2001, Katchar et al., 2007). Patients who 
suffer CDAD develop anti-toxin A/B antibodies (IgG and IgA) (Giannasca & Warny, 
2004, Viscidi et al., 1983). This then raises the possibility for using antibodies for 
passive immunisation, that is, administering anti-toxin A/B antibodies directly to an 
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affected person (Hussack & Tanha, 2010). In animals data has supported this 
therapeutic approach. For example, intra-peritoneal injection of toxin-specific 
antibodies prevented clindamycin-induced colitis in hamsters (Allo et al., 1979). 
Monoclonal antibodies have also been used by the oral route and protected hamsters 
from a fatal injection of toxin A (Lyerly et al., 1986). Using IgY antibodies 
(produced in poultry) specific to toxins A and B oral administration to hamsters 
prevented CDI and relapse but oral delivery of only anti-toxin A IgY prevented 
infection only but not relapse (Kink & Williams, 1998). The fact that an antibody can 
survive transit across the gastric barrier is surprising and may reflect the robustness 
of hen IgY antibodies. For human therapeutics humanised antibodies must be used to 
reduce immunogenicity and studies using anti-toxin monoclonal mAbs against toxin 
A and B and reduced hamster mortality following intraperitoneal injection (Babcock 
et al., 2006).  
 
A number of studies have now shown that passive immunisation is suitable for 
treatment of chronic relapsing CDI in humans. So far these studies have used 
systemic delivery. In the most successful study to date Lowy et al examined 200 
patients who each received an intravenous dose of anti-toxin A/B mAbs. A 
significant reduction in CDAD recurrence (relapse) was observed with an incidence 
of 7% in treated individuals compared to a 25% relapse rate in patients receiving a 
placebo (Lowy et al., 2010). This approach is now being pursued by Merck & Co. 
(USA). 
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Table 1.1 Summary of treatment options for CDI 
      
Treatment options Pro Con 
Antibiotic therapy • Works in most cases • Can induce relapse 
• Increases probability of 
antibiotic resistance 
• Side effects 
• Therapy only 
Vaccine • Will provide long 
term protection 
• No vaccine yet 
• Not clear what are the 
required components for a 
vaccine 
Probiotic • Provides an adjunct 
to antibiotic therapy 
• Some efficacy shown 
• Does not provide long term 
protection 
• Mechanism not understood 
• <100% protection 
Faecal transplant • Method works • Therapy only 
• Complicated and unsuitable  
Passive 
immunotherapy 
• Method works • Therapy only 
• Systemic delivery 
• Not 100% protection 
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1.5 Thesis Objectives 
 
The long-term goals of this work are to develop a prophylactic treatment to CDI.  
This thesis project initiated with two questions. 
1. Can a mucosal vaccine to CDI be developed? 
2. What is the role, if any, of spores in CDI? 
 
A mucosal vaccine 
Current evidence suggests that parenteral vaccination relying on injection of toxoid 
antigens is insufficient for full protection to CDI. Since CDI is acquired by the oral 
route a mucosal vaccine may be most appropriate for full protection. To address 
mucosal vaccination a delivery system based on antigen expression using Bacillus 
subtilis spores will be used for delivery of toxin antigens. Heat-stable B. subtilis 
spores are convenient for delivery by the oral route and have been shown to provide 
mucosal immune responses to heterologous antigens displayed on the B. subtilis 
spore. The approach to be used was to express domains of toxin A and toxin B on B. 
subtilis spores and administer to animal models of CDI. 
 
The role of the spore 
Relatively little is known about the C. difficile endospore. Particularly its surface 
composition and the regulation of genes involved in differentiation. As a first step 
the spore coats will be examined and the principal spore coats proteins will; be 
identified. Secondly, the spore surface properties will be characterised and finally, 
the regulation of representative developmental genes defined. This will provide a 
framework for others to decipher the biosynthesis of C. difficile spores and their 
relationship to CDI. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
 
2.1 General methods  
General methods for working with B. subtilis are described elsewhere (Harwood & 
Cutting, 1990). Work with E. coli including cloning are as described by Sambrook et 
al. (Sambrook & Russell, 2001). 
 
2.2 Bacterial Strains 
630 is a toxigenic (tcdA+ tcdB+) strain of C. difficile isolated from a patient with 
pseudomembraneous colitis during an outbreak of CDI (Wust et al., 1982) and 
obtained from N. Fairweather (Imperial College, UK). CD196 is a non-epidemic, 
hypervirulent, strain of C. difficile isolated in Paris in 1985 with the 027 ribotype, 
REA (restriction endonuclease analysis) type BI and PFGE (pulse-field gel 
electrophoresis) type NAP1 (Stabler et al., 2009) and was obtained from T. Lawley 
(Wellcome Trust Genome Campus, UK). CD630 and M68 were routinely grown in 
vegetative culture by overnight growth (10ml) at 37°C in TGY-vegetative medium 
(3% tryptic soy broth, 2% glucose, 1% yeast extract, 0.1% L-cysteine) (Paredes-
Sabja et al., 2008). S. mutans GB1 was obtained from Phan Nghia (Hanoi Univ., 
Vietnam); B. subtilis strain PY79 is a prototrophic (Spo+) laboratory strain and a lab 
stock as was B. clausii O/C. B. licheniformis strain HU14 was obtained from the 
Bacillus Genetic Stock Center (Ohio, USA). 
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2.3 Sporulation of C. difficile 
All manipulations were made in an anaerobic incubator (Don Whitley, UK). A single 
bacterial colony was grown on BHIS (brain heart infusion supplemented with L-
cysteine, 0.1% and yeast extract, 5 mg/ml; (Smith et al., 1981) agar overnight at 
37oC. One fresh single colony from the BHIS plate was inoculated in 10 ml of TGY 
medium (3% tryptic soy broth; 2% glucose; 1% yeast extract; 0.1% L-cysteine) 
(Paredes-Sabja et al., 2008) and incubated at 37oC overnight. 1 ml of TGY culture 
was then sub-cultured into SMC broth (90 g, peptone; 5 g, proteose peptone; 1 g, 
(NH4)2SO4; 1.5 g, Tris) containing 0.1% L-cysteine (modified from Wilson et al. 
(1982)) incubated overnight and then plated onto SMC agar. After 7 days incubation 
at 37oC sporulation efficiency was confirmed by phase-contrast microscopy and 
measurement of heat-resistant CFU and spore crops harvested immediately or after 
overnight incubation at 4oC.  
 
2.4 Spore purification 
The methods used were modified from Lawley et al (2009b). Spores were washed in 
water two times, then suspended in PBS containing 125 mM Tris, 200 mM EDTA, 
0.3 mg/ml proteinase K (E00492; Fermentas) and 1% sarcosyl, and incubated with 
gentle shaking at 37oC for 2 h. Spores were centrifuged (6,500 g, 10 min) and pellets 
resuspended in water and washed a further 10 times. After the final suspension in 
water, spores were heat-treated (60oC, 20 min) to kill any residual cells; aliquots 
were stored at 40C until use. To calculate the spore CFU aliquots were serially 
diluted in PBS and plated onto BHIS agar supplemented with 0.1% sodium 
taurocholate (Sigma, UK). Plates were incubated for 24-48 h before CFU were 
enumerated. 
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2.5 Spore coat extractions (Chapter 3) 
The spore coat extraction procedure has been described elsewhere (Tsuzuki & Ando, 
1985) but in brief C. difficile spores (2 x 109) were suspended in freshly prepared 100 
ml of sodium borate-SDS-DTT buffer consisting of sodium borate (0.1 M, pH 10), 
0.5% sodium dodecyl sulfate (SDS) and 50 mM dithiothreitol (DTT), and then 
incubated at 68oC for 75min with gentle agitation. After centrifugation (6500 g for 
15 min) the supernatant was removed, mixed with 4X SDS-PAGE loading buffer and 
fractionated by SDS-PAGE. For B. subtilis and B. clausii spores, coat proteins were 
extracted using the SDS-DTT buffer described elsewhere (Nicholson & Setlow, 
1990). 
2.6 Peptide fingerprinting (Chapter 3) 
Spore coat proteins were fractionated on 12.5% SDS-PAGE mini-gels and bands 
excised and digested with trypsin before analysis by MALDI mass spectrometry. 
Digestions and analysis were conducted by the University of Cambridge Protein & 
Nucleic Acid Chemistry Facility (PNAC) (http://www.bioc.cam.ac.uk/pnac). 
 
2.7 Antibody production (Chapter 3) 
pET28b expression vectors that express the complete C. difficile cotA, cotB, cotCB 
and cotD ORFs were constructed by amplifying the respective DNA by PCR from 
CD630 chromosomal DNA and ligating to cleaved pET28b. For cotE it proved 
impossible to clone the entire ORF so a fragment encoding the N-terminal, 
peroxiredoxin domain was cloned instead. Primers used for construction of pET28b 
clones are shown in (Table 2.1) High levels of expression were obtained upon IPTG 
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induction and purification of proteins by passage of the cell lysate through a HiTrap 
chelating HP column on a Pharmacia AKTA liquid chromatography system. 
Polyclonal antibodies were raised in mice immunized by the intra-peritoneal route 
with 2!g of purified recombinant proteins on days 1, 14 and 28. Anti-spore 
antibodies were made by treating spores in 2% formalin (2% v/v formaldehyde in 
PBS) overnight at 4oC. Spores were washed 5-times with PBS and used to dose mice 
(2 X 108 spores/dose) mice on days 1 and 14. 
 
Table 2.1 Primers used for construction of pET clones for antibody production 
 
Primer Direction Sequence1 Res. site 
cotA 
CotA-NcoI-F forward GATCCATGGCTGTGGAAAATAATAAATG NcoI 
CotA-XhoI- R reverse ATCCTCGAGTGCAATATAATCTATAGAATCTA
CACATAC 
XhoI 
cotB 
CotB-NcoI-F forward GATCCATGGCTATAGATAATCAAAAATATG NcoI 
CotB-XhoI-R reverse ATCCTCGAGCATGTTTTTATAACTCTC XhoI 
cotC 
CotC-NcoI-F forward GATCCATGGCTTGGATTTATCAAAAAAC NcoI 
CotC-XhoI-R reverse ATCCTCGAGAAACTGATGCTTGCACTC XhoI 
cotD 
CotD-NcoI-F forward GATCCATGGCTTGGATATATCAGAAAAC NcoI 
CotD-XhoI-R reverse ATCCTCGAGGAACATTTTTTGAGATTC XhoI 
cotEN 
CotEN-NcoI-F forward GGCCCATGGGCGTGATTTACATGCCAAATTT NcoI 
CotEN-XhoI-R reverse CCGCTCGAGTGGTACAAAACATAAGTACCAG XhoI 
 
1  5’-3’, restriction site  in italics 
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2.8 Confocal microscopy (Chapter 3 & 5) 
Spores were labeled with mouse anti-Cot serum (1:1000 dilution) followed by an 
anti-mouse IgG-TRITC conjugate. Images were taken using a Nikon Eclipse 
fluorescence microscope equipped with a BioRad Radiance 2100 laser scanning 
system.   
 
2.9 Transmission electron microscopy (TEM) (Chapter 3) 
TEM methodology using suspensions of purified CD630 spores (7-days old) were as 
described previously for B. subtilis spores (Hong et al., 2009). TEM studies were 
performed by Prof. Alain Brisson (Laboratoire de Microbiologie, UMR5248 CNRS-
Université ENITA de Bordeaux, France). 
 
2.10 Zeta potential measurements (Chapter 3) 
Zeta potentials of spores were measured at 24°C with a 3000HS Malvern Zeta-sizer 
(Malvern Instruments Ltd, UK). Aliquots of 30 !l of spores suspended in Milli-Q 
water at a density of 5 x 109 spores ml-1 were added to 3 ml solutions of defined pH 
and ionic strength. The pH was adjusted using HCl or NaOH. The mean of two 
separate measurements from the same sample were determined. The zeta potential 
was calculated from the electrophoretic mobility using the Smoluchowski equation 
(Sze et al., 2003). 
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2.11 Spore adhesion to hydrocarbon (SATH) assay (Chapter 3) 
The surface hydrophobicity of spores was determined using the spore adhesion to 
hydrocarbon (SATH) assay using n-hexadecane as hydrocarbon (Seale et al., 2008). 
Purified spores were washed in either Milli-Q water or 1 M NaCl in Milli-Q water by 
centrifugation at 16,000 g for 10 min and resuspended in 0.1 M NaCl at a density of 
1 x 108 spores ml-1. Spore suspensions (2 ml) were added to 1 ml n-hexadecane 
(Aldrich) and vortexed for 1 min, incubated at 37°C for 10 min, and vortexed again 
for 30 sec. The absorbance of the aqueous phase was measured at 600 nm. The mean 
of two measurements was determined. The percent hydrophobicity (%H) was 
determined from the absorbance of the original spore suspension (Ai) and the 
absorbance of the aqueous phase after incubation with hexadecane (Af) according to 
the following equation : %H = [(Ai – Af) / Ai] x 100. 
 
2.12 In vitro cell adhesion studies (Chapter 3) 
Adherence of spores to Caco-2 cells was carried out using a method modified from 
Rowan N.J. et al (Rowan et al., 2001). Caco-2 cell monolayers of 70–80% 
confluence grown in a 5% CO2  atmosphere at 37°C in DMEM (Dulbecco's Modified 
Eagle Medium) supplemented with 10% fetal calf serum (FCS; Gibco BRL) were 
seeded with approximately 105 cells per well on 24-well cell culture plates. Prior to 
assays, the monolayers were washed two times with DMEM, inoculated with 107 
purified spores (in DMEM with 10% FCS) in duplicate, and incubated for 2 h at 
37°C in a 5% CO2 atmosphere. After incubation, the monolayers were washed five 
times with DMEM to remove any non-adherent cells, and then the tissue culture cells 
were lysed with 1 ml of 1% Triton X-100 (vol/vol in distilled water) for 5 min at 
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37°C. Samples (0.1 ml) of lysate from each tissue culture plate were serially diluted 
in 0.9 ml of sterile distilled water, with subsequent enumeration by plating of 100 µl 
of appropriate 10-fold dilutions on BHI supplemented with 1% sodium taurocholate 
agar plates. % adhesion =(number of adhered spores/initial number of spores) X 100. 
 
2.13 Growth and sporulation (Chapter 4) 
C. difficile strains were stored as glycerol stocks and routinely streaked out on BHIS 
(Brain heart infusion) agar supplemented with 0.1% (w/v) cysteine and 5 mg/ml 
yeast extract (Smith et al., 1981). All culturing of C. difficile was made in an 
anaerobic chamber (80% N2, 10% H2, 10% CO2; Don Whitley, UK). Assays for 
growth and sporulation included optical density readings (OD600, total cfu/ml by 
serial dilution and plating on BHIS agar (supplemented with 0.1% w/v sodium 
taurocholate), direct counting of phase bright spores using a haemocytometer (in 
duplicate), heat (60oC, 1 h) and ethanol resistance (50% ethanol, 1 h, RT) and mRNA 
extraction.  
 
2.14 Capture ELISA for detection of toxins A and B (Chapter 4) 
Toxin A and toxin B were measured by capture ELISA. Briefly, ELISA plates 
(Greiner, high binding) were coated overnight, at RT, with rabbit polyclonal 
antibodies (1 mg/ml; Sigma) against toxin A or toxin B in PBS buffer.  After 
blocking plates with 2% BSA (1 h at 37oC), samples and reference toxin A or toxin 
B (AbD Serotec) were added to plates. Incubation was made at 30oC for 3 h. For 
detection antibodies, monoclonal antibodies against toxin A (1/500; AbD Serotec) 
and toxin B (1/500; AbD Serotec) were used with incubation for 1 h at 30oC. After 
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washing, the secondary antibody, HRP conjugated anti-mouse  IgG  was added, with 
incubation at RT for 1 h. Colour was developed with the TMB substrate and 
measurement at OD 450nm. The titers of toxin in samples were calculated against the 
commercial reference toxins A or B (AbD Serotec). The sensitivity of the assay for 
toxin A was 5 ng/ml and  5 ng/ml for toxin B. 
 
2.15. Cytotoxicity assays (Chapter 4) 
The assays used to measure cytotoxicity of toxin A and toxin B in cell culture was 
that described by Kuehne et al (2010). 
 
2.16 RT-PCR analysis (Chapter 4) 
a) Synchronised sporulation in liquid broth 
In each case a fresh, single, colony of the C. difficile strain was inoculated into BHIS 
broth (Brain heart infusion medium supplemented with 0.1% (w/v) cysteine and 5 
mg/ml yeast extract (Smith et al., 1981) and grown overnight (17-18 h) in an 
anaerobic incubator (Don Whitley, UK). The overnight culture was then diluted 
1/104 in BHIS in a volume sufficient for the planned sampling regimen. As discussed 
elsewhere, a 1/104 dilution is essential to promote synchronized sporulation in liquid 
culture (a). Assays for growth and sporulation included optical density readings 
(OD600nm), total CFU/ml by serial dilution and plating on BHISS agar (BHIS 
supplemented with 0.1% w/v sodium taurocholate to promote spore germination, 
(Wilson et al., 1982), heat (60oC, 1 h) and ethanol resistance (50% ethanol, 1 h, RT) 
and sampling for mRNA extraction.  
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b) RNA extraction 
Culture samples (60 ml) were centrifuged at 6500 g for 10 min and the pellet 
dissolved in 1ml of denaturing solution and cells or spores disrupted (40 sec) using a 
Fastprep-24 (MP Biomedicals) cell disruptor. RNA was extracted using a single step 
method described elsewhere (Chomczynski & Sacchi, 2006). Extracted RNA was 
then dissolved in DEPC-treated water (Sigma) and stored at -80°C. The integrity of 
extracted RNA was verified using a NanoDrop spectrophotometer and by 
formaldehyde agarose gel electrophoresis. A purity ratio of between 1.9 and 2.1 
(A260/A280) was acceptable for RNA work.  
 
c) Real-time PCR (RT-PCR) analysis  
cDNA was made using the SensiMix SYBR No-ROX kit (Bioline Reagents, London, 
UK) and stored at -20oC. Primers for gene expression analysis are given in         
(Table 2.2) and were designed by PrimerDesign (PrimerDesign Ltd. Southampton, 
UK). Primers were first tested by conventional PCR with genomic DNA to confirm 
specificity and product sise. RT-PCRs were performed in triplicate in 20 !l volumes 
using 100 ng of cDNA, 100ng of primers and 10 !l of SYBR Green (Promega, UK). 
Gene expression of target genes was normalised using the housekeeping gene rpoA 
as a reference (Merrigan et al., 2010, O'Connor et al., 2006). To establish the 
efficiency of reaction a standard curve was generated for each reference or target 
gene by diluting primer concentration. This identified the optimal dilutions for use in 
subsequent analysis. Thermal profiles used were: initial denaturation (95oC, 10 min) 
followed by 40 cycles of denaturation (95oC, 15 sec), annealing (56oC, 30 sec) and 
extension (72oC, 10 sec). This was followed by a dissociation curve to check product 
specificity. The expression of target genes was normalised to that of rpoA and 
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calculated by the Pfaffl method (Pfaffl, 2001) using the amplification efficiencies (E) 
determined in each run according to the following equation: Ratio = (Etarget)"CT, target 
(calibrator – test) / (Eref)"CT, ref (calibrator – test), where "CT, target (calibrator – test) is the CT of 
target gene in the calibrator minus CT of the target gene in the test sample and "CT, 
ref (calibrator – test) is the CT of reference gene in the calibrator minus CT of the 
reference gene in the test sample. PCR was performed using a Rotor-Gene 6000 
(Corbett Life Science).  
 
2.17 Recombinant B. subtilis vaccine strains (Chapter 5) 
B. subtilis merodiploid strains contained chimeric genes of cotB and/or cotC fused at 
their 3’-ends to the C-terminal domains of toxin A (A26-39; codons Ser2388-Pro2706 
(Dove et al., 1990)) or toxin B (B15-24; codons Glu2137-Glu2366 (Barroso et al., 
1990)). The entire cotC gene was used for fusion to the toxin domains, while for 
cotB a 3’-deletion was used so that the encoded CotB segment was 33 kDa. Genes 
were integrated into the chromosome by a stable, double crossover, recombination 
and were placed in trans to the indigenous cotB or cotC genes. The general strategy 
for constructing strains carrying chimeric genes has been reported elsewhere (Isticato 
et al., 2001, Duc le et al., 2007, Hoang et al., 2008) and is summarised as follows. 
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Step 1.  
The cotB and cotC genes including their sporulation-specific promoters were cloned 
in either pDG364 or pDG1664 using primers CotBF and CotBR for cotB and CotCF 
and CotCR for cotC (Table 2.3). For cotB the 3’-codon (codon 275, serine) was used 
producing a truncated cotB gene (the entire cotB ORF is 380 codons) encoding a 33 
kDa species while for cotC the terminal codon (codon 118, tyrosine). Both these 
plasmids enable cloned genes to be integrated into the chromosome of B. subtilis by 
a double crossover recombinational event (Guerout-Fleury et al., 1996) occurring at 
either the amyE (pDG364) or thrC loci (pDG1664) by selection for either 
chloramphenicol (pDG364) or erythromycin (pDG1664) resistance. 
 
Step 2.  
Toxin domains A26-39 and B15-24 were amplified by PCR from chromosomal 
DNA of C. difficile strain 630. Primers (Table 2.4) were designed to enable 
restriction and ligation, in frame, to either the cotB or cotC 3’-termini contained in 
the pDG364 or pDG1664 clones described in step 1.  
• Toxin A primers (TcdAF and TcdBR) were designed to amplify DNA 
between codons 2388 (serine) and 2706 (proline) of the tcdA gene (Dove et 
al., 1990) corresponding to toxin domain A26-39.  
• Toxin B primers (TcdBF and TcdR) were designed to amplify DNA between 
codons 2137 (glutamic acid) and 2366 (glutamic acid) of the tcdB gene 
(Barroso et al., 1990) corresponding to toxin domain B15-24. 
Recombinant plasmids were sequenced to confirm integrity of cloning. 
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Table 2.2 Primer pairs used to amplify genes studied by real time PCR 
Gene Direction Primer sequence (5’-3’) 
F GTCGGATTGCAAGTAATTGACAATA 
tcdA 
R TAACAGTCTGCCAACCTTTTGAGA 
F ACCATATAGCTTTGTAGATAGTGAAGGAAA 
tcdB 
R AAGAACTACATCAGGTAATTCAGATACAAA 
F AACTCAGTAGATGATTTGCAAGAAA 
tcdR 
R TCTGTTTCTCCCTCTTCATAATGT 
F CTTTCAAAAGTACCATCAAGTCCAG 
cotA 
R TCTCAGATTTCTTTATAGTAGGTGCTA 
F ATATCAAGAACATTACAGAAGAAACTC 
cotB 
R CATGGTCTGCTAAAAGTGGTAATAT 
F ATGTCTTTGGCGATTCGGTAA 
cotC 
R AATATATCTTTCAAATCAGGGTCATCA 
F CTTGTGACCCTAGAATGGCTAAA 
cotD 
R AGGCATTGTATATCTTTGGCTTAAAT 
F CCTAGATTTTTAAACCAATTACTTGCT 
cotE 
R TGTAGGTGTTAATGCTGCATCA 
F GGATGATATGATGAAGGTTAGAAACCT 
rpoA 
R CCCAATCCAAGTTCTTCTAGTTTTTG 
F GCGCAATAAATCTAGGAGCA 
spoOA 
R AGGTTTTGGCTCAACTTGTGT 
F GGGGGAGATTTACATGTTGG 
sigH 
R TTTTATCCCCTTCACTTGCTC 
F GTTGCTGGAATGCTTGGAAT 
sigE 
R TCATTTCTTTTTGCAACCTTGA 
F TGGAAGTAACTGTTGCCAGAGA 
sigF 
R TCTTTTGCCTCTTCATCTCCA 
F TGATGCCATACAAGACCCAAT 
sigG 
R TCTTGCAACCAATTTTCATCA 
F TCAACGGAAGATCAGGATGA 
sigK 
R GCATATGTTGCTAATCGAGTTCC 
F=Forward,  R= Reverse 
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 Step 3 
Plasmids were linearised by restriction digestion and then introduced into competent 
cells of B. subtilis PY79 (a laboratory strain of B. subtilis (Youngman et al., 1984)). 
Chloramphenicol-resistant (pDG364-derived) or erythromycin-resistant (pDG1664-
derived) transformants were then colony purified, checked by PCR and finally by 
immunoblotting for expression of the appropriate chimeric protein. 
 
Table 2.3 PCR primers for vaccine constructions 
Primer Direction Sequence1 Restriction site 
TcdAF forward CCCAAGCTTGCCTCAACTGGTTATAC HindIII 
TcdAR reverse GGAATTCTTAAGGGGCTTTTACTCCATC EcoR1 
TcdBF forward CCGAAGCTTATAGAATCTGGAGTACAAAAC HindIII 
TcdBR reverse CCGGAATTCCTATTCACTAATCACTAATTG EcoR1 
CotBF forward GCGGATCCACGGATTAGGCCGTTTGTCC BamHI 
CotBR reverse CCCAAGCTTGGATGATTGATCATCTGAAG HindIII 
CotCF forward GCGGATCCTTCACAAAAATACTCG BamHI 
CotCR reverse CCCAAGCTTGTAGTGTTTTTTATGC HindIII 
1 restriction site is in italics; bold = C. difficile or B. subtilis sequence is in bold. 
The following strains were made: 
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 PP059 (thrC::cotB-A26-39): encodes a fusion of A26-39 to the C-terminus of CotB 
(predicted mwt. 69 kDa). The chimeric gene was carried at the thrC locus of B. 
subtilis.  
PP052 (amyE::cotC-A26-39): encodes a fusion of A26-39 to the C-terminus of the 
CotC (predicted mwt. 49 kDa). The chimeric gene was carried at the amyE locus of 
B. subtilis. 
PP108 (thrC::cotB-A26-39 amyE::cotC-A26-39): created by transforming competent 
cells of  PP052 with chromosomal DNA of PP059 with selection for ErmR conferred 
by the thrC::cotB-A26-39 cassette. 
PP132 (thrC::cotB-B15-24): encodes a fusion of B15-24 to the C-terminus of CotB 
(predicted mwt. 60 kDa).  
PP142 (thrC::cotB-B15-24 amyE::cotC-A26-39): was created by transforming 
competent cells of PP052 with chromosomal DNA of PP132 (thrC::cotB-B15-24) 
with selection for ErmR conferred by the thrC::cotB-B15-24 cassette. 
 
2.18 Recombinant proteins (Chapter 5) 
Recombinant A26-39 (36.6 kDa) and B15-24 (29.4 kDa) were produced in E. coli 
BL21(DE3)(pLys) from a pET28b expression vector that separately carried the 
rA26-39 and rB15-24 ORFs fused to a C-terminal poly-histidine tag. Primers used 
for cloning are shown in (Table 2.4). High levels of expression were obtained upon 
IPTG induction and purification of rA26-39 and rB15-24 by passage of the cell 
lysate through a HiTrap chelating HP column on a Pharmacia AKTA liquid 
chromatography system. 
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Table 2.4 PCR primers for pET expression vectors 
 
Primer Direction Sequence1 
Restriction 
site 
pETA26-39F forward CATGCCATGGCCTCAACTGGTTATAC NcoI 
pETA26-39R reverse CCGCTCGAGAGGGGCTTTTACTCCATC XhoI 
pETB15-24F forward CATCCATGGATATAGAATCTGGAGTCAAAA NcoI 
pETB15-24R reverse CCGCTCGAGTTCACTAATCACTAATTCAG XhoI 
1 restriction site is in italics; bold = C. difficile or B. subtilis sequence is in bold. 
 
2.19 Protein quantification (Chapter 5) 
Coat proteins were extracted from purified spore suspensions of PP108 and PP142 
using two extraction procedures, i) SDS-DTT and ii) alkali extraction as described 
elsewhere (Duc et al., 2003). SDS-DTT solubilises both CotB and CotC while alkali 
extraction preferentially solubilises CotC. Quantification was made using a Bio-Rad 
Gel Doc imaging system. 
 
2.20 Polyclonal antibodies (Chapter 5) 
Polyclonal antibodies were raised in mice immunised by the intra-peritoneal (i.p.) 
route with 2 !g of purified protein on days 1, 14 and 28. Dilutions used were 1:3,500 
for anti-A26-39 and 1:1,500 for anti-B15-24. 
 
2.21 Immunisations in mice (Chapter 5) 
Animals used in this work were pathogen-free, Balb/c mice (Charles River) for 
antibody production, and for analysis of immune responses. In all cases females, 
aged 6-8 weeks were used. All animal procedures were performed under the Home 
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Office project license PPL 70/6126. Mice were dosed o.g. (0.2 ml by gavage) on 
days 0, 14, 35 and 57 with a dose of 5x1010 spores (PY79, PP108 or PP142). A naïve 
group of un-immunised animals was included in all experiments as well a group 
receiving a mixture of the rA29-36 (10 !g) and rB15-24 (10 !g) proteins. i.p. 
immunisations consisted of doses on days 0, 7 and 28 with the rA26-29 + rB15-24 
proteins (10 !g of each). 
 
2.22 Determination of mouse antibody titers by indirect ELISA 
(Chapter 5) 
For analysis of responses, serum was taken on days -1, 34 and 56 (o.g. groups) or 
day 42 (i.p groups) and feces collected on days 21, 42 and 67 and kept at -80°C. 
Sample extractions were made at 1/5 (weight/vol) dilution in extraction buffer (2% 
FCS DMEM medium plus protease inhibitor cocktails; trypsin 0.1mg/ml, leupeptin 
1µg/ml, benzamide 1µg/ml, aprotinin 10 µg/ml, phenylmethylsulphonyl fluoride 
1mM and ethylenediaminetetraacetic acid (EDTA) 0.05 mg/ml). Samples were 
gently shaken for 30 min at 4°C to disrupt solid material and then centrifuged 
(14,500 g 15 min). Supernatants were filtered (0.45 µM) before analysis. Antibodies 
from serum and feces were determined by indirect ELISA. Greiner 96 well plates 
(Maxisorp) were coated with purified 10ug/ml rA26-39 or rB15-24 proteins 
(50µl/well) in PBS buffer, overnight at RT. After blocking for 1h at 30°C with 2% 
bovine serum albumin (BSA) two-fold serially diluted samples were added, starting 
at 1/50 in diluent buffer (0.01 M PBS [pH7.4], 0.5% (w/v) BSA, %5 (v/v) fetal 
bovine serum (FBS), 0.1% (v/v) triton X-100, 0.5% (v/v) tween 20). Replicate 
samples were used together with a negative control (pre-immune serum). Plates were 
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incubated for 2 h at RT before addition of appropriate horseradish peroxidase 
conjugated anti-mouse antibodies in conjugate buffer (5% FBS (v/v), 1% BSA (w/v) 
0.05% tween-20 in 0.01 M PBS). Plates were incubated for 1 h at RT and then 
developed using tetramethyl benzidine (TMB) substrate (0.1 mg/ml 3.3’, 5.5’-
tetramethylbenzidine in 0.1 M sodium acetate buffer (pH 5.5) in distilled water). 
Reactions were stopped using 2 M H2SO4. and optical densities were read at 450nm. 
Dilution curves were created for each sample and end-point titers for each specific 
antibody were estimated at the maximum dilution of serum giving an absorbance 
reading of 0.1 units over the OD of naïve samples.  
 
2.23 Neutralisation assays (Chapter 5) 
The ability of the antibody samples to neutralise C. difficile toxins in vitro was 
determined as described recently (Lyras et al., 2009) with some modifications. HT29 
and VERO cells were grown in McCoys 5A and Dulbeccos Modified Eagle complete 
medium (10% v/v fetal calf serum and 1% v/v penicillin and streptomycin). Cells 
were cultured at 37°C, 5% (v/v) CO2 in air (100% humidity). HT29 and VERO cells 
were seeded in 96-well plates (0.5x104/well 2.5x104/well respectively). After 24 h 
cells were washed twice in sterile PBS. Before the assay, toxins were incubated with 
serially diluted pooled serum or fecal samples (1:1 v/v) in medium containing 2% 
FCS and incubated for 1 h at 37°C before addition to the pre-washed cell monolayer. 
Cells were evaluated at 24 h (HT29) and 48 h (VERO). Toxins used were a A+B 
toxin (toxin 630) obtained from the culture supernatant of strain 630 that had been 
partially purified by ammonium sulphate precipitation (60%). The presence of toxin 
A and B was confirmed in the supernatant of 630 cultures by Western blotting. Toxin 
A and toxin B had been purified from cell supernatants. Appropriate toxin 
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concentrations were determined by the highest dilutions causing 100% cytopathicity 
(i.e., cell rounding), Toxin 630 [120 ng/ml], Toxin A [4.5 ng/ml], Toxin B [6.2 
pg/ml]. All assays were carried out in duplicate. 
 
2.24 Hamster challenge (Chapter 5) 
Groups of 6-10 female, Golden Syrian hamsters (70-80 g; Charles River, UK), were 
immunised o.g. (0.2 ml) with either, i) recombinant (PP108, PP142) and non-
recombinant PY79 spores (5x1010/ dose/ hamster), or ii) a mixture of the 
recombinant proteins rA26-39 (10 !g) and rB15-24 (10 !g). One further group was 
dosed with the protein mixture delivered by the i.p. route (0.2 ml). Hamsters were 
dosed o.g. on days 0, 14, 35 and 57 and i.p. on days 0, 7 and 28. The challenges were 
performed as described by Goulding et al (2009). with some minor modifications. In 
brief, 14 days after the last dose hamsters were transferred to individual sterile cages 
(including all food, bedding and water) and treated with clindamycin (30 mg/kg).    
12 h later hamsters were o.g. infected with 100 C. difficile  spores (strain 630). 24 h 
after challenge and every two days thereafter, hamsters were repeatedly transferred 
to new sterile cages.  Hamsters were intensively monitored 38 to 60 h after 
challenge. Hamsters showing clear symptoms were killed and considered 
unprotected.  
 
2.25 Statistics (Chapter 5) 
The unpaired t test was used to compare between groups. A P value of > 0.05 was 
considered non-significant. 
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CHAPTER 3 
CHARACTERISATION OF  
C. difficile  SPORES 
 
 
3.1 Introduction 
 
Spores of C. difficile are dormant life forms that can remain metabolically inactive 
unless triggered to germinate. Spores are produced at the end of the stationary phase 
of growth after which a mature endospore is produced. Examined under microscopy 
(phase-contrast) the spore is approximately 1 µm in length and ellipsoidal in shape. 
Characteristically, the spores are phase bright and resemble other classical bacterial 
endospores of the Bacilli and Clostridia. Spores are only produced under anaerobic 
conditions and spores are resistant to high temperatures (~60oC) and desiccation 
(Henriques & Moran, 2000). Spores of C. difficile carry a structure common to other 
bacterial endospores, a core containing the germ-line chromosome, a thick layer of 
loosely-linked peptidoglycan (the cortex) and a thick shell referred to as the spore 
coat which is thought to be proteinaceous in composition. Under electron-
microscopy, the spore coat is electron dense and therefore grey-black in appearance 
and the cortex electron-transparent and therefore white. A thin layer of membrane, 
the inner forespore membrane lies between the core and cortex and will form the cell 
wall of the vegetative cell when the spore germinates. C. difficile spores carry an 
additional layer, the exosporium that encases the mature spore in a loose-fitting sac-
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like layer and is thought, based on work conducted in other spore formers, to be rich 
in glycoproteins (Henriques & Moran, 2007). The function of the exosporium is 
unclear in all spore formers and is the least understood structure. Not all spore 
formers carry an exosporium, for example, B. subtilis lacks an exosporial layer, but a 
role in adhesion is a likely candidate role (Henriques & Moran, 2000). Studies 
examining the attachment of C. difficile spores to agar surfaces has shown that the 
exosporium of C. difficile may play an active role in anchoring the spore while the 
spore then proceeds to germinate (Panessa-Warren et al., 1997). Some studies with 
other clostridia have shown hair like appendages that may aid attachment (Pope et 
al., 1967, Yolton et al., 1968). A likely candidate is the BclA protein, a collagen-like 
protein, that in spores of B. anthracis and B. cereus are linked to adhesion (Todd et 
al., 2003, Sylvestre et al., 2002). Interestingly, the BclA protein of B. anthracis has 
also been shown to be involved in enhancing uptake of spores by phagocytes (Bozue 
et al., 2007) so a role in opsonophagocytosis can not be excluded for C. difficile. A 
BclA protein has been identified in C. difficile strain 630 based on a proteomic study 
(Lawley et al., 2009b) and it seems highly probable that C. difficile spores carry hair 
like appendages on the spore surface. 
 
The importance of the C. difficile spore should not be overlooked for a number of 
reasons. First, spores are the main agent of transmission and survival in the 
environment and the control of CDI can only be achieved after the role of the spore 
in infection is fully understood. Second, almost all studies on colonisation and 
adhesion of C. difficile have focused on the vegetative cell and not the spore. Third, 
spores are known to convert from a benign form in the GI-tract to a supershedder 
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state following antibiotic treatment and the onset of CDI (Lawley et al., 2009a). This 
supershedder state leads to the production of large quantities of C. difficile spores 
being shed in the faeces and which are highly transmissible. It is not clear why or 
how this occurs. Finally, hypervirulent strains of C. difficile that are linked to 
numerous epidemics over the last decade are all strains that show increased levels of 
sporulation.  
 
For these reasons, it is clear that the considerable work needs to be conducted on the 
C. difficile spore. This has not arisen because until recently because no suitable 
method for growing crops of C. difficile in liquid culture have been developed. This 
has been compounded by the lack of genetic methods that have prevented mutational 
analysis. In the last 5 years the genome of C. difficile has been completed (Sebaihia 
et al., 2006), the spore proteome deciphered (Lawley et al., 2009b) and the 
CLOSTRON method for insertional gene developed (Heap et al., 2010).  
 
In this chapter the aim was to develop a reproducible method for producing C. 
difficile spores. Spores would then be examined for their surface properties (charge 
and hydrophobicity), adhesion and then the proteins found on the spore coat layers 
solubilised and examined by mass-spectrometry to identify the putative genes which 
could be retrieved from the genome sequence. This was work which could provide 
the first dissection of the surface composition of C. difficile spores. 
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3.2 Results 
!
3.2.1 C. difficile spore formation  
Using an empirical approach we adapted existing methods (Wilson et al., 1982) to 
generate high levels of spore formation on a solid medium using CD630 (tcdA+ 
tcdB+). After seven days growth on agar we routinely obtained >75% sporulation 
(Figure 3.1) with crops consisting of mature, released, spores which were then 
purified further providing suspensions devoid of viable vegetative cells.  
 
 
Figure 3.1 Sporutaion of C. difficile on solid medium. 
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C.difficile 630 was grown on agar at 37oC. Each day samples were removed and 
examined for the number of spores by either phase contrast microscopy using a 
haemocytometer to count phase bright spores and vegetative cells, or, by heating the 
spore suspension for 60oC for 20 min and plating for CFU/ml with comparison to    
un-treated CFU/ml. 
 
TEM analysis of spores (Figures 3.2A and 3.2B) revealed a structure common to 
those produced by the majority of Gram-positive spore formers (Henriques & Moran, 
2007), namely an inner core surrounded by a primordial germ cell wall 
(peptidoglycan derived from vegetative cell walls) and a thick cortical layer (loosely 
cross-linked peptidoglycan specific to the spore) (Figure 3.2B). Finally, above the 
cortex a thick, more electron dense, layer was present on all spores, this being the 
spore coat. Closer examination revealed further definition to this layer including 
laminations resembling the striated outer coats of Bacillus spores (Henriques & 
Moran, 2007). In other work spores of C. difficile have been reported to carry an 
exosporium (Lawley et al., 2009b, Panessa-Warren et al., 1997), a loose fitting sac-
like structure enveloping the mature spore (Henriques & Moran, 2007). In our 
studies we have observed an exosporial layer resembling that of earlier studies and 
an example is shown in Figure 3.2C. However, we found observation of this 
structure to be inconsistent. The exosporium was only apparent in samples harvested 
and processed immediately (Figure 3.2C) and, for those spores where it was 
detected, the layer was only partially attached. In contrast, the images of Figures 
3.2A and 3.2B were from CD630 spore preps that had been left overnight at 4oC 
before spore purification.  
Chapter 3                                                                                       Characterisation of C. difficile spores 
 
 67!
 
Figure 3.2 Ultrastructure of C. difficile 630 spores. Panels A to C show 
representative images of CD630 spores after seven days incubation on solid medium. 
Panel B shows the basic structural features found in a mature endospore; CR, core; 
GCW, germ-cell wall; CX, cortex and CT, coats. Panel C shows a spore containing a 
partially attached exosporium (EX). Panels D and E show seven-day-old spores 
subjected to ten cycles of sonication. Panel E shows angular projections found to be 
more abundant in sonicated samples (performed by Prof. A. Brisson, Univ. 
Bordeaux, France). 
 
 
3.2.2 Surface properties of CD630 spores 
The surface hydrophobicity of CD630 spores was determined using the SATH assay. 
The method measures the hydrophobicity of spores and has been used elsewhere as a 
reliable indicator of spore hydrophobicity (Huang et al., 2010, Seale et al., 2008). 
Spores of B. subtilis (hydrophobic) and B. clausii (hydrophilic) were used as 
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comparators. As shown in Figure 3.3A CD630 spores were markedly hydrophobic at 
low, medium and high pH (>90%). 
 
Figure 3.3A Surface hydrophobicity of CD630 spores. The SATH assay was used 
to calculate % hydrophobicity of purified CD630 spores. As controls, spores of B. 
subtilis PY79 and B. clausii O/C were used for comparison. 
 
 
The hydrophobicity of vegetative cells was also measured and as shown in Figure 
3.3B was substantially lower than spores. Moreover, sonicated CD630 spores (ten 
rounds of sonication) showed a reduced level of hydrophobicity. As will be shown 
later sonication efficiently removes not only the exosporium but also the other spore 
coat proteins from CD630 spores. 
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Figure 3.3B Surface hydrophobicity of CD630 spores and vegetative cells. The 
SATH assay was used to calculate % hydrophobicity of purified CD630 vegetative 
cells, spores and sonicated spores. 
 
 
The electro-kinetic properties of CD630 spores were measured using a Zeta-sizer to 
determine zeta potential of CD630 spores at different pHs. The zeta potential is a 
measure of the net surface charge and has been used to show that spores of B. subtilis 
carry a net negative charge even at low pH (Huang et al., 2010). As shown in Figure 
3.4 CD630 spores carried a net negative charge at all pH values. The charge 
diminished at lower pH but the spores still retained a negative charge (-2). 
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Figure 3.4 Surface charge. Zeta potential measurements of CD630 spores in water 
at low, medium or high pH.  
  
 
3.2.3 Adhesion of CD630 spores to enteric cells 
Next, we used purified suspensions of CD630 spores and measured the ability of 
spores to adhere to enteric cell lines using in vitro cell culture. Three human 
intestinal cell lines, Caco-2, HT29M and HT29 were used for this analysis and 
adhesion to 2-day old and 7-day old cultures was determined. HT29M is a mucus 
producing cell line and is isogenic to HT29 which does not produce mucus. As 
controls we also measured adhesion of vegetative cells of CD630 and of B. subtilis 
PY79 as controls. It was not possible to measure adhesion of spores of B. subtilis 
strain PY79 to cell lines since B. subtilis spores were shown to germinate and 
outgrow in the cell culture medium (data not shown). 
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Our results (Figure 3.5) which have been repeated more than two times in full and 
with similar results show that CD630 spores are very efficient in binding to the 
enteric cell lines we evaluated. Interestingly, we could not observe increased 
adhesion to the mucus-producing cell and indeed increased binding was observed to 
HT29 cells which do not produce mucin. This adhesion is in marked contrast to the 
binding of vegetative cells of CD630 where adhesion was almost 100-times less 
efficient when measured in parallel. This finding which will be discussed later and 
implies that the spore may play a role in colonisation. 
 
 
 
Figure 3.5 Adhesion of CD630 to enteric cell lines. 
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Caco-2 and HT29 (mucus and non-mucus producing) intestinal cell lines were 
cultured for 2 and 7 days and inoculated with spores of CD630 or vegetative cells of 
CD630 and B. subtilis PY79 as controls. The percentage of viable cells/spores 
adhering was determined as described in Materials and Methods (section 2.12). 
 
3.2.4 Electron microscopic analysis of adhesion 
Cultured Caco-2 cells (2 days) were co-incubated with spores or vegetative cells of 
CD630 and examined using TEM. Our results showed (Figures 3.6A and 3.6B) that 
C. difficile spores bound to the pseudopods of immobilised Caco-2 cells. 
 
Caco-2 cells were immobilised on plastic supports and sections examined by TEM. 
Spores appeared were attached in clusters to protruding pseudopods. No binding of 
vegetative cells was observed. TEM studies were performed by Prof. A. Brisson, 
Univ. Bordeaux, France. 
 
3.2.5 Identification of C. difficile spore coat proteins 
In B. subtilis reverse genetics has been used to examine the spore coat; proteins are 
solubilised and subjected to Edman–amino-terminal sequencing and the resulting 
polypeptide sequences used to clone the genes from phage libraries (Donovan et al., 
1987, Zheng et al., 1988, Cutting et al., 1991). This approach was able to identify 
most of the principle spore coat proteins found in the spore coat of B. subtilis 
(Henriques & Moran, 2007). The approach adopted here was similar in principle but 
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Figure 3.6A Adhesion of C. difficile spores to Caco-2 cells 
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Figure 3.6B Adhesion of C. difficile spores to Caco-2 cells. 
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 using mass-spectrometry to identify the amino acid sequences of fractionated spore 
coat proteins on SDS-PAGE gels. These sequences were then compared to the 
database of CD630 encoded proteins predicted from the CD630 genome sequence. 
 
Coat proteins were extracted from freshly prepared spores of CD630 grown on solid 
medium using a sodium borate-SDS-DTT buffer and fractionated by SDS-PAGE 
(Figure 3.7). Since spores were processed immediately we reasoned that they may 
carry some residual exosporial material as shown in Figure 3.2C. Eleven protein 
bands were excised from Coomassie-stained gels and subject to peptide mass 
fingerprinting using trypsin digestion and MALDI mass spectrometry. This analysis 
revealed that a number of protein bands corresponded to truncated, breakdown, 
products (Table 3.1). One high molecular weight species of 118 kDa could not be 
identified and may be an aggregate. Two further bands, were chain E of proteinase K 
which was a contaminant derived from the spore purification process. The remaining 
eight protein species corresponded to five different proteins which we refer to as 
CotA, CotB, CotCB, CotD and CotE and their genes as cotA-cotE (Figure 3.8) based 
on nomenclature used in B. subtilis (Henriques & Moran, 2007); orthologues are 
shown in Figure 3.9. CotA shared no homology with other proteins in existing 
databases but CotB had orthologues in a number of Bacilli and Clostridia. CotCB 
and CotD were homologous with both each other (70% conserved residues) and to 
manganese catalases including the CotJC inner spore coat protein (and putative 
catalase) found in B. subtilis (Figure 3.10). 
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Figure 3.7 Proteins extracted from CD630 spores. Proteins extracted from CD630 
spores (seven day old cultures grown on solid medium) using a sodium borate-SDS-
DTT extraction buffer. Proteins were fractionated by SDS-PAGE (12.5%) and 
samples loaded as dilutions, lane 1, no dilution; lane 2, ! dilution; lane 3, " dilution; 
lane 4, 1/8 dilution. M, markers. Alongside the gel the identities of the bands excised 
and analysed by mass spectrometry are shown. Partially truncated proteins (D) are 
indicated"!!!
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Figure 3.8 CD630 Spore coat genes. Chromosomal positions of genes referred to in 
this work. 
  
 
As will be discussed later the 25kDa protein is most probably encoded by the second 
cistron of an operon so we refer to the gene and protein as cotCB and CotCB 
respectively. CotE based on its amino acid sequence, corresponded to a novel 
bifunctional protein with amino-terminal peroxiredoxin (1-cys peroxiredoxin) and 
carboxy-terminal manganese chitinase activity (Figure 3.11). The predicted mwt of 
this protein was 81 kDa although the full-length protein was not clearly discernable 
in our SDS-PAGE fractionations but rather a 20 kDa truncated species. CotE had 
orthologues in a number of spore formers (Figure 3.9). As a single bifunctional 
protein, no orthologues were found in other Bacilli or Clostridia but matches were 
found to either the peroxiredoxin or chitinase domains carried in CotE. This included 
a putative peroxiredoxin YkuU in B. subtilis (BS938810) and a number of putative 
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chitinases from exosporium-containing species including Bacillus anthracis, B. 
cereus, Bacillus thuringiensis, Bacillus clausii and Bacillus halodurans (Figure 3.9). 
 
Table 3.1 SDS-PAGE and MALDI peptide fingerprint analysis of C. difficile 630 
spore coat proteins. 
 
abased on peptide mass fingerprinting of tryptic digestions ND, no determination. 
bcoding sequences as described in Sebaihia et al (2006). 
 
Fragment  
mwt. Protein ID
a 
Coding 
sequence 
Nob 
Predicted 
mwt 
Assigned 
Gene 
118 ND - - - 
47 Hypothetical protein CD1613 34 cotA 
40 Hypothetical protein CD1511 35 cotB 
37 Hypothetical protein CD1511 35 cotB 
32 Proteinase K (contaminant 
from purification steps) 
- - - 
30 Hypothetical protein CD1613 34 cotA 
25 Putative spore-coat protein; 
Manganese catalase; similar to 
CotJC of B. subtilis. 
CD0598 21 cotCB 
23 Putative spore-coat protein; 
Manganese catalase; similar to 
CotJC of B. subtilis. 
CD2401 21 cotD 
22 Putative spore-coat protein; 
Manganese catalase; similar to 
CotJC of B. subtilis. 
CD0598 21 cotCB 
20 Putative bifunctional protein: 
peroxiredoxin/chitinase 
CD1433 81 cotE 
19 Proteinase K (contaminant 
from purification steps)  
- - - 
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Figure 3.10 (see previous page) CotCB and CotD Panel A shows the entire CotCB 
polypeptide and its similarity with the manganese catalases (a family of ferritin-like 
diron enzymes). Residues involved in forming the dimanganese centre are indicated 
(*). Panel B shows the homology of CotD with the ferritin-like family of catalases 
and amino acids involved in forming the dinuclear metal binding motif (*). Panel C 
shows the amino acid sequence homology between CotCB and CotD which share 
consensus and identity positions at 80.6% and 70.2% respectively. 
 
 
3.2.6 Immuno-analysis of spore coat proteins 
Polyclonal antibodies to recombinant Cot proteins were raised in mice. In the case of 
CotE we used the amino-terminal, peroxiredoxin domain, of CotE to generate 
antibodies. Using confocal imaging of antibody-labelled C. difficile spores (purified 
after overnight incubation at 4oC) we observed uniform surface decoration using all 
antisera (Figure 3.12) while naive serum gave no labelling  (not shown). Since, as 
mentioned earlier, these spores lacked an exosporium our data suggests that each of 
the five coat proteins must be exposed on the outermost layers of the spore and 
components of the spore coat, rather than the exosporium.  
 
These antibodies were used in a Western blot to probe spore coat protein extractions 
(Figure 3.13A). CotA, CotB and CotD were present as single bands of 47, 40 and 23 
kDa respectively corresponding to the predicted mwts of each of these proteins. CotE 
antisera identified two strongly reacting bands of 81 and 40 kDa. But the 20 kDa 
species (identified as a peptide fragment in Figure 3.13A) was not observed. 
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The most likely explanation is that this 20 kDa species is a C-terminal fragment that 
is not recognised by the polyclonal CotE antibodies that were raised against the N-
terminus of CotE. For CotCB when probed with anti-CotCB we could sometimes 
discern two bands of 25 and 23kDa although this is not apparent in Figure 3.13A. 
Since CotCB and CotD were homologous we wondered whether these proteins 
shared related epitopes. Using recombinant proteins (rCotCB and rCotD) we probed 
each with anti-CotCB and anti-CotD sera. As shown in Figure 3.13B CotD was 
recognised by both anti-CotCB and anti-CotD sera. On the other hand, CotCB was 
detectable using anti-CotCB antibodies but only very weakly by anti-CotD. 
 
Using antisera raised against formalin-inactivated CD630 spores we probed spore 
coat proteins extracted from CD630, B. subtilis and B. clausii (Figure 13C).              
C. difficile serum showed no cross-reaction against either B. subtilis or B. clausii 
spore coat proteins, the latter of which carries an exosporium (Henriques & Moran, 
2007, Driks, 2007). Similarly, antiserum raised against formalin-inactivated B. 
subtilis spores showed no reaction against CD630 spores but some cross-reaction to 
B. clausii (Figure 13D). These results support bioinformatic analysis that has shown 
little conservation between C. difficile and Bacillus spores (Lawley et al., 2009b, 
Sebaihia et al., 2006). 
 
3.2.7 Effect of sonication on spore coat proteins 
An exosporium has been documented for C. difficile spores prepared in liquid 
medium (Panessa-Warren et al., 1997, Lawley et al., 2009b). The exosporium 
remains the least understood component of the bacterial endospore. 
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Figure 3.13 Immunoanalysis of spore coats. Panel A. Spore coats of CD630 were 
extracted and separate lanes probed with polyclonal (mouse) antibodies to CotA-E. 
Molecular weights of the relevant bands are shown. For CotE two principal bands of 
81 and 40 kDa were found. Serum from unimmunized mice did not react with C. 
difficile spore coat proteins. Panel B. Purified recombinant CotC and CotD proteins 
(2 #g) were fractionated on SDS-PAGE gels and probed with either CotC or CotD 
antibodies at 1/1500 and 1/3000 dilutions respectively. Positions of CotC (25 kDa) 
and CotD (23 kDa) bands are indicated. Panel C. Coat proteins extracted from 
spores of CD630, B. subtilis PY79 and B. clausii O/C were fractionated and probed 
with antiserum to formalin-inactivated CD630 spores. Positions of CotA-E are 
shown. Panel D. As panel C but proteins were probed with antiserum to formalin 
inactivated B. subtilis PY79 spores. 
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remains the least understood component of the bacterial endospore (Henriques & 
Moran, 2007) and harsh physical methods such as sonication and shear stress are 
reported to remove the exosporial layer (Redmond et al., 2004). 
 
Although the majority of spores present in our preparations of CD630 did not appear 
to carry a recognisable exosporium we subjected CD630 spores to repeated cycles of 
sonication. Spore pellets and supernatants were then separated. Pellets were then 
extracted with Na borate-SDS-DTT buffer and extracts run on 12.5% SDS-PAGE 
gels together with supernatant fractions (Figure 3.14A). Our results showed that as 
few as two cycles of sonication were sufficient to remove almost the entire 
component of sodium borate solubilised proteins all of which were found in the 
supernatant fraction. Examination of the sonicated spores by phase-contrast 
microscopy revealed that phase-bright spores remained intact and analysis of CFU 
before and after sonication demonstrated no change in viability. Analysis by TEM 
revealed no clear-cut differences between sonicated spores (Figure 3.2C) and 
unsonicated spores (Figure 3.2D). Although, precise quantification was not possible 
we observed that in sonicated samples many spores carried angular projections on 
the surface layers (shown in Figure 3.2D). These crystalline-like structures might 
indicate an underlying layer of coat resulting from sonication and removal of one or 
more layers of coat material. 
 
Following sonication the spore pellet and supernatant fractions were probed with 
antiserum to CotA-E (Figure 3.14). CotA, CotB and CotCB were not detectable in 
the spore pellets and found only in the supernatant fractions. CotD and CotE 
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although not visibly apparent in Coomassie-stained gels were present in both the 
spore pellet and supernatant fractions using immuno-analysis. If CotD was still 
present in the spore coat fraction then why was it not detected using anti-CotCB 
serum since CotCB and CotD share related epitopes? We reason that although the 
recombinant proteins, at high concentration, could be detected this does not reflect 
the composition and abundance of CotCB and CotD in the spore coat but rather the 
different binding strength and specificity of the respective antibodies. In the case of 
CotE only the 40 kDa CotE fragment was found in the spore pellet fraction. We used 
confocal imaging to examine antibody-labelled sonicated spores (Figure 3.12). This 
analysis revealed that in each case, following sonication, surface labelling was 
massively reduced. Labelling correlated well with the western blotting analysis 
(Figure 3.14B) with CotA, CotB and CotCB showing almost no labelling and weak 
labelling with CotD and CotE antibodies suggesting that some CotD and CotE 
remained in the sonicated spores. These results then show that all five Cot proteins 
are located on the spore surface and can be liberated either by sonication or using a 
sodium borate-SDS-DTT extraction buffer. 
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Figure 3.14 Removal of Cot proteins using sonication (see next page for legand) 
 
 
Chapter 3                                                                                       Characterisation of C. difficile spores 
 
 89!
Figure 3.14 (see previous page) Removal of Cot proteins using sonication. Panel 
A. C. difficile spores were sonicated (30 sec cycles), 2-times, 5-times and 10-times 
and pellets and supernatants separated. Pellets were treated with Na-borate-SDS-
DTT extraction buffer and extracted proteins mixed with SDS-PAGE loading dye 
(4X) and fractionated by SDS-PAGE (12.5%). Supernatants were mixed with 
loading dye and run directly. Panel B. Spores were sonicated and pellet and 
supernatant fractions (Panel A) were probed with antiserum to each of the five Cot 
proteins. Molecular weights of Cot proteins are shown. For both panels UT, 
untreated spores. M, markers. 
 
 
3.2.8 The enzymatic properties of spores 
Based on the amino acid sequences of CotC, CotD and CotE and their surface 
location we would predict that spores carry enzymatic activity, either latent or active. 
Accordingly, we conducted a number of assays to measure catalase, peroxiredoxin 
and chitinase activity. 
 
Using pure suspensions of spores the enzyme activities were evaluated by a PhD 
student working in the Cutting laboratory, Elisabeth Tolls. The summary of this data 
is presented in Table 3.2 and in Permpoonpattana et al (2011a). 
Table 3.2 Enzymatic properties of CD630 spores. 
 
Enzyme Vegetative cells Spores 
catalase - + 
peroxiredoxin - + 
chitinase - + 
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3.3 Discussions 
 
This study has provided an initial examination of the of C. difficile spores. This work 
has focused on two aspects, surface properties and the composition of the spore coat. 
 
3.3.1 Surface properties 
CD630 spores were found to be negatively charged and hydrophobic at all pH ranges 
evaluated. In one study of spores of 12 Bacillus species all were found to be 
hydrophobic yet this property has been proposed as being related to the exosporium, 
that is, species or strains carrying an exosporium were more hydrophobic than those 
that did not (Koshikawa et al., 1989). In our study here we showed that C. difficile 
spores were as hydrophobic as B. subtilis which does not carry an exosporium. 
Moreover, we also found that vegetative cells were far less hydrophobic and that 
sonication reduced the hydrophobicity. Interestingly, spores of B. clausii were 
distinctly hydrophilic yet this species carries an exosporium. Thus, the role of 
exosporium in determining hydrophobicity is unclear. One potential issue is whether 
the C. difficile spores we produced do uniformly carry an exosporium and our belief 
is that using the methods described here the majority of spores probably lack an 
exosporium. Thus, the exosporium may actually increase the hydrophobicity further. 
In any event, we can state that CD630 spores are hydrophobic. 
 
The most interesting finding we have made relates to adhesion. CD630 spores were 
found to bind efficiently to human enteric cells in vitro by as much as 100-times 
greater levels vegetative cells evaluated in parallel. This was unexpected since 
substantial data now supports the notion that live vegetative cells mediate adhesion 
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and colonisation to the gut mucosa. While this is true our data suggests that spores 
may themselves play a hitherto unnoticed role in gut colonisation and it possible that 
the hydrophoic nature of C. difficile spores may play a role in this process. Calabi et 
al (Calabi et al., 2002) have demonstrated strong binding to the surface epithelium of 
gastrointestinal tissues including the epithelium lining of the digestive cavities and 
the lamina propria. This has been shown to be mediated by the high MW S-layer 
proteins (Calabi et al., 2002). Using Vero cells three surface proteins of C. difficile 
were found important for host cell attachment with mwts of 70, 50 and 40 kDa 
(Waligora et al., 1999) one of which was identified as a 66 kDa cell wall protein, 
Cwp66 (Waligora et al., 2001). Antibodies specific to Cwp66 were able to block 
adhesion, but only partially and this inhibition only occurred with heat-shocked 
bacteria. It has been proposed that there is likely to be multiple adhesins on C. 
difficile (Calabi et al., 2002).  
 
3.3.2 Spore composition 
We have identified five proteins that are exposed on the outermost layer of the spore 
coat. These have been named these as Cot proteins and their genes, cot, since this 
study clearly shows that they are located in the outermost layers of the spore coat. 
However, it should be noted that with two distinct structures, coat and exosporium, 
found on the outermost layers of the spore assigning names should be approached 
with caution. With the exception of an unidentified 118 kDa species these five 
proteins represented the major proteins extractable using procedures followed here. 
We believe however, that the coats of C. difficile are far more complex and that these 
five represent just a fraction of the total protein content of the spore coat. We base 
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this assumption on existing bioinformatic analysis and the extraction studies 
performed here. In B. subtilis more than 70 proteins are thought to be found in the 
coat layers (Henriques & Moran, 2007) and 18 orthologues have been identified in 
C. difficile (Henriques & Moran, 2007, Lawley et al., 2009b). Using anti-CD630 
serum no cross-reaction was found with B. subtilis spore coat proteins suggesting 
that the functional composition and organisation of the coat may be very different in 
C. difficile. Interestingly, the recent spore proteome studies made on CD630 (Lawley 
et al., 2009b) identified five potential spore coat proteins which included CotCB and 
CotD but not CotA or CotB (n.b., CotE, as a chitinase, was identified but not as a 
spore coat bifunctional protein). Regarding extraction procedures, our method was 
based on the use of sodium borate, SDS and DTT and previously used for 
Clostridium perfringens (Tsuzuki & Ando, 1985), and shown here to efficiently 
extract five proteins. However, the presence of a number of truncated protein species 
suggests that this method may be overly harsh (it should be noted that inclusion of a 
proteinase K treatment step might contribute to this observed partial degradation of 
some proteins). It is also possible that these products arise from cleavage reactions 
occurring during spore maturation. SDS-PAGE analysis revealed that sonication of 
spores was able to remove all five Cot proteins recovered by extraction with buffer. 
Interestingly though, residual spores, which were still viable, released no additional 
protein when extracted with borate-SDS-DTT buffer. Sonicated spores when 
examined by TEM showed that the spore coat layers were still essentially intact 
suggesting that sonication removes one component (possibly one or more layers of 
coat) of the spore coat and that the remaining underlying coat is impervious to 
further extraction or sonication. We believe then that deciphering the inner layers of 
Chapter 3                                                                                       Characterisation of C. difficile spores 
 
 93!
the spore coat will require the development of new extraction procedures. One 
additional structure of the spore is the exosporium, although note that this should not 
be considered part of the spore coat per se. We have shown here that C. difficile 
spores do carry an exosporium but at best, this is loosely attached, to the spore, and it 
is possible that the stability of exosporium is linked to the conditions required to 
prepare (e.g., solid vs liquid medium) and/or store spores. By comparison the 
exosporium of B. anthracis spores is reasonably well characterised yet there are 
conflicting reports over how stable this structure is with recent studies suggesting 
that the exosporium is not easily removed by either sonication or shear stress 
(Thompson et al., 2011). If the C. difficile exosporium is particularly fragile then 
what, if any, is the biological significance? Since our initial extraction and 
identification of proteins was made on spores carrying some exosporial material we 
believe one or more exosporial proteins may have been recovered and perhaps are 
present in low abundance in the our protein extractions shown in Figure 3.7. One 
candidate could be the collagen rich glycoprotein BclA1 (CD0332) which has 
orthologues in a number of other spore formers including B. anthracis where it forms 
filaments that are attached to the exosporium and facilitates interaction with host 
cells including enhancing spore uptake by macrophages (Bozue et al., 2007). 
Interestingly, BclA is extracted from exosporium-containing Bacillus spores as a 
high mwt. species and its identification using conventional proteomic tools is 
problematic (Sylvestre et al., 2002, Daubenspeck et al., 2004). It will therefore be of 
interest to determine whether the 118 kDa species is in fact BclA.   
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One of the most interesting findings from this work are the enzymatic properties of 
the spores and the identification of three enzymatic coat proteins (CotCB, CotD and 
CotE) that most probably reside in the exosporium. Although absolute confirmation 
will require inactivation of the chromosomal genes and preferably, evidence of 
enzyme activity of the purified proteins this assumption is supported by several lines 
of evidence. First, vegetative cells were shown to exhibit no enzyme activity so this 
is unlikely to arise from any contaminating cells. Second, analysis of the spore 
proteome (Lawley et al., 2009b) has revealed no additional genes that could encode 
these enzyme activities although it must be emphasized that the spore proteome is 
incomplete.  
 
What then are the functions of these putative spore-associated enzymes? The catalase 
(CotCB and CotD) and peroxiredoxin (CotE) activities are potential antioxidants and 
at first glance all three would reduce the cellular toxicity of H2O2 by conversion to 
oxygen and water. In the case of C. difficile, which is a strict anaerobe the presence 
of oxygen would, in turn, be harmful to the cell. Since the cell is irreversibly 
committed to dormancy it is conceivable that this is not actually harmful and C. 
difficile spores can be maintained in an oxic environment. Presumably though, there 
is a need to remove H2O2? Studies made on B. subtilis sporulation show that H2O2 
may play a key role in spore coat synthesis and could serve as a substrate in the 
oxidative cross-linking of spore coat monomers (Henriques et al., 1998). Here, the 
enzyme superoxide dismutase (SodA) is essential to the cross-linking of tyrosine-rich 
spore coat proteins and in CD630 a manganese-dependant SodA orthologue has been 
identified in the spore proteome (CD1631).  CotE, as a 1-cys-peroxiredoxin would be 
Chapter 3                                                                                       Characterisation of C. difficile spores 
 
 95!
expected to have the same enzymatic activity as a peroxidase and could participate in 
the cross-linking of tyrosine-rich spore coat proteins. None of the other coat proteins 
identified in this work are tyrosine rich but examination of the C. difficile genome 
has revealed at least one gene (CD0597) that would encode a tyrosine rich protein 
(10.34% tyrosines). This protein is homologous to CotJB of B. subtilis and in C. 
difficile its ORF lies immediately upstream of cotC which, in turn, encodes an 
orthologue of B. subtilis CotJC. The ORFs are separated by 61bp and probably lie 
within the same operon so we propose to name CD0597 as cotCA and the 
downstream cistron as cotCB (Figure 3.8).  
 
For chitinase activity the presence of this enzyme in the spore coat is intriguing since 
it would be expected to be involved in the breakdown of fungi and other biological 
matter whether in the soil or in the intestine. However, spores are dormant so we 
speculate that chitinase activity may be released (or activated) during spore 
germination enabling a potential source of nutrients as the C. difficile cell emerges 
from its coats. We have evidence to support this, firstly, chitinase activity decreased 
as spores matured but increased during both spore germination and secondly, 
following sonication; both of these being events that would rupture the spore coat 
layers. Interestingly, CotE (the putative chitinase) was detectable in the supernatant 
fraction as either a full-length species (81 kDa) or as a single 40 kDa species 
following sonication and we wonder whether the smaller species is actually the 
active chitninase enzyme. Another interesting aspect to CotE, based solely on its 
sequence prediction, is its bifunctionality and one of a growing number of 
‘moonlighting proteins’ (Jeffery, 1999) which carry multiple functions including a 
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mammalian protein, 1-cys-peroxiredoxin, that carries peroxidase and phospholipase 
activities (Chen et al., 2000). There is possibly, a more important consequence of a 
chitinase and peroxiredoxin displayed on the surface of C. difficile spores that should 
not be overlooked. This relates to the potential link between peroxiredoxins, 
chitinases and inflammation. Peroxiredoxin 1 (a 2-cys-peroxiredoxin), secreted from 
tumour cells (Neumann et al., 2003), has been shown to induce proinflammatory 
cytokines in macrophages via interaction with Toll-like receptor 4 and to promote 
chronic inflammation which could support tumour growth (Riddell et al., 2010). 
Regarding chitinases, it is now clear that some inflammatory conditions of the GI-
tract (inflammatory bowel disease, IBD and ulcerative colitis, UC) lead to induction 
of host-cell chitinases by triggering the increased uptake of intracellular bacteria by 
colonic cells (Kawada et al., 2008, Kawada et al., 2007) and in potentiating the 
development of epithelial tumorigenesis (Eurich et al., 2009). Considering that some 
symptoms of CDAD resemble both IBD and UC the C. difficile chitinase may play a 
direct role in infection and not simply in macromolecular degradation. 
Chapter 3                                                                                       Characterisation of C. difficile spores 
 
 97!
3.4 Conclusion 
 
This work described the first detailed dissection of C. difficile spores. We have found 
that proteins can be solubilised from the spore coat but in reality better methods for 
solubilising the coat material will be required to reveal all. Despite this five proteins 
were resolved three of which had novel enzymatic properties. Two of these enzyme 
activities are undoubtedly required for maturation of the spore coat while the third, 
the chitinase is intriguing. It seems unlikely that a spore, which can in principal 
survive 100’s of years, can maintain an enzyme on it spore surface for which it has 
no use; rather we predict that this enzyme is only activated when the spore 
germinates providing a useful mechanism to obtain digest macronutrients as the 
spore germinates. Our interest in this protein though is in its potential role as an 
agent of inflammation and as a potential vaccine target, i.e., as a antigen. This work 
has also illuminated that spores are better at adhering to enteric cells than vegetative 
cells and we wonder whether in vivo the  is the spores key agent of colonisation. 
 
The work described in this chapter has been published in Journal of Bacteriology 
(Permpoonpattana et al., 2011a) and a second publication describing the in vitro 
adhesion of spores is in preparation. The following studies are now in progress or 
planned. 
 
1. Inactivation of each of the cot genes using the ClosTron gene knockout 
system followed by characterisation of the cot mutants. 
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2. Inactivation of the bclA gene of CD630 using the Clostron system to evaluate 
the role of BclA in spore function. 
3. Antibodies to BclA have been made with the aim to use this as a rapid tool to 
detect the exosporium. 
4. A detailed mass-spectrometry study of spore coat proteins from C. difficile 
using soluble and insoluble fractions has been initiated with Prof. S. Brul and 
Prof. C. de Koster of the University of Amsterdam, Netherlands. This study 
will attempt to identify all components of the spore coat. 
5. Antibodies to the Cot proteins are being used to examine inhibition of 
adhesion to enteric cells to determine if any of the spore coat proteins serve 
as specific ligands. 
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CHAPTER 4 
TEMPORAL EXPRESSION OF SPORE 
COAT GENES 
 
 
4.1 Introduction 
Relatively few studies have been made on spore formation in C. difficile. Spores 
have been typically produced on solid medium and visualised by electron 
microscopy. This has revealed the spore structure and the presence of an exosporium. 
Spores are the primary agents of transmission of infective C. difficile and their 
control is of major importance to the prevention of epidemics especially with the 
emergence of hypervirulent strains in the last decade since these strains are known to 
form much higher levels of spore formation than the classical strains (Merrigan et 
al., 2010, Kuijper et al., 2007, Vohra & Poxton, 2011). Interestingly, the 
hypervirulent strains not only produce higher levels of spores but also of the toxins 
suggesting the possibility of co-regulation (Vohra & Poxton, 2011, Merrigan et al., 
2010). Studies have shown that toxin production occurs at the same time as 
sporulation and when a sporulation inhibitor (e.g., acridine orange) is used to inhibit 
spore formation, toxin production is simultaneously reduced (Kamiya et al., 1992), 
although not abolished. In these studies in liquid culture spores were first detected  
12 h post inoculation and maximum levels >48 h. Toxins though were first produced 
12 h post inoculation and maximum levels after 24 h. Expression of the tcdA and 
tcdB genes has been shown to increase as cells enter stationary phase (Dupuy & 
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Sonenshein, 1998). More recent studies have shown that in 027 hypervirulent strains  
maximal levels of toxin A and toxin B are produced after 12h in liquid culture 
(Vohra & Poxton, 2011). Interestingly, these studies also show a correlation between 
a developmental gene, spoOA, which encodes a regulatory protein that initiates spore 
formation and toxin production (Vohra & Poxton, 2011). In C. difficile strains that 
lack SpoOA reduced levels of spore formation and toxin production are found 
(Underwood et al., 2009). 
 
The control of toxin gene expression has recently been shown to be independent 
from sporulation gene expression (Saujet et al., 2011). By examining gene 
expression in a sigH mutant that encodes sigma H (!H) a transcription factor that 
regulates developmental gene expression, it was found that although spore formation 
was essentially abolished, and spoOA expression blocked, expression of the tcdA and 
tcdB genes was upregulated (Saujet et al., 2011). This shows that toxin production is 
not associated with sporulation but it is subject to some level of developmental 
control mediated by !H. 
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Figure 4.1 Hypothetical events during C. difficile spore formation. !H is the first 
developmental-specific sigma factor and controls the 1st phase of temporal gene 
expression. In a sigH mutant that cannot make !H, toxin gene expression is 
upregulated. 
 
 
!H is the first transcription factor to initiate gene expression during spore formation 
in C. difficile and it carries a similar homolog in B. subtilis. Indeed, genomic analysis 
has revealed genes in C. difficile that are similar to many of the key sporulation 
genes and operons in B. subtilis  that are required for spore formation (Paredes et al., 
2005). Although not all genes are currently identified the basic framework of spore 
formation is similar to that of B. subtilis with five principal sigma factors regulating 
development in an ordered cascade (Paredes et al., 2005). The major difference 
appears to be in the timing of sporulation. Whereas in B. subtilis heat resistant 
endospores are first detectable 5-6 h after the onset of sporulation in C. difficile 
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studies suggest 12 h (Merrigan et al., 2010, Kamiya et al., 1992, Vohra & Poxton, 
2011). 
 
The genetic control of sporulation in B. subtilis has been well characterised and 
serves as a useful model to compare with C. difficile (Stragier, 2002). In this work 
we have been focused on the expression of the spore coat (cot) genes identified in the 
C. difficile spore coat. In B. subtilis the expression of cot genes is controlled by two 
sigma factors, !E and !K (Henriques et al., 2004) both of which have homologues in 
C. difficile (Paredes et al., 2005, Haraldsen & Sonenshein, 2003). !E directs the first 
phase of spore coat gene expression followed by !K acting about 1 - 1.5 h later. Both 
sigma factors control expression of cot genes in the mother cell chamber of the 
sporulating cells and the action of both of these sigma factors is further modulated by 
DNA-binding proteins (SpoIIID and GerE). Our aim in this chapter was to examine 
the profile of expression of the toxin genes, regulatory sigma factor genes and the 
spore cot genes using real time PCR, a technique successfully used in C. difficile 
(Vohra & Poxton, 2011, Saujet et al., 2011). 
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4.2 Results  
4.2.1 Establishing synchronous sporulation in liquid medium 
Although a number of publications report the production of spores and of sporulation 
in liquid culture (Merrigan et al., 2010, Vohra & Poxton, 2011, Saujet et al., 2011, 
Kamiya et al., 1992, Lawley et al., 2009) we are not aware of any reports that have 
attempted to accurately define the initiation of sporulation. We established a protocol 
that could produce synchronous sporulation in liquid BHIS medium (Methods). First 
we evaluated a number of media for preparation of an overnight culture of CD630, 
specifically TGY (tryptic-glucose-yeast extract medium; (Paredes-Sabja et al., 
2008), BHIS and BHISS (BHIS supplemented with sodium taurocholate (0.1% w/v) 
to ensure spore germination in the starter inoculum (Wilson et al., 1982). After 16 h 
standing growth at 37oC all cultures were found to contain ethanol-resistant spores; 
TGY contained 485 spores/ml (total CFU/ml = 2 X 108); BHIS, 580 spores/ml (total 
CFU/ml = 3.4 X 107) and BHISS 386 spores/ml (total CFU/ml = 2.4 X 107). Since 
overnight cultures carried spores and therefore, by inference, an even greater number 
of cells ‘committed’ to sporulation, that is, cells that were irreversibly bound to form 
spores (Sterlini & Mandelstam, 1969) we reasoned that inoculation of fresh cultures 
with these overnight starter cultures would lead to non-synchronous sporulation 
unless diluted. Using BHIS as the medium of choice, since this has been used most 
commonly for sporulation in C. difficile, we made dilutions (1/10 to 1/10,000) of the 
overnight culture in fresh BHIS and evaluated growth and sporulation. We found that 
a 1/10,000 dilution of the overnight BHIS culture produced synchronous sporulation 
as judged by the production of ethanol resistant spores beginning at about hour 8-9 
(Figure 4.2).  
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Next, using a 1/10,000 dilution we evaluated growth and sporulation of C. difficile 
strains, 630 (tcdA+ tcdB+) and the 027 hypervirulent strain CD196 (tcdA+ tcdB+) in 
finer detail  
 
Figure 4.2 Growth and sporulation of C. difficile CD630 and CD196. C. difficile 
strains CD630 and CD196 were grown in BHIS medium at 37oC. Growth was 
measured by OD600nm (!) and determination of CFU/ml (!) over 20 h. Sporulation 
was assessed by the examination of spore formation by phase contrast microscopy 
and quantified by the determination of heat (!) and ethanol (") resistant spores at 
each time point. This experiment was repeated in its entirety three times with similar 
results. The arrows indicate the initiation of sporulation (T0) determined as the point 
at which cells left the exponential phase of growth. 
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measuring optical density, viable counts (CFU/ml) and spores resistant to heat and to 
ethanol treatment (Figure 4.2). Cells reproducibly reached stationary phase of growth 
after approximately 6-8h with both strains containing equivalent numbers of cells. 
Growth characteristics and optical density readings were in good agreement with 
other liquid culture studies albeit it using different media (Vohra & Poxton, 2011, 
Merrigan et al., 2010, Kamiya et al., 1992). Based on the principles of defining the 
onset of sporulation by exhaustion in B. subtilis (Schaeffer et al., 1965) we 
extrapolated the point at which cell growth was no longer logarithmic as the start 
point of sporulation; this point we refer to as T0. The precise point at which cell 
growth left logarithmic phase was difficult to define and in Figure 4.2 T0 could be 
later, at most by 1h. For simplicity we will use this point as a reference for all 
experiments discussed hereafter. 
 
Based on our trial experiments the first spores resistant to either heat or ethanol (no 
differences between these treatments were observed) were detectable at about eight 
hours (T8) after the onset of sporulation (note, as mentioned above that if T0 is in fact 
later than out prediction then the earliest appearance of heat resistant spores would 
then be after seven hours). No substantial differences could be detected between 
CD630 and CD196 although with the latter resistant spores were detectable 
approximately 30 minutes earlier in CD196 and at slightly higher amounts. The 
levels of resistant spores steadily increased and after 20h post initiation of 
sporulation had reached maximum levels of ~103/ml. 
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4.2.2 Toxin production 
Considerable evidence has shown that production of toxins A and B occurs in late 
stationary phase but also during sporulation per se (Kamiya et al., 1992, Merrigan et 
al., 2010, Vohra & Poxton, 2011). Moreover, expression of the genes encoding toxin 
A (tcdA) and toxin B (tcdB) are subject to regulation by both SpoOA and !H, both 
key regulators of the early stages of spore formation in C. difficile (Underwood et al., 
2009, Saujet et al., 2011). We examined production of toxins A and toxins B during 
sporulation in BHIS media (Figure 4.3). Toxin A was expressed at higher levels than 
toxin B in both CD630 and CD196. This is the first report showing the levels of both 
toxin A and toxin B, as opposed to other studies which have measured toxins A + B 
together (Merrigan et al., 2010) or have used a modified cytotoxicity assay (Vohra & 
Poxton, 2011) and demonstrates that, at least in these strains, toxin A levels are at 
least five-times than that of toxin B. Toxin A was produced at much higher levels 
(five-times) in strain CD196 and is consistent with reports showing that toxin 
production is higher in hypervirulent strains of C. difficile (Merrigan et al., 2010, 
Vohra & Poxton, 2011). As a measure of functional toxin production a cell culture 
based cytotoxicity assay was used (Figure 4.3) demonstrating that peak cytotoxicity 
correlated with maximum levels of toxin accumulation. 
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Figure 4.3 Toxin production (see previous page). Production of toxins A and toxins 
B in cell supernatants were measured from the growth and sporulation experiments 
shown in Figure 4.2 using ELISA-based methods described in Methods. Duplicate 
samples were examined and SD error bars shown. The sensitivity of the ELISA was 
5 ng/ml for toxin A and 5 ng/ml for toxin B. Cytotoxicity assays were made using 
HT29 or Vero cells where HT29 cells show greatest sensitivity to toxin A and Vero 
cells to toxin B (Lyras et al., 2009, Torres et al., 1992).  
 
 
4.2.3 Expression of the toxin genes, tcdA and tcdB 
To evaluate expression of the tcdA and tcdB genes that encode toxin A and toxin B 
respectively, a quantitative RT-PCR assay was used (Figure 4.4). Our findings show 
some interesting differences between strains. CD630 showed that tcdA expression 
initiated in early stationary phase approximately 3 h before the onset of sporulation 
(T0). By contrast tcdB expression initiated 3 h later corresponding to the 
commencement of sporulation. In CD196 tcdB expression commenced 6h prior to 
the start of spore formation and, comparing to the growth curve of Figure 4.2, this 
would equate to constitutive expression. On the other hand tcdA expression was 3h 
later. Comparison of both strains then, shows that tcdA expression initiates at the 
same time (3 h prior to T0) while the timing of tcdB expression is delayed 
significantly in CD630. 
 
4.2.4 Expression of the developmental transcription factors 
Based on what is known from the regulation of spore formation in B. subtilis 
(Errington, 1993) six regulatory factors encoded by the spoOA, sigH, sigF, sigE, 
sigG and sigK are present in the C. difficile genome and, based on comparative 
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genomics most probably control sporulation-specific gene expression (Paredes et al., 
2005). To date some studies have examined expression of two regulatory genes, 
spoOA and sigH (Underwood et al., 2009, Saujet et al., 2011, Vohra & Poxton, 
2011) but expression of the other genes has not been examined. spoOA and sigH are 
present in all Clostridia and, based on their functions in B. subtilis, are essential to 
initiating the sporulation cascade. SpoOA when phosphorylated leads to expression 
of sigH which encodes the first sporulation-specific sigma (!) factor, !H, in turn, can 
then transcribe both the sigF and sigE genes encoding the sigma factors, !F and !E. 
After these proteins are activated they are then able to transcribe the sigG (!F) and 
sigK (!E) genes leading to production of !G and !K. Using quantitative RT-PCR we 
examined expression of each of these six regulatory genes in sporulating cultures of 
CD630 and CD196 (Figure 4.5). 
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Expression of spoOA and sigH initiated first with expression commencing at about 
T0 and maximum levels reached at T9 for SpoOA and T6 for sigH. The timing of 
expression was essentially identical in both strains although more rapid in CD196. 
For sigE, sigF and sigG expression was noticeably different in CD630 and CD196. 
In CD196 expression of sigF, sigE and sigG initiated at about T3 and reached 
maximal levels at T9. In CD630 however, expression commenced between T5 and T6, 
at least 2h later than in CD630. Maximum levels were reached at the same time in 
both strains however. Finally, sigK expression commenced at T6 in both strains and 
with similar kinetics with maximum levels being reached at T12. In sum, expression 
of the key regulatory genes in C. difficile could be broken down into three phases. An 
early phase consisting of transcription of spoOA and sigH, a second, middle, phase 
consisting of sigF, sigE and sigG, and a final late phase consisting of sigK. For the 
early and middle phases, expression was more rapid in the hypervirulent strain 
CD196. 
 
4.2.5 Expression of the spore coat genes 
In a recent seminal study of the spore coats of C. difficile CD630 five spore coat 
proteins, CotA, CotB, CotCB, CotD and CotE have been identified of which three 
are putative enzymes, CotCB and CotD being manganese catalases and CotE a novel 
bifunctional protein carrying a periredoxin and a chitinase domain (Permpoonpattana 
et al., 2011"). Each of these proteins is exposed on the surface of the spore coats and, 
based, on what is known of the spore coat. 
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Figure 4.5 Temporal expression of regulatory genes. Transcription of spoOA, 
sigH, sigF, sigE, sigG and sigK in CD630 (") and CD196 (!) sporulating cultures 
was determined using quantitative RT-PCR. The times indicate hours after the 
initiation of sporulation T0. Expression is shown as percentage of maximum. The 
experiment has been repeated two-times in its entirety with similar results. 
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In B. subtilis spore coat biosynthesis the corresponding structural gene is likely to be 
transcribed in the mother cell compartment of the sporulating cell (Henriques & 
Moran, 2007). Using quantitative RT-PCR we examined expression of the cotA, 
cotB, cotCB, cotD and cotE genes in sporulating cultures (Figure 4.6). Based on this 
analysis for four genes, cotA, cotB, cotCB and cotD, we could identify two basic 
phases of temporal expression. Early expression beginning at T6 (cotA, cotB and 
cotD) and late expression beginning at T6 (cotC). Two genes, cotA and cotB showed 
distinctive biphasic patterns of gene expression with expression starting at T3, 
dipping at T12 and then increasing again. This biphasic gene expression is seen in 
some genes of B. subtilis that are transcribed by two sigma factors, for example, 
bofC, a regulatory protein that is transcribed by !F followed by !G (Wakeley et al., 
2000). It is likely then that both cotA and cotB are subject to dual regulation in the 
mother cell chamber. Finally, for cotE in CD630 cells expression initiated at T6 but 
in CD196 cells expression was 3h earlier beginning at T3.  
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Figure 4.6 Expression of spore cot genes. Transcription of cotA, cotB, cotCB, cotD 
and cotE in CD630 (") and CD196 (!) sporulating cultures was determined using 
quantitative RT-PCR. The times indicate hours after the initiation of sporulation T0. 
Expression is shown as percentage of maximum. The experiment has been repeated 
two-times in its entirety with similar results. 
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4.3 Discussion 
We have been able to demonstrate synchronous sporulation of C. difficile in liquid 
medium. It is not clear why this has not been approached previously but in part this 
may be due to the low levels of spore formation that occur in this organism. Our 
method has been synthesised from previous studies and the key attribute for 
achieving synchronous sporulation is generating a starting culture that contains cells 
in the vegetative phase of growth and devoid of cells committed to spore formation. 
Under these circumstances spore formation initiates at the end of the logarithmic 
phase of cell growth enabling the start point of sporulation, T0, to be defined. Having 
defined T0 we have shown that resistant spores are first detectable 7-8 hours post 
initiation. This is significantly faster than that reported for the solventogenic 
Clostridia (Paredes et al., 2005, Santangelo et al., 1998, Jones et al., 1982). The time 
required to form resistant spores in C. difficile is only 1-2h more than that required in 
B. subtilis (Schaeffer et al., 1965) and demonstrates that the basic program of 
sporulation is likely to be similar. In our studies we observed somewhat higher levels 
of sporulation in the hypervirulent CD196 strain but in all other respects spore 
formation as observed microscopically and at a physiological level that was no 
different between CD196 and CD630. 
 
The number of cells that entered sporulation, while measurable, was very low 
(<0.1%). In other studies CD630 has been reported to produce much higher yields of 
spores, for example, 9.3% after 72 h growth in BHIS medium (Saujet et al., 2011) 
and 14% after 72 h growth in BHI medium (Underwood et al., 2009). In both of 
these studies incubation was considerably longer (2 days) and it is possible that in 
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our experiments counts of spores would have gradually risen. Indeed using BHI 
medium after 48 h spore yields of ~0.66% were found for CD630 (Merrigan et al., 
2010) while using AIM (anaerobic incubation medium) ~2 X 102 spores/ml were 
found after 24 h (Vohra & Poxton, 2011) which more closely resembled the yields 
we achieved here. We have shown here that if the objective of the study is to produce 
synchronous sporulation then the quality of the overnight inoculum is critical and 
must be devoid of cells committed to sporulation. If the overnight inoculum carries 
spores or sporulating cells it is not possible to obtain synchronous sporulation.  
 
Production of toxins A and B correlates with stationary phase and spore formation 
(Kamiya et al., 1992, Hundsberger et al., 1997). Expression of the tcdA and tcdB 
genes is controlled negatively by TcdC and positively by the TcdR sigma factor both 
of which are encoded from the pathogenicity locus, PaLoc (Mani & Dupuy, 2001). 
Additional modulation of toxin production comes from CodY (Dineen et al 2007) 
and two regulatory proteins that also participate in the control of development, 
SpoOA and !H (Underwood et al., 2009, Saujet et al., 2011). We saw a marked 
contrast in transcriptional profiles of tcdA and tcdB expression in the CD630 and 
CD196 strains. In CD630 tcdA was transcribed during log phase while tcdB was 
expressed at late stationary phase and at the onset of sporulation. By contrast, in 
CD196 tcdB expression was constitutive and tcdA expression was expressed during 
late stationary phase/early sporulation. Analysis of toxins in cell free supernatants 
showed maximal levels of toxin A and toxin B at hours 15-18 after the onset of 
sporulation in agreement with other studies (Kamiya et al., 1992). Since toxins were 
being measured in supernatants the maximum levels would also correspond to the 
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presumed time at which the mother cell lyses releasing the mature endospore. Our 
results do show that toxin A levels were five-times higher in the hypervirulent strain 
CD196 than those found in CD630 which supports other studies suggesting that toxin 
A levels are higher in hypervirulent strains (Merrigan et al., 2010, Vohra & Poxton, 
2011). Interestingly though, we did not see any difference in toxin B levels and we 
wonder whether toxin A, both its amounts and temporal appearance, plays the key 
role in defining the hypervirulent phenotype. Studies have shown that toxin A and B 
act cooperatively and, in the absence of toxin A, toxin B is unable to induce cell 
damage in the host. What is clear from our analysis of toxin gene expression is that 
the timing and order of toxin gene expression differs markedly between the two 
strains examined here. In CD630 tcdA expression is produced first while in the 
hypervirulent strain this is reversed with a basal level of tcdB expression being 
followed by a burst of tcdA expression. This temporal difference in toxin gene 
expression may play a defining role in the virulence of these strains possibly 
enabling the hypervirulent strain to release active toxins prematurely. In any event, 
two important steps now need to be addressed, first, to understand the physiological 
and/or genetic signals that modulate the temporal profiles of gene expression and 
second, to correlate this with toxin production in GI-tract. Other studies have shown 
considerable variation in the levels of toxin production in C. difficile strains although 
as mentioned above it is not possible to relate this to the present study since 
sporulation would not have been synchronous (Merrigan et al., 2010, Vohra & 
Poxton, 2011). Moreover, we believe it prudent not to pursue a direct link between 
toxin production ‘in vitro’ to what occurs in the animal host. Studies in gnotobiotic 
mice have shown that while high levels of toxin A can be produced in vitro this is not 
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the case in the animal host (‘in vivo’) where levels of toxin A diminish substantially 
and in some C. difficile strains are no longer detectable (Vernet et al., 1989). A 
similar lack of correlation between toxin production and virulence has been observed 
in hamsters (Borriello et al., 1987). 
 
Regarding sporulation-specific gene expression, we have shown that expression of 
the six key transcriptional regulators falls into three temporal phases. SpoOA and 
sigH are expressed at the onset of spore formation. This contrasts to B. subtilis where 
low levels of basal expression occur (Errington, 1993) although we recognise that 
our definition of T0 could be ±1h so stationary phase expression cannot be wholly 
excluded. Our analysis of sigF, sigE and sigG show that all three genes appear to be 
expressed at the same time and about 3h after the onset of sporulation. Bioinformatic 
analysis of the C. difficile genome has shown that most of the genes required for 
activation of !F, !E and !G are present so it is likely that, as with B. subtilis, !F, !E 
and !G are activated post-translationally by intercompartmental signals or 
checkpoints (Losick & Stragier, 1992). Based on this we would expect expression of 
sigG to be later than that of sigF and sigE since both !F and !E are required for 
expression and activation of !G in the forespore. In B. subtilis sigG is transcribed 
approximately 1h after sigF and sigE (Errington 1993) and a more detailed dissection 
of sigG gene expression may reveal such a delay. sigK transcription was shown to 
differ in the two C. difficile strains. In CD196 expression was 3h after expression of 
sigF-sigE-sigG while for CD630 expression was concurrent. sigK in C. difficile 
carries a sigK gene that is interrupted with a 14.6 kb prophage-like insertion, known 
as skinCd (Haraldsen & Sonenshein, 2003). B. subtilis also carries a skin element and 
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of all spore formers evaluated to date only B. subtilis and C. difficile carry this 
insertion (Haraldsen & Sonenshein, 2003). Excision of skinCd occurs following 
expression of a !E-transcribed site-specific recombinase so sigK should be expressed 
soon after post-translational activation of !E which would account for the delay seen 
in CD196. In CD630 no delay was observed suggesting some other mode of 
regulation must account for this premature expression. 
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4.4 Conclusion 
This work firstly demonstrated the establishment of synchronous sporulation in 
C.difficile. We have found that using overnight starter cultures could lead to the non-
synchronous sporulation unless diluted. A 1/10,000 dilution of overnight BHIS 
culture was used to generate the synchronous sporulation as determined by the 
production of ethanol resistant spores at approximately hour 8-9 which differs from 
that of Bacillus subtilis at about hour 6. In addition to synchronous sporulation, we 
have also found that the expressional level of toxin A was higher than that of toxin B 
in both CD630 and CD196 in which toxin A was expressed five times higher than 
toxin B and the cytotoxicity was shown to correlate with the maximum levels of 
toxin accumulation. Moreover, the results showed that tcdA expression initiates three 
hours prior to the commencement of sporulation, at the same time in both strains 
while tcdB expression was significantly delayed in CD630. By examining the 
developmental transcription factors, our findings showed the initiation of spoOA and 
sigH expressions at T0 reaching the plateau at T9 and T6, respectively with a more 
rapid expression in CD196 compared to CD630. Even though sigF, sigE and sigG 
expressions were different between both strains, sigK expression reached the 
maximum at the same time with similar kinetics. Finally, the expressions of five 
spore coat genes were analysed. cotA, cotB and cotD in both strains expressed at the 
same time, T6 with the biphalic phase of cotA and cotB whereas cotCB expression 
initiates at T9. Interestingly, cotE expression in CD196 commences three hours 
earlier than that of CD630. 
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The following study is now in progress or planned Inactivation of each 
developmental transcription factor (sigH, sigE and sigK) using ClosTron 
mutagenesis followed by the study of the developmental transcription factor 
dependency on spore coat genes 
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CHAPTER 5 
MUCOSAL VACCINATION AGAINST CDI 
 
 
5.1 Introduction 
!
5.1.1 Vaccine strategies 
Current strategies to vaccinate CDI are focused on generating humoral immunity, 
specifically anti-toxin A and anti-toxin B IgG responses. Although toxA- toxB+ 
strains of C. difficile can produce disease most researchers are focused on both toxins 
A and B (Lyerly et al., 1988). An effective vaccine to CDAD should target both 
toxin A and B since protection has been shown to correlate with high anti-toxin A 
and anti-toxin B antibody titres (Aboudola et al., 2003, Kink & Williams, 1998, Leav 
et al., 2010). Human MAbs directed against toxins A and B prevent C. difficile-
induced mortality in hamsters (Babcock et al., 2006) and reduced recurrence in 
humans (Lowy et al., 2010). Although most studies to date have focused on 
parenteral delivery of the toxoids there is mounting evidence that mucosal immunity 
is the key determinant of protection and specifically secretory or polymeric IgA 
(Johnson et al., 1992, Johnson et al., 1995, Stubbe et al., 2000, Kelly et al., 1992, 
Johnson, 1997). It cannot be excluded though that mucosal IgG could also play a role 
in protection. 
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Both the tcdA and tcdB genes carry at their carboxy termini an elaborate array of 
repeated domains (Figure 5.1) (von Eichel-Streiber et al., 1992a, von Eichel-Streiber 
et al., 1992b). The carboxy-terminus of TcdA has been shown to be involved in host 
cell recognition and binding prior to insertion of the toxin in the endosomal 
membrane (Jank et al., 2007). Substantial evidence suggests that this carboxy-
terminal domain may be suitable as an antigen target for vaccination against CDAD. 
For example, a MAb directed against this domain prevents cytoxicity (Sauerborn et 
al., 1997). A defined segment of the carboxy-terminal domain of TcdA known as 
14CDTA expressed in a Salmonella vaccine elicited local (mucosal) and systemic 
immunity as well as toxin A neutralising activity when administered orally (Ward et 
al., 1999a, Ward et al., 1999b). The carboxy terminal cell-binding domain of TcdA 
has also been used in a DNA vaccine which when administered by injection 
conferred protection against challenge with a parenteral dose of toxin (Gardiner et 
al., 2009).  
 
 
Figure 5.1 The Carboxy-cell binding domains of TcdA and TcdB. Shown are the 
catalytic, glycosyltransferase domain (black), the cysteine protease domain (grey), 
the translocation domain (white) and the repetitive sequences involved in cell 
binding (stripes). The A26-39 and B15-24 segments expressed in Bacillus vaccine 
strains are labelled. A26-39 was formerly known as 14CDTA. 
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5.1.2 Animals models of CDI 
 
Currently there exist a number of models with which to experimentally study CDI. 
Although a piglet model has been described recently (Steele et al., 2010) only the 
following three, which are applicable to normal laboratory conditions will be 
described. 
 
The hamster model of infection 
This model uses Golden Syrian hamsters and is considered the gold-standard for 
assessing protective immunity (Goulding et al., 2009, Sambol et al., 2001, Sambol et 
al., 2002). Hamsters are immunised and then, approximately 14 days after the last 
dose, given a single dose of clindamycin (30mg/kg body weight). Twelve hours later 
animals are given a dose of 100 spores of a pathogenic strain of C. difficile. Animals 
are monitored hourly for symptoms (diarrhoea) and unprotected animals will 
normally die after 42-45h. The challenge dose is either spores (100 CFU) or 
vegetative cells (105-106 CFU) of C. difficile. It is now considered more appropriate 
to use spores as the challenge dose since using live vegetative cells of C. difficile in 
an aerobic environment is technically impossible resulting in a reduction in the 
administered/challenge dose (Goulding et al., 2009). One of the problems with this 
model though is that the end point is death and it has proven difficult to examine the 
colonisation of animals during infection. In addition, obtaining bleeds from hamsters 
is technically demanding requiring withdrawal of blood either from the retro-orbital 
or saphenous veins. It has also been questioned as to whether an infection that kills 
animals in 2-3 days truly resembles the human disease. 
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The mouse models 
In this model mice (C57 BL/6) are exposed to a mixture of antibiotics (kanamycin, 
gentamycin, colistin, metronidazole and vancomycin) for three days (Chen et al., 
2008). After two days they are injected with clindamycin and challenged 1 day later 
with C. difficile live cells. Disease manifests itself in mice varying from mild to 
fulminant depending on the challenge dose. Symptoms measured include 
colonisation, weight loss and histology and mice that survive CDI were protected 
against relapse. 
 
A further model using mice has been reported recently (Sun et al., 2011). Animals 
(C57 BL/6 mice) are treated for 3 days with the antibiotic cocktail described 
followed by 2 days of water and then clindamycin. Animals are then challenged with 
C. difficile (106 CFU of live cells). Surviving animals are then divided into two 
groups, one receives vancomycin only while the second group receives vancomycin 
+ C. difficile to determine whether surviving animals suffer relapse. Colonisation, 
diarrhoea, humoral and mucosal antibodies and histology are all determinants of 
protection in this model. 
 
5.1.3 Bacterial spores as a vaccine delivery system 
The potential of bacterial spores as vaccines is based on two important attributes: 
first, their heat-stability and second, their use worldwide as dietary supplements 
(probiotics), in both humans and animals (Hong et al., 2005). It is now also believed 
that bacterial spores possess immunomodulatory properties that can be utilised for 
adjuvant development. Using B. subtilis, the Cutting group at RHUL have 
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engineered a number of antigens for display on the surface of spores. Oral (or intra-
nasal) dosing of these recombinant spores into mice has provided protection in the 
case of tetanus (Duc et al., 2003), Clostridium perfringens (using alpha toxin; 
(Hoang et al., 2008)) and Bacillus anthracis (using a parenteral approach; (Duc le et 
al., 2007). More recently, a non-GM approach to using spores has been developed 
making use of a novel attribute of the spore surface, which is the capacity to adsorb 
heterologous antigens (Huang et al., 2010). Remarkably, heat-killed spores are as 
efficient as live spores as an antigen carrier using adsorption. Studies on the nature of 
humoral and cell-mediated immune responses in mice have shown that spores co-
administered with protein antigens augment antigen-specific sIgA (secretory IgA) 
and induce a balanced Th1/Th2 response (Barnes et al., 2007, Huang et al., 2010).  
 
5.1.4 A spore based vaccine to CDAD 
The approach taken here is to focus on the carboxy-terminal cell-binding domains of 
toxin A and toxin B and to clone and express these antigens on the surface of B. 
subtilis spores. Next, to evaluate these spores in mice to evaluate immune responses 
and then to evaluate protection in a hamster model of infection. 
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5.2 Results 
 
5.2.1 Expression of the C-terminal domains of C. difficile toxin A and toxin B on 
B. subtilis spores 
B. subtilis was engineered to express the A26-39 domain of toxin A (TcdA) and the 
B15-24 domain of toxin B (TcdB) on the outermost layer of the spore coat. Both 
A26-39 and B15-24 lie within the C-terminal repeat domains of each toxin and carry 
repetitive sequences (von Eichel-Streiber et al., 1992a) (Figure 5.1). Expression was 
achieved by fusing A26-39 and B15-24 to the C-termini of the outer spore coat 
proteins CotB (43 kDa) and CotC (12 kDa) both of which have successfully been 
used for surface display and mucosal delivery of heterologous antigens (Isticato et 
al., 2001, Mauriello et al., 2004) (in the case of CotB, fusions were made to a C-
terminally truncated, version of CotB). Two different spore constructions were made; 
PP108 (cotB-A26-39 cotC-A26-39) that expressed A26-39 attached to both CotB and 
CotC, and PP142 (cotB-B15-24 cotC-A26-39) that co-expressed two chimeras, CotB-
B15-24 and CotC-A26-39. Surface expression of A26-39 and B15-24 on PP142 spores 
and A26-39 on PP108 spores was confirmed by confocal imaging of spores (Figure 
5.2A-C).  
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Figure 5.2 (A to C) Immonofluorescence microscopic images. Surface display of 
A26-29 and B15-24, confirmed using confocal imaging of samples labelled with 
mouse anti-A26-39 or B15-24 serum followed by an anti-mouse IgG-tetramethyl 
rhodamine iso-thiocyanate (TRITC) conjugate. Spores of PP108 were labeled with 
anti-A26-39 (A), and spores of PP142 were labelled with either anti-A26-39 (B) or 
anti-B15-24 (C). 
 
 
5.2.2 Antibodies to the C-terminal domain of toxin A cross react with the 
corresponding domain of toxin B 
The coat proteins of PP108 and PP142 were extracted and probed with antibodies to 
confirm expression of the chimeric CotB and CotC proteins (Figure 5.2D-E). PP108 
spore coat protein extracts when probed with anti-A26-39 antibodies revealed bands 
of 69 kDa (CotB-A26-39) and 49 kDa (CotC-A26-39). Their molecular weights (mwt) 
were in agreement with the predicted size of the fusion proteins (Figure 5.2D) and 
corresponded in size to proteins in extracts taken from spores carrying each chimera 
alone. Quantification revealed that PP108 spores carried 2.2 X 10-4 pg/spore of A26-
39. When PP142 extracts were probed with anti-B15-24, one principal band of 60 
kDa was detectable (lane 10, Figure 5.2E) corresponding in size to CotB-B15-24. 
Using anti-A26-39, CotC-A26-39 was observed as a 49 kDa species but also a second 
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band of 60 kDa (lane 5, Figure 5.2E). We predict that this higher mwt species is  
CotB-B15-24 and could be explained by the fact that the C-terminal cell-binding 
domains of TcdA and TcdB share some sequence identity (30% identical residues; 
Figure 5.3) and may, as shown elsewhere, carry related epitopes (von Eichel-Streiber 
et al., 1992a). In support of this we demonstrated that anti-A26-39 antibodies could 
cross-react with both purified rA26-39 (36.6 kDa) and rB15-24 (29.4 kDa) 
polypeptides yet anti-B15-24 antibodies reacted only with rB15-24 (Figure 5.2F). 
Protein expression was quantified and each spore of PP142 was shown to contain 
2.45 X 10-5 pg of B15-24 and 1.9 X 10-4 pg of A26-39. In additional work we 
verified using anti-CotB and anti-CotC polyclonal antibodies that the expected 
change in the molecular masses of the chimeric CotB and CotC spore coat proteins in 
PP108 and PP142 spores (Figure 5.4).  
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Figure 5.2 (D to F) Expression of A26-39 on spores of PP108 (CotB-A26-39 
CotC-A26-39) Lane 1 to 4 were probed with anti-A26-39. Lane 1 rA26-39 protein; 
lane 2, coat proteins from PP052 (CotC-A26-39); lane 3, coat proteins from PP059 
(CotB-A26-39); and lane 4, PP108-extracted spore coat proteins. (E) Expression of 
A26-39 and B15-24 on spores of PP142 (CotB-B15-24 CotC-A26-39) probed with anti-
A26-39 (lane 1-5) and anti-B15-24 antibodies (lanes 6 to 10). Lanes 1 and 6, 
nonrecombinant PY79 spore coat proteins; lane 2, rA26-39 protein (36.6 kDa); lanes 
3 and 8, PP052 extracts (CotC-A26-39); lanes 4 and 9, PP132 extracts (CotB-B15-24); 
lanes 5 and 10, PP142 extracts; lane 7, rB15-24 protein (29.4 kDa). (F) Purified 
rA26-39 (lanes 1 and 3) (36.6 kDa) and rB15-24 (lanes 2 and 4) (29.4 kDa) 
polypeptides were probed with anti-A26-39 or anti-B15-24. Numbers at the left of 
the blots are molecular masses (in kilodalton).  
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Figure 5.4 Analysis of CotC and CotB recombinant proteins in PP108 (CotB-
A26-39 CotC-A26-39) and PP142 (CotB-B15-24 CotC-A26-39). Panel A shows blots of 
coat proteins extracted from PY79, PP108 and PP142 probed with anti-CotB (mouse 
polyclonal, 1/4000). CotB runs at 59 kDa, recombinant CotB-A26-39 at 69 kDa and 
CotB-B15-24  at 60 kDa. For PP108 and PP142 the 59 kDa species corresponds to 
CotB encoded by the endogenous cotB gene in these partial diploids where the 
recombinant genes are inserted in trans on the chromosome. Panel B shows western 
blots of spore coat proteins extracted from PY79, PP108 and PP142 spores probed 
with antiserum to CotC (mouse polyclonal, 1/3000 dilution). The 12 kDa CotC band 
and the 49 kDa CotC-A26-39 bands are indicated.  
 
 
5.2.3 Oral delivery of the C-terminal domains of toxin A and toxin B displayed 
on spores induces systemic and mucosal antibodies 
Immune responses were determined in mice dosed orogastrically (o.g.) with PP108 
or PP142 spores. Control groups included, naïve and groups dosed (o.g.) with non-
recombinant spores (PY79). In addition, we included one group dosed (o.g.) with a 
mixture of the recombinant rA26-39 (10 !g/dose) and rB15-24 (10 !g/dose) proteins 
using the same dosing regimen. 10 !g was chosen for each protein since this equaled 
A B 
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or exceeded the dose of rA26-36 or rB15-24 delivered in one o.g. dose of PP108 (11 
!g of A26-39) or PP142 (9.5 !g of A26-39 and 1.25 !g of B15-24) spores. 
 
Specific antibodies (serum IgG, and faecal IgA) against A26-39 and B15-24 were 
measured by indirect ELISA. Compared to control groups (naïve mice, mice dosed 
with PY79 spores or mice receiving proteins alone) significant (p < 0.01) levels of 
A26-39 and B15-24 (cross reacting) IgG were detected in the serum of animals 
dosed with PP108 (Figures 5.5A and 5.5B). In mice dosed with PP142 spores anti-
A26-39 IgG responses were not significantly greater (p > 0.05) than control groups, 
while anti-B15-24 IgG responses were significantly greater (p < 0.01) (Figure 5.5B) 
and showed seroconversion. IgG isotypes were also determined (Figures 5.6 and 5.7) 
and significant (p < 0.01) levels of anti-A26-39 and anti-B15-24 (cross-reacting) 
IgG1 and IgG2a were found in the PP108 groups compared to the control groups. 
However, in the PP142 groups significant levels (p < 0.01) of the IgG1 and IgG2a 
isotypes were found only against B15-24. Analysis of the IgG1:IgG2a ratios over 
time (Figure 5.8) showed a clear increase (3-fold) after the third dose indicative of a 
Th2 biased immune response. Anti-spore IgG responses were also measured and 
found to be markedly low with no responses substantially greater than the control 
groups (Figure 5.9). IgG present in the serum of PP108 immunised mice was found 
to bind in a Western blot to rA26-39 and rB15-24 while from PP142-dosed mice IgG 
bound only to rB15-24 (Figure 5.5C). 
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Figure 5.8 Isotype Ratios. The ratio of IgG1 to IgG2a antibodies obtained in serum 
obtained from mice dosed orogastrically with a protein mixture (rA26-39 + rB15-24) 
or with PP108 or PP142 spores is shown. IgG values come from figures 5.6 and 5.7. 
Increasing ratios indicate a Th1 bias. 
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Figure 5.9 Anti-spore IgG response measurement. All groups were immunised via 
oral dose, with the exception of A29-36+B15-24 PY79(i.p.)(right hand column) 
which received the dose by inter-parentally. IgG titres determined by indirect ELISA 
in mice. Plates were coated with PY79 spores (Duc et al. 2004. Intracellular fate and 
immunogenicity of B. subtilis spores. Vaccine 22: 1873-85). The end-point IgG titer 
was calculated as the dilution of serum producing the same optical density as 1/40 
dilution of a pooled pre-immune serum. 
 
 
Secretory IgA (sIgA) was measured in fecal samples (Figure 5.10) and anti-A26-39 
responses were found to be particularly high (Figure 5.10A) with clear 
seroconversion in animals dosed with PP108 spores (p  < 0.001) but not with PP142 
(p > 0.05). Anti-B15-24 sIgA responses were lower but seroconversion was found in 
animals dosed with both PP108 and PP142 (Figure 5.10B; p < 0.05). The anti-B15-
24 cross-reacting IgG and sIgA responses found in animals dosed with PP108 spores 
expressing only the A26-39 protein further supports our finding that antibodies 
against the A26-39 domains are cross-reactive to B15-24.
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5.2.4 In vitro neutralisation of cytotoxicity 
Both toxin A and toxin B exhibit cytotoxicity on cultured cells with HT29 cells being 
most sensitive to toxin A and VERO cells to toxin B (Torres et al., 1992, Lyras et al., 
2009). Serum (IgG) and mucosal (fecal sIgA) antibodies from mice were assessed 
for their ability to neutralise toxin A and toxin B-mediated cytotoxicity using either 
purified toxins or partially purified supernatants from strain 630 (toxin 630) (Table 
5.1). Cytotoxicity was confirmed by examination of cells over a 24-48 h period with 
susceptible cells showing a rounded cell morphology (Figures 5.11A and B).  
 
Antibodies from PP108 o.g. immunised mice were found to neutralise both toxin A 
and toxin B using either HT29 and VERO cells with higher titers shown by HT29 
cells (toxin A specific). By contrast, antibodies produced by PP142 o.g. immunised 
animals only neutralised toxin B. These results show first, that in mice, o.g. delivery 
of recombinant spores expressing A26-39 or B15-24 can generate systemic and 
mucosal neutralising antibodies. Second, using PP108 spores, expressing only A26-
39, neutralising antibodies to toxin A as well as toxin B could be elicited. 
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5.2.5 Protection in hamsters 
The hamster model of C. difficile infection closely resembles the human disease and 
is the best indicator of protective immunity (Sambol et al., 2001, Goulding et al., 
2009). We dosed hamsters o.g. with PP108 and PP142 spores, treated with 
clindamycin and then challenged them with 100 spores of C. difficile strain 630 
(Figure 5.12).  Control groups included hamsters dosed with non-recombinant PY79 
spores and animals dosed with a mixture of the rA26-39 and rB15-24 proteins (10 !g 
of each). Spores of C. difficile were used instead of live cells since, as shown 
recently, they better mimic the natural infection process (Goulding et al., 2009) as 
well as minimising the difficulties of administering live anaerobic bacteria. All naïve 
animals (10/10) were susceptible to C. difficile and showed symptoms of disease 
after just 40-42h in close agreement with a previous study (Goulding et al., 2009). 
Interestingly, most of the animals dosed with PY79 spores showed delayed 
symptoms as did those dosed with a mixture of the rA26-39 and rB15-24 proteins but 
in both cases all animals succumbed. Hamsters dosed with PP142 spores showed no 
protection with every animal displaying symptoms. PP108 immunised animals 
however showed protection with six out of eight animals surviving the duration of 
the experiment.  
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Figure 5.12 Protection in Golden Syrian hamsters. Hamsters were given four o.g. 
doses (days 0, 14, 35, and 57) of recombinant spores (PP108 or PP142) and then 
challenged with C. difficile 630 (A+B+). Control groups included naïve animals, a 
group dosed with nonrecombinant PY79 spores, and, finally, a group receiving a 
mixture of the rA26-39 and rB14-24 proteins (10 µg each). Further groups were 
hamsters dosed parenterally (i.p.) with rA26-39 plus rB14-24 (10 µg each). 
Colonisation of hamsters is presented as time from inoculation to signs of first 
symptoms, when animals were killed. Animals showing no symptoms after 14 days 
were considered protected (i.e., the PP108 group). For animals showing signs of 
infection, the mean times (±standard deviations) to visible symptoms were, for naïve 
hamsters, 40.9 h (±1.7 h), for PY79 hamsters, 53.2 h (±2.3 h), for PP108 hamsters, 
55.6 h (±1.7 h), for PP142 hamsters, 50.9 h (±0.9 h), and for hamsters dosed o.g. 
with the protein mixture and for hamsters in the i.p. group, 51.8 h (±2.4 h) and 48.6 h 
(± 2.3), respectively. 
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5.2.6 Protection against reinfection 
All surviving hamsters that showed no symptoms of C. difficile infection were then 
re-challenged 16 days after the first challenge using clindamycin to induce C. 
difficile colonisation. Control groups included unimmunised (naïve) hamsters and 
animals dosed o.g. with non-recombinant PY79 spores. We found that only PP108 
hamsters were 100% protected to C. difficile challenge and showed no symptoms of 
infection (Figure 5.13). These results show that o.g. immunisation of hamsters with 
the A26-39 domain of toxin A displayed on the surface of B. subtilis spores is 
sufficient to confer protection against a strain of C. difficile that produces both toxin 
A and toxin B. Moreover, protected animals were fully resistant to re-infection. 
 
5.2.7 Parenteral immunisation of the cell binding domains of toxin A and   
toxin B  
As a comparator of oral versus parenteral delivery mice were dosed (intra-peritoneal, 
i.p.) with a mixture of rA26-39 (10 !g/dose) and rB15-24 (10 !g/dose). High ELISA 
titers of IgG antibodies specific to A26-39 (34,161 ± 9,838) and B15-24 (21,475 ± 
7,152) were found two weeks after the last dose (day 45) significantly greater than 
naïve animals (p < 0.001) and higher than serum samples from PP108 immunised 
mice (p < 0.001). By contrast, no significant (p > 0.05) levels of sIgA were 
detectable in feces. Serum antibodies were shown to be able to neutralise the 
cytotoxic effects of both toxin A and toxin B (Table 5. 1). In the hamsters dosed i.p. 
with the recombinant proteins 25% protection was achieved (Figure 5.12) but 
animals failed to survive re-infection with C. difficile (Figure 5.13). 
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Figure 5.13 Protection against reinfection. Hamsters immunised orally with PP108 
spores or parenterally with recombinant proteins that had survived challenge with C. 
difficile 630 (as shown in Figure 5.12) were then rechallenged with C. difficile 630 
spores 16 days after the end of the first challenge. Kaplan-Meier survival estimates 
are shown. Results are also shown for control groups of naïve hamsters and animals 
dosed with nonrecombinant PY79 spores (dosed on days 0, 14, 35, and 57). 
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5.2.8 Protection against a ToxA- ToxB+ strain of C. difficile 
The studies described so far show that antibodies to toxin A are cross-reactive and 
can neutralise toxin B. We wondered therefore whether PP108 spores that expressed 
only the cell-binding domain of toxin A could protect against a tcdA- tcdB+ strain. 
Accordingly, we repeated the immunisation experiments in hamsters (5 animals) 
using four oral doses of PP108 (5 X 105 spores/dose). In parallel, we dosed hamsters 
(n = 5) 3-times (intra-muscular) with the rA26-39 protein (8 !g/dose). Hamsters 
were challenged with 100 spores of strain M68 (tcdA- tcdB+) that expresses only 
toxin B. 
 
All hamsters failed to be protected to M68 challenge with either immunisation 
regimen showing that antibodies to toxin A are unable to protect against toxin B. 
Figure 5.15 shows the end point IgG titres specific to rA26-39, toxin A and toxin B 
obtained in hamster serum. Although IgG titres were higher in animals dosed with 
rA26-39 these clearly fail to protect.  
Chapter 5                                                                                            Mucosal Vaccination Against CDI 
 
 
149!
 
Figure 5.14 Comparision of ELISA serum IgG responses between 
intramuscular (i.m.) and orgastrical (o.g.) routes of administration in serum 
hamster model. IgG titers specific to rA26-39, toxin A and toxin B obtained in 
hamster serum are shown. 
 
 
5.2.9 Formalin inactivation of spore vaccines 
Formalin (formaldehyde in aqueous solution) is known to be effective as a method to 
inactivate biological entities and is used for inactivating live organisms in a number 
of vaccine formulations. The action of formalin has been recently shown to enhance 
the immunogenicity of biological particles compared to other methods of inactivation 
(Sander et al., 2011). We inactivated PP108 spores using three treatments, 
autoclaving (121oC, 15 psi, 30 mins), UV-C irradiation and by formalin treatment 
(2% formaldehyde in PBS, pH 7.4, RT 3 h). In each case 100% loss of viability was 
confirmed by serial dilution and plating out on agar plates. Mice (n = 4) were dosed 
(i.p.) 3-times (days 0, 14 and 28) with inactivated PP108 spores (1X109 CFU/dose). 
As controls groups of mice were also dosed with rA26-39 protein (5 !g/dose) and 
Chapter 5                                                                                            Mucosal Vaccination Against CDI 
 
 
150!
with live PP108 spores (1 X 109/dose). In these experiments one dose of PP108 
spores would equate to 0.2!g of rA26-39. rA26-39-specific IgG responses were 
determined at day 45 and revealed that very high antibody titres were observed in 
animals dosed with either rA26-39 and formalin inactivated PP108 spores (Figure 
5.15). Formalin inactivated PP108 spores produced the same titres of IgG as found in 
rA26-39 immunised mice but surprisingly, the total dose of rA26-39 delivered using 
PP108 spores was 25-times less than dosing by protein alone. By contrast much 
lower responses were observed in animals dosed with live PP108 spores and no 
responses in animals dosed with autoclaved or UV-C irradiated PP108 spores. These 
results show that formalin appears to enhance the immunogenicity of the rA26-39 
domain expressed on PP108 spores, presumably, by fixing the protein in its natural 
conformation rather than by denaturing it. Moreover, in agreement with recent 
studies on the use of formalin for inactivation of microbial entities immunogenicity 
is enhanced (Sander et al., 2011). 
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Figure 5.15 ELISA IgG responses of spores with different treatments. Serum 
IgG responses obtained from mice dosed orogastrically with spores of PP108 
individually treated with either formaldehyde or UV-C or autoclaving compared to 
live spores and A26-39 proteins are shown. 
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5.3 Discussion 
 
Our use of B. subtilis spores as a vehicle for C. difficile vaccination demonstrated a 
number of important findings that will be invaluable to the design of an effective C. 
difficile vaccine. First, that only toxin A antibodies are required for protection, 
second, the importance of mucosal immunity and, finally, protection against relapse. 
We discuss each of these in turn. 
 
5.3.1 Toxin A antibodies and protection 
Expression of the toxin A (A26-39) and toxin B (B15-24) C-terminal domains on B. 
subtilis spores was shown to generate high titers of specific IgG and sIgA antibodies. 
Using spores (PP108) displaying only the toxin A domain, A26-39, serum and fecal 
antibodies were found to be cross-reactive to B15-24. Moreover, they neutralised 
both toxin A and toxin B in vitro and hamsters immunised with A26-39 were 
protected against C. difficile disease. Further evidence of the cross-reactivity of toxin 
A antibodies came from Western blotting which showed that anti-A26-39 antibodies 
could recognize B15-24. The repeat domains of both toxins share limited sequence 
identity which could explain this cross-reactivity. In particular, the sequences 
YFAPANT, MQIGVF, AAT and YYF are conserved between the toxin A and B 
repeat used here and together they may contain epitopes responsible for the observed 
cross reactivity. 
 
We infer that antibodies to A26-39 are of higher avidity than those to B15-24 since, 
in mice, ELISA antibody titers to A26-39 and B15-24 were equivalent. PP142 spores 
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present both toxin A and toxin B antigens, so why do these spores not provide 
protection against disease after administration? Although anti-B15-24 neutralising 
antibodies were produced, no neutralising antibodies to A26-39 were detected. This 
implies, that for protection, antibodies to toxin A are of greater importance than 
those to toxin B. PP142 spores do express the A26-39 domain yet no neutralisation 
of toxin A was observed. To account for this we predict that insufficient A26-29 was 
expressed since PP142 spores carried nine times less A26-39 than PP108 spores. Of 
course, we cannot completely rule out the potential contribution of anti-B15-24 
antibodies in protection but rather our work shows that anti-A26-39 responses are 
sufficient. It is possible that our prototype vaccines simply do not elicit sufficiently 
high anti-toxin B neutralising titers possibly due to B15-24 being displayed in a 
partially denatured form that impairs the generation of appropriate neutralising 
antibodies. This may reflect its fusion partner, the spore coat protein CotB, although 
this has been used successfully previously (Duc et al., 2003, Hoang et al., 2008). Full 
protection to challenge using PP108 spores might be achieved either by changing the 
dosing regimen or by increasing the dose of heterologous protein expression 
(whether A26-39 and/or B15-24). 
 
This work agrees with a number of studies linking protection against C. difficile 
infection with toxin A. For example, a passive immunisation study using oral 
delivery of anti-toxin A antibodies (Kink & Williams, 1998) and studies showing 
that there is strong association between serum antibody responses to toxin A and 
protection against C. difficile in humans (Kotloff et al., 2001, Kyne et al., 2000, 
Aboudola et al., 2003). Of particular note is the study of Kim et al (Kim et al., 1987) 
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where hamsters immunised (sub-cutaneous) with C. difficile toxoid A were fully 
(100%) protected but no protection was observed in hamsters immunised with toxoid 
B. Our work does show however that a vaccine expressing only A26-39 should be 
protective to all known naturally virulent strains of C. difficile (A+B+ and A-B+). 
However, a challenge experiment using an A-B+ strain is required for confirmation 
this finding is important for the design of future C. difficile vaccines. 
 
5.3.2 Mucosal immunity 
Considerable effort has been directed towards parenteral vaccines to C. difficile and 
the generation of systemic responses. However, far less attention has been spent on 
examining the role of local immunity despite a number of reports demonstrating the 
importance of sIgA. First, a correlation between neutralising sIgA and protection in 
hamsters has been reported using mucosal delivery of toxoids with 100% protection 
using intra-nasal delivery and 40% with o.g. (Torres et al., 1995). Second, and most 
importantly, several studies that demonstrate unequivocally that sIgA is both capable 
of neutralising toxin A and is superior to both IgG and monomeric serum, IgA 
(Johnson et al., 1995, Stubbe et al., 2000). 
 
Oral delivery of A26-39 using PP108 spores promoted high titers of fecal sIgA with 
levels of anti-toxin A and anti-toxin B (cross reacting) neutralising sIgA correlating 
with protection. By contrast, i.p. delivery of the rA26-39 + rB15-24 proteins 
produced high titers of serum neutralising IgG to toxin A and toxin B, no localised 
immune responses (sIgA) and lower levels of protection. In another study however, 
Torres et al (Torres et al., 1995) used parenteral delivery (including i.p.) of toxoids A 
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and B and demonstrated 100% protection in hamsters. A number of factors might 
account for why we did not observe complete protection when using the recombinant 
proteins. For example, in the Torres study the complete toxoids were administered 
together with an adjuvant and a different virulent strain of C. difficile was used for 
challenge (Torres et al., 1995).  
 
5.3.3 Relapse 
PP108 immunised hamsters that survived C. difficile challenge were fully protected 
against re-challenge, a phenomenon particularly important for treatment of CDAD 
where patients succumb to relapse. Up to 20% of patients with CDAD two to eight 
weeks after discontinuation of antibiotic therapy (metronidazole or vancomycin) 
relapse and a further 30% of these patients may do so again after a second course of 
therapy (Buggy et al., 1987, Jobe et al., 1995). Antibiotic treatment may disrupt the 
normal human microflora and lead to overgrowth of toxigenic strains of C. difficile, a 
condition favoring relapse. Vaccination then may provide the only rationale 
treatment to control CDAD so it is encouraging that we found no symptoms of 
disease in rechallenged animals. This is consistent with an earlier study that has 
shown that antibodies to toxins A and B, administered orally, can prevent relapse 
(Kink & Williams, 1998) and also mucosal and parenteral delivery of toxoids A and 
B where 75% protection to relapse was found (Torres et al., 1995). In our studies, we 
only observed protection against relapse for hamsters dosed with PP108 spores and 
not with animals that had been vaccinated with the recombinant proteins using a 
parenteral dosing regimen. Interestingly, animals dosed parenterally all failed to 
generate significant sIgA responses and it is possible that production of mucosal 
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antibodies is important for protection from re-infection. Some probiotic formulations 
have been shown to significantly reduce the occurrence of relapses in double-blinded 
controlled trials (Surawicz et al., 2000, Hickson et al., 2007). Potentially, live spores 
may share some attributes with these ‘probiotic’ bacteria and it is notable that B. 
subtilis is itself used extensively as a probiotic (Hong et al., 2005). B. subtilis spores 
can germinate and resporulate in the GI-tract and possibly even transiently colonize 
(Tam et al., 2006). PP108 spores may therefore be able to promote a more extensive 
production of anti-A26-39 sIgA sufficient to protect against re-infection. With regard 
to their potential probiotic attributes, it is noteworthy that even non-recombinant 
PY79 spores, when administered orally to hamsters provided a noticeable delay to 
the onset of symptoms and it is possible that this phenomenon may reflect 
involvement of an innate immune response such as interaction with Toll-like 
receptors. Althernatively, although highly speculative, we can not rule out 
sequestration of the toxin in the animal GI-tract since Bacillus spores have been 
shown able to adsorb C. difficile toxin in vitro (Huang et al., 2010). 
 
Finally we have used C. difficile spores, in contrast to vegetative cells or toxins, as 
our challenge in the vaccine protection experiments which, as has been shown 
recently, best mimics the natural course of infection in humans (Goulding et al., 
2009). Our study confirms that in the hamster model of infection, there is a 
correlation between neutralising antibodies and protection in hamsters with HT29 
cells providing a more precise in vitro indicator of protection. In summary, we 
demonstrate a strategy for C. difficile vaccination that is based on mucosal 
administration generate antibodies to toxin A. Further, we describe a vaccine that is 
Chapter 5                                                                                            Mucosal Vaccination Against CDI 
 
 
157!
particularly suitable for its end user, i.e., a vaccine that is both heat stable, can be 
administered orally and is in current use as a probiotic. 
 
In summary, we show that oral delivery of B. subtilis spores displaying high levels of 
toxin A repeats can confer immunological protection to hamsters to a lethal dose of 
C. difficile spores. The basis of the vaccination strategy is induction of secretory IgA 
which shows cross reactivity to toxin B. Such a vaccine would be particularly 
attractive to the end user as it can be delivered orally, is heat stable and the vehicle is 
currently used as a probiotic.  
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5.4 Conclusion 
 
This work shows that B. subtilis spores have potential as a vaccine delivery system 
for CDAD. The most important finding was that antibodies to the cell-binding 
domain of TcdA are cross-reactive to TcdB. This may be assumed based on the 
extensive homology between these domains but this work is the first that shows this. 
Although spores as a vaccine confer protection this is not 100% and to consider a 
fully protective vaccine we plan to construct spores with a higher level of TcdB 
expression of the spore surface. Our work also shows the importance of mucosal 
antibodies and further experiments are in progress where we are evaluating mucosal 
IgG responses in hamsters (note, that to date, no commercial secondary antibodies to 
IgA from hamsters are available). The use of formalin may provide a useful approach 
to vaccinating against CDAD using spores and we plan to dose hamsters with 
formalin inactivated spores and evaluate protection. Finally, the use of spores as an 
oral vaccine is attractive and could be viable and to this aim we are also evaluating 
spore vaccines using sub-lingual dosage. Sub-lingual delivery has been used for 
Bacillus vaccines (Amuguni et al., 2011) and is an attractive route for antigen 
delivery since the oral immune system is targeted yet reduced levels of antigen are 
required and oral tolerance is avoided (Cuburu et al., 2009, Song et al., 2008). 
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CHAPTER 6 
GENERAL DISCUSSION 
 
 
6.1.  Sporulation of C. difficile 
Until the seminal studies by Lawley et al (2009) it has proven almost impossible to 
prepare good crops of C. difficile spores. Till this point the presence of spores could 
be assumed from the analysis of heat-resistant CFU in samples and EM pictures 
showing the presence of mature endospores or spores maturing within sporulating 
cells. The spores closely resemble endospores of other Bacillus and Clostridial 
species in size and shape and they all carry a thick proteinaceous coat. In the study of 
Lawley et al (2009) an exosporial layer was shown and the studies shown here also 
suggest that C. difficile spores carry an exosporium but we believe that this layer is 
either very fragile or is produced (or lost) under certain conditions. We assume this is 
because we could not always discern the exosporium and routinely produced crops of 
spores that lacked the exosporium.  Our analysis of spore coat proteins most 
probably was made on spore crops where most spores lacked the exosporium and as 
such we may have missed proteins found in the exosporial layer. One protein we did 
not identify was BclA for which three structural genes are known from the genome 
sequence of C. difficile (Lawley et al., 2009). In other spore formers such as B. 
anthracis and B. cereus BclA is a collagen-like protein that has  three subunits forms 
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filaments resembling flagella and which protrude from the surface of the spore 
(Thompson & Stewart, 2008, Brahmbhatt et al., 2007, Bozue et al., 2007, Sylvestre 
et al., 2002). They do this by assembling in the exosporium. Since C. difficile carries 
both an exosporium and a bclA gene we believe our spore preps have mostly lost the 
exosporium and this would account for why we cannot detect the protein using 
Mass-spec analysis of extracted spore coat proteins. Another possibility is that the 
BclA protein is indeed present but is not amenable to Mass spec analysis as a result 
of its highly unusual structure. One question is the function of the exosporium? Our 
analysis of adhesion shows that spores are almost 100-times more efficient at binding 
to host intestinal cells than live vegetative cells. This is important and suggests that 
spores themselves could play an important role in host colonisation and we argue this 
to be more so than vegetative cells. It has always been thought that the live cell of C. 
difficile would be responsible for colonisation, that is, spores germinate, outgrow and 
the live cell secretes toxins and colonises the GI-tract. Further, the S-layer protein, 
SlpA, which encases the live cell could play an important role in adhesion. While the 
SlpA protein is able to adhere to host cells (Calabi et al., 2002) studies using it as a 
decolonisation factor in vaccine formulations have been disappointing. Indeed, 
injecting SlpA into animal models showed no significant reduction of C. difficile 
counts in the GI-tract suggesting that antibodies raised against SlpA have little effect 
on colonisation (Ni Eidhin et al., 2008). We reason then that C. difficile spores and 
not live cells are key to C. difficile colonisation and infection. The role of the 
exosporium could be in adhesion and the BclA-filaments could play a role. Our 
opinion is that the BclA filaments (which of course were not shown in this study) are 
not themselves key to adhesion, rather they may be involved in aggregation of spores, 
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rather like tethers or anchors, whether by aggregating C. diffcile spores or tethering 
to other bacteria.  Our studies to date have used standard methods of adhesion using 
cultured cell lines and this of course is artificial and does not closely resemble the 
natural condition. However, long-term studies should examine the adhesion and 
colonisation of wild type and mutant C. difficile spores. A mutant could be made 
using the ClosTron system (Heap et al., 2010) developed by the Minton lab in 
Nottingham and cot and bclA mutants examined for adhesion in vitro as well as 
colonisation in a mouse model. This type of analysis would reveal the importance of 
spore coat proteins and the exosporium in cell adhesion. 
 
Our work also showed that the spore coats of C. difficile carry a number of 
interesting proteins of which three carry enzymatic properties. The catalase and 
peroxiredoxin activities are thought to be involved in reducing the toxic effects of 
hydrogen peroxide that are produced during spore coat biosynthesis and are 
necessary for cross-linking of spore coat proteins. The chitinase activity is more 
interesting since it does not seem logical for a dormant spore to carry an active 
enzyme on its surface since by definition this entity (the spore) is dormant. Rather 
we believe the chitinase (which may also have cellulase activity) is only rendered 
active when the spore germinates. In such a scenario the spore when it germinates 
would release an active enzyme that can digest macromolecules and make these 
available for the newly germinated and outgrowing cell. Perhaps even more 
intriguing is that chitinases and peroxiredoxins have important links with 
inflammatory responses. Specifically, production of these enzymes can be linked to 
the production of the pro-inflammatory cytokines. These molecules are often 
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produced during inflammation resulting from acute infection or disease and of note, 
in colitis and other inflammatory bowel disease pro-inflammatory responses occur. 
We wonder then whether CotE plays some role in inflammation and the action of this 
protein plays some role in the manifestations of CDI. To address this the entire CotE 
protein should be expressed and the protein used in an in vitro assay using cell 
culture to measure the stimulatory effects of CotE on the proinflammatory cytokines, 
for example, TNFa, IL-2 and IL-6. The expressed protein should also retain 
enzymatic activity and could be used to verify that, in vitro, the protein is both a 
peroxiredoxin and a chitinase. In addition, a cotE mutant made using the ClosTron 
system could be used to evaluate the CotE phenotype in comparison to the wild type 
strain, 630. A cotE mutant should lack both peroxiredoxin and chitinase activity. 
This work is currently being performed in this laboratory and initial indications show 
that CotE does indeed carry chitinase and peroxiredoxin activity. 
 
In other spore forming bacteria, most notably B. subtilis, the genetic control of gene 
expression that drives sporulation has been well characterized (Errington, 1993, 
Errington, 2003). Here, spore formation is controlled by developmental genes 
normally referred to as sporulation or spo genes (Stragier, 1994, Stragier, 2002). 
Their gene products are either structural proteins or regulatory factors that further 
fine tune developmental gene expression. Central to this is the activation of five 
sporulation-specific sigma factors, !H, !E, !F, !G and !K, each of which directs 
transcription of a subset or sporulation genes (Stragier, 1991, Stragier & Losick, 
1990). This ensures that temporal gene expression as well as spatial gene expression 
since the sigma factors, !F and !G are confined to the forespore compartment of the 
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developing sporangial cell. Gene expression is further refined using developmental 
checkpoints where each sigma factor is itself activated by signals tightly coupled 
with the developing cell. These post-translational events ensure a high fidelity to 
spore formation and are often referred to as checkpoints (Losick & Stragier, 1992). 
Interestingly though, with regard to !K, no post-translational control is present and 
expression of active !K is dependent only on transcriptional control of the sigK gene 
and its chromosomal rearrangement brought about by excision of the skinCd element 
(Haraldsen & Sonenshein, 2003, Paredes et al., 2005).  One important finding from 
this work is that we have been able to develop a protocol for synchronous sporulation. 
The approach requires a substantial dilution of the overnight culture before 
inoculation into fresh medium. Failure to extensively dilute does not stop spore 
formation but rather leads to asynchronous sporulation. Based on our studies it takes 
approximately 7-8h to form a spore in C. difficile which is faster than the other 
solventogenic Clostridia. Expression of the key regulatory factors in C. difficile 
appears similar to that of B. subtilis but interestingly differences between strains 
occurs. One area of work that needs to be conducted is to define why and how 
expression differs so markedly between strains. In our case we showed that 
expression of the toxin, tcd, genes is different between virulent and hypervirulent 
strains which is intriguing and we wonder whether this reflects the increased 
virulence of the hypervirulent. 
The spore coat proteins that are assembled onto the outermost layers of the spore are 
also sporulation genes but normally are referred to as Cot and their genes as cot. 
Most cot genes are expressed in the mother cell chamber of the sporulating cell and 
are controlled by either !E or !K (Henriques & Moran, 2007). Temporal expression 
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of the spore cot genes ensures that these proteins can accumulate and assemble as 
defined layers. Evidence for self-assembly of at least some Cot proteins has been 
found in B. subtilis (Krajcikova et al., 2009).  
Spores of C. difficile are similar to those of other Gram-positive spore formers and a 
comparison made using bioinformatics has shown that Clostridia and specifically C. 
difficile share similar pathways of regulatory gene expression. Based on this analysis 
the principal components for coordinating sporulation-specific gene expression in B. 
subtilis are also found in C. difficile, this includes the major sigma factors as well as 
the regulatory proteins such as SpoOA, SpoIIID etc (Paredes et al., 2005). 
Interestingly, though, a proteomic study of C. difficile spores while arriving at 
similar conclusions also showed some significant differences (Lawley et al., 2009). 
Specifically, of the 70 or so cot genes found in B. subtilis only 18 orthologues were 
found in C. difficile. This shows that substantial differences may occur in the 
structural composition of C. difficile spores despite their apparent similarity at a 
visual and genetic level. 
Our analysis of cot gene expression showed two distinct phases of gene expression 
which we assume is mediated by !E (1st phase) followed by !K (2nd phase). In 
addition, some of the cot genes showed a biphasic pattern of gene expression which 
resembles that of some genes in B. subtilis (for example, cotE) which are transcribed 
by RNAP associated with !E and then by !K. Further work will need to be done to 
clarify spore cot gene expression. Specifically, the dependence of gene expression 
must be determined. To do this Clostron mutations must be made in the sigE and 
sigK genes and then expression of the cot genes determined again, by qPCR. If gene 
expression is blocked in both mutants then the cot gene must be dependent on !E 
Chapter 6                                                                                                                    General Discussion 
 165 
while if it is blocked only in a sigK mutant then it must be !K transcribed. These 
experiments are now in progress and the aim will be to define spore coat gene 
expression in C. difficile and provide a framework for understanding developmental 
gene expression. 
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6.2. The Requirements of a Better Vaccine to C. difficile  
One of the most important findings from this work is first the demonstration that 
delivery of the carboxy-terminal segment of tcdA can confer protection in hamsters 
and second, that antibodies against this C-terminal domain are cross-reactive to the 
same C-terminal domain of tcdB. Although other studies have highlighted the 
importance of the C-terminus of toxin A (CDTA) as being important for generating 
neutralising antibodies (Ward et al., 1999a, Ward et al., 1999b) this is the first study 
to demonstrate this in a challenge model. We also show that using live bacterial 
spores we can get protection to relapse, i.e., animals surviving the first challenge 
were fully protected to challenge. This is in marked contrast to animals vaccinated 
using the parenteral route where surviving animals died. We believe that mucosal 
antibodies play the most important role in preventing primary infection and this may 
be the case for prevention to relapse. In humans IgA specific to toxin A was found in 
57% of colonic aspirates in patients with colitis (Kelly et al., 1992). Also, in 
postpartum women 64% of colostral samples had toxin A-specific neutralising IgA 
(Kim et al., 1984). It has also been shown that intestinal IgA responses to toxin A 
accompany serum IgG responses in patients with CDI (Johnson et al., 1992). These 
studies also looked at the levels of toxin A-specific IgA in patients with C. difficile 
associated diarrhea where levels of sIgA are higher than serum IgG (Johnson et al., 
1992). However, it is well known that mucosal responses, particularly, secretory 
polymeric IgA are short-lived so this may be one explanation why relapse occurs. It 
is also possible that other factors are required for protection to relapse. Studies have 
shown that immunodominant antigens exist in C. difficile notably a 36-37 kDa 
surface exposed cell wall protein, SlpA (Cerquetti et al., 1992, Pantosti et al., 1989). 
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Is it possible then that full protection to both infection and relapse requires more than 
only an anti-toxin response. Support of this comes from work made with non-
toxigenic strains of C. difficile that when used as a prophylactic oral treatment 
prevent CDI in animal models (Sambol et al., 2002). In our studies we have shown 
that PP108 recombinant B. subtilis spores confer protection to infection and relapse. 
This is intriguing and shows that some aspect of the Bacillus spore itself is playing a 
role in protection. Is it possible that the B. subtilis spore shares an antigen or epitope 
similar to C. difficile. While possible we have shown here that antibodies to B. 
subtilis do not cross-react with C. difficile spores and visa versa. Another possibility 
is that live B. subtilis is able to colonise the gut and perhaps spores are able to bind to 
the mucosal epithelium preventing C. difficile binding. This may or may not be the 
case but we wonder whether the mucosa has receptors for C. difficile spores and 
whether B. subtilis spores could bind to the same site. Some support comes from our 
adhesion studies which show that C. difficile spores have very high binding to 
epithelial cells. This assay cannot be conducted though with B. subtilis spores since 
spores germinate rapidly in cell culture media, outgrow and proliferate which 
prevents a direct measurement of spore binding. We believe that recombinant spores 
could be used in a vaccine formulation. One concern may be that spores are 
recombinant, that is, GM (genetically modified). We have evidence that spores can 
be inactivated with formaldehyde and this treatment actually enhance the 
immunogenicity of spores. Formalin is commonly used for fixing proteins and 
maintains the polypeptide antigen in its natural 3D shape. Further, we have 
considered using spores in a sub-lingual delivery where the vaccine would be 
delivered under the tongue facilitating entry of spores and antigens to the buccal cells 
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which are part of the oral immune system. Sub-lingual delivery would also offer two 
advantages, reduced dose of antigen and the potential to reduce oral tolerance. We 
consider it possible that the reason we did not obtain 100% protection in hamsters 
using PP108 spores is because of oral tolerance although we have no evidence of this. 
Another possibility is that of modifying the dosing regimen to improve 
immunogenicity, for example 2-3 early doses followed by 2 at day 14 or 28. These 
studies are in progress currently in the laboratory. 
 
In conclusion this thesis has addressed two aspects, the structural dissection of the 
spore with a first attempt at defining the composition of the spore surface, its surface 
properties and role in adhesion. Second, to evaluate a novel mucosal vaccine to C. 
difficile. The spore structure analysis potentially could illuminate potential 
candidates for vaccine design or as decolonisation factors. The identity of enzymes, 
particularly the chitinase could prove useful in the identification of drugs that reduce 
chitinase activity and therefore inflammation. 
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Clostridium difficile is an important human pathogen and one where the primary cause of disease is due to
the transmission of spores. We have investigated the proteins found in the outer coat layers of C. difficile spores
of pathogenic strain 630 (CD630). Five coat proteins, CotA, CotB, CotCB, CotD, and CotE, were shown to be
expressed on the outer coat layers of the spore. We demonstrate that purified spores carry catalase, perox-
iredoxin, and chitinase activity and that this activity correlates with the predicted functions of three spore coat
proteins identified here, CotCB, CotD, and CotE. CotCB and CotD are putative manganese catalases, and CotE
is a novel bifunctional protein with peroxiredoxin activity at its amino terminus and chitinase activity at its
carboxy terminus. These enzymes could play an important role in coat assembly by polymerizing protein
monomers in the coat. CotE, in addition to a role in macromolecular degradation, could play an important role
in inflammation, and this may be of direct relevance to the development of the gastrointestinal symptoms that
accompany C. difficile infection. Although specific enzyme activity has not yet been assigned to the proteins
identified here, this work provides the first detailed study of the C. difficile spore coat.
Clostridium difficile is the most common cause of nosocomial
antibiotic-associated diarrhea in developed countries (32).
Morbidity and mortality rates have been steadily increasing in
recent years and probably result from the emergence of more
virulent strains of C. difficile as well as the changing patterns of
antibiotic usage. Recent estimates of the incidence of C. diffi-
cile-associated diarrhea (CDAD) in the United States suggest
that there are as many as 500,000 cases per year, with up to
20,000 mortalities (29). C. difficile colonizes the intestinal tracts
of infected patients, and antibiotic treatment can promote the
overgrowth of this bacterium, which in turn leads to clinical
symptoms of disease, from diarrhea to, in more severe cases,
pseudomembranous colitis (32).
CDAD is caused by the secretion of two toxins, toxin A
(TcdA) and toxin B (TcdB), both monoglucosyltransferases
that are cytotoxic, enterotoxic, and proinflammatory (3).
CDAD is particularly problematic to treat and to contain be-
cause of the ability of this bacterium to form robust endospores
(spores) that can persist and be easily transferred from person
to person in a hospital environment (9, 37). Currently, the only
treatment for CDAD is the use of antibiotics such as vanco-
mycin and metronidazole, and a relapse of CDAD (i.e., diar-
rhea recurring within 30 days after the first treatment) is a
particular challenge in a hospital environment (9, 10). More-
over, evidence has now arisen showing that antibiotic treat-
ment suppresses the diversity of resident intestinal microflora
and promotes the growth and proliferation of highly infectious
C. difficile spores (18). This “supershedder” state ends once
antibiotic treatment is terminated, providing an important clue
to both the transmission of C. difficile infection in humans in a
hospital environment and the importance of the spore as the
pathogenic agent.
With the advent of genomics and proteomics and by com-
parison with the extensive data available for unicellular differ-
entiation in Bacillus subtilis, some invaluable information is
now emerging on C. difficile sporulation. C. difficile strain
QCD-32g58 has been found to contain 18 orthologues of B.
subtilis spore coat proteins and 3 orthologues of proteins found
in the exosporium of spores of Bacillus anthracis and Bacillus
cereus (13). Bioinformatic analyses of the genome of C. difficile
strain 630 (CD630) (30) coupled with recent studies of the
spore proteome (19) have revealed only 18 orthologues of B.
subtilis spore coat proteins (30). B. subtilis coats are comprised
of about 70 different proteins, so it is probable that C. difficile
and, indeed, other clostridial spore formers will have equiva-
lent complexities, which in turn suggests that C. difficile spore
coat proteins have diversified considerably.
In this work, we have made the first attempt at characteriz-
ing the spore coats of CD630. Using coat protein extractions,
we have identified five coat (Cot) proteins, three of which,
based on bioinformatics analysis, could have enzymatic activity
(two catalases and one bifunctional peroxiredoxin-chitinase).
We also show that these enzymes may be confined to the
outermost coat layer, where they could play a key role in spore
coat polymerization and maturation.
MATERIALS AND METHODS
General methods and strains. Methods for the preparation of Bacillus spores
were described previously (23). C. difficile 630 is a pathogenic strain that pro-
duces tcdA! tcdB! and was obtained from Neil Fairweather (Imperial College,
United Kingdom). CD630 was routinely grown in vegetative culture by growth
(10 ml) overnight at 37°C in TGY-vegetative medium (3% tryptic soy broth, 2%
glucose, 1% yeast extract, 0.1% L-cysteine) (25). Streptococcus mutans GB1 was
* Corresponding author. Mailing address: School of Biological Sci-
ences, Royal Holloway, University of London, Egham, Surrey TW20
0EX, United Kingdom. Phone: 44-1784-443760. Fax: 44-1784-414224.
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obtained from Phan Nghia (Hanoi University, Vietnam); B. subtilis strain PY79
is a prototrophic (Spo!) laboratory strain and a laboratory stock, as was Bacillus
clausii O/C. Bacillus licheniformis strain HU14 was obtained from the Bacillus
Genetic Stock Center (Columbus, OH).
Sporulation of C. difficile. All manipulations were made in an anaerobic incu-
bator (Don Whitley, United Kingdom). A single bacterial colony was grown on
BHIS agar (brain heart infusion agar supplemented with 0.1% L-cysteine and 5
mg/ml yeast extract [31]) overnight at 37°C. One fresh single colony from the
BHIS plate was inoculated into 10 ml of TGY medium (3% tryptic soy broth, 2%
glucose, 1% yeast extract, 0.1% L-cysteine) (25) and incubated at 37°C overnight.
One milliliter of TGY culture was then subcultured into SMC broth [90 g
peptone, 5 g proteose peptone, 1 g (NH4)2SO4, 1.5 g Tris] containing 0.1%
L-cysteine (modified from methods reported previously by Wilson et al. [38]),
incubated until an optical density at 600 nm (OD600) of 0.4 to 0.7 was reached,
and then plated onto SMC agar. After 7 days of incubation at 37°C, the sporu-
lation efficiency was confirmed by phase-contrast microscopy and measurements
of heat-resistant CFU, and spore crops were harvested immediately or after
overnight incubation at 4°C.
Spore purification. The methods used for spore purification were modified
from those described previously by Lawley et al. (19). Spores were washed in
water two times and then suspended in phosphate-buffered saline (PBS) con-
taining 125 mM Tris, 200 mM EDTA, 0.3 mg/ml proteinase K (catalog number
E00492; Fermentas), and 1% sarcosyl and incubated with gentle shaking at 37°C
for 2 h. Spores were centrifuged (8,000 rpm for 10 min), and pellets were
resuspended in water and washed a further 10 times. After the final suspension
in water, spores were heat treated (60°C for 20 min) to kill any residual cells;
aliquots were stored at 4°C until use. To calculate the spore CFU, aliquots were
serially diluted in PBS and plated onto BHIS agar supplemented with 0.1%
sodium taurocholate (Sigma, United Kingdom). Plates were incubated for 24 to
48 h before CFU were enumerated.
Spore coat extractions. The spore coat extraction procedure was described
previously (36), but in brief, 2 " 109 spores were suspended in 100 #l of freshly
prepared sodium borate-sodium dodecyl sulfate (SDS)-dithiothreitol (DTT) buf-
fer consisting of sodium borate (0.1 M; pH 10), 0.5% SDS, and 50 mMDTT, and
then incubated at 68°C for 75 min with gentle agitation. After centrifugation
(8,000 rpm for 15 min), the supernatant was removed, mixed with 4" SDS-
PAGE loading buffer, and fractionated by SDS-PAGE. For B. subtilis and B.
clausii spores, coat proteins were extracted by using an SDS-DTT buffer de-
scribed previously (23).
Peptide fingerprinting. Spore coat proteins were fractionated on 12.5% SDS-
PAGEminigels, and bands were excised and digested with trypsin before analysis
by matrix-assisted laser desorption ionization (MALDI) mass spectrometry. Di-
gestions and analysis were conducted by the University of Cambridge Protein
and Nucleic Acid Chemistry Facility (PNAC) (http://www.bioc.cam.ac.uk/pnac).
Antibody production. pET28b expression vectors that express the complete
cotA, cotB, cotCB, and cotD open reading frames (ORFs) were constructed by
amplifying the respective DNAs by PCR from C. difficile 630 chromosomal DNA
and ligating them into cleaved pET28b. For cotE, we were unable to clone the
entire ORF, so a fragment encoding the N-terminal peroxiredoxin domain was
cloned instead. Primers used for the construction of pET28b clones are shown in
Table S1 in the supplemental material. High levels of expression were obtained
upon isopropyl-$-D-thiogalactopyranoside (IPTG) induction and the purification
of proteins by the passage of the cell lysate through a HiTrap chelating HP
column on a Pharmacia Akta liquid chromatography system. Polyclonal antibod-
ies were raised in mice immunized by the intraperitoneal route with 2 #g of
purified recombinant proteins on days 1, 14, and 28. Antispore antibodies were
made by treating spores with 2% formalin (2% [vol/vol] formaldehyde in PBS)
overnight at 4°C. Spores were washed 5 times with PBS and were used to dose
mice (2 " 108 spores/dose) on days 1 and 14.
Confocal microscopy. Spores were labeled with mouse anti-Cot serum (1:1,000
dilution), followed by an anti-mouse IgG-tetramethyl rhodamine isocyanate
(TRITC) conjugate. Images were taken by using a Nikon Eclipse fluorescence
microscope equipped with a Bio-Rad Radiance 2100 laser scanning system.
TEM. A transmission electron microscopy (TEM) methodology using suspen-
sions of purified CD630 spores (7 days old) was described previously for B.
subtilis spores (14).
Spore germination. Spores (1" 108) were suspended in 100 #l of 0%, 3%, and
5% sodium taurocholate in PBS (pH 7.4). Spore suspensions were routinely
agitated, and absorbance (A580) readings were determined until no further
change in absorbance [OD580 (tn) % OD580 (t0)] could be detected.
Catalase assay. A catalase assay was performed as described previously (1).
Spores or vegetative cells (1" 107 CFU) were pelleted and resuspended in 60 #l
of 50 mM potassium phosphate buffer (pH 7.0). H2O2 (1.94 ml) was added to the
mixture to start the reaction at room temperature (RT). Samples were centri-
fuged, and the OD240 of supernatants was measured immediately.
Peroxiredoxin assay. The peroxiredoxin assay was described previously (11,
20). Spores or vegetative cells (1 " 108) were pelleted by centrifugation and
suspended in a reaction buffer that included H2O2. Reactions were made at 37°C,
and after 15 min, cells were pelleted, and the OD340 of supernatants was mea-
sured.
Chitinase assay. The chitinase activity was determined by using a presupplied
kit (catalog number CS0980; Sigma) using spore or cell suspensions (1 " 108
CFU/assay) in water. 4-Nitrophenyl-N-acetyl-$-D-glucosaminide (1 mg/ml) was
used as a substrate, and after the reaction was stopped (200 #l of 0.04 g/ml
sodium carbonate), the suspension was centrifuged, and the OD405 of superna-
tants was measured. The reaction time was 3 h at 37°C. The assay was also
performed on spores that had been pregerminated or following sonication. For
germination, 1 " 108 spores were suspended in 100 #l of 0%, 3%, and 5%
sodium taurocholate in PBS (pH 7.4) for 30 min at 37°C, after which the
chitinase activity was determined. For sonication, 1" 108 spores were suspended
in 100 #l PBS (pH 7.4). The solution was sonicated for 2 or 7 times (3-mm
microtip probe and 10% amplitude for 30 s) (S-450D sonicator; Branson), after
which the assay was performed.
RESULTS
C. difficile spore formation. Using an empirical approach, we
adapted existing methods (38) to generate high levels of spore
formation on a solid medium using C. difficile strain 630 (tcdA!
tcdB!), which we refer to here as CD630. After 7 days of
growth on agar, we routinely obtained &75% sporulation (see
Fig. S1 in the supplemental material), with crops consisting of
mature, released spores, which were then purified, further pro-
viding suspensions devoid of viable vegetative cells. TEM anal-
ysis of spores (Fig. 1A and B) revealed a structure common to
those produced by the majority of Gram-positive spore form-
ers (13), namely, an inner core surrounded by a primordial
germ cell wall (peptidoglycan derived from vegetative cell
walls) and a thick cortical layer (loosely cross-linked pepti-
doglycan specific to the spore) (Fig. 1B). Finally, above the
cortex, a thick, more electron-dense layer was present on all
spores, this being the spore coat. A closer examination re-
vealed further definition to this layer, including laminations
resembling the striated outer coats of Bacillus spores (13). In
other work, spores of C. difficile were reported to carry an
exosporium (19, 24), a loose-fitting saclike structure envelop-
ing the mature spore (13). In our studies, we have observed an
exosporial layer resembling that described by previous studies,
and an example is shown in Fig. 1C. However, we found ob-
servations of this structure to be inconsistent. The exosporium
was apparent only in samples harvested and processed imme-
diately (Fig. 1C), and for those spores where it was detected,
the layer was only partially attached. In contrast, the images
shown in Fig. 1A and B were from CD630 spore preps that had
been left overnight at 4°C before spore purification.
Identification of C. difficile spore coat proteins. Coat pro-
teins were extracted from freshly prepared spores of CD630
grown on solid medium using a sodium borate-SDS-DTT buf-
fer and fractionated by SDS-PAGE (Fig. 2). Since spores were
processed immediately, we reasoned that they may carry some
residual exosporial material, as shown in Fig. 1C. Eleven pro-
tein bands were excised from Coomassie-stained gels and sub-
jected to peptide mass fingerprinting using trypsin digestion
and MALDI mass spectrometry. This analysis revealed that a
number of protein bands corresponded to truncated break-
down products (Table 1). One high-molecular-mass species of
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118 kDa could not be identified and may be an aggregate. Two
further bands were chain E of proteinase K, which was a
contaminant derived from the spore purification process. The
remaining eight protein species corresponded to five different
proteins, which we refer to as CotA, CotB, CotCB, CotD, and
CotE, and we refer to their genes as cotA to cotE (Fig. 3),
based on the nomenclature used for B. subtilis (13) (ortho-
logues are shown in Fig. S2 in the supplemental material).
CotA shared no homology with other proteins in existing da-
tabases, but CotB had orthologues in a number of bacilli and
clostridia. CotCB and CotD were homologous with both each
other (70% conserved residues) and manganese catalases, in-
cluding the CotJC inner spore coat protein (and putative cat-
alase) found in B. subtilis (see Fig. S3 in the supplemental
material). As will be discussed below, the 25-kDa protein is
most probably encoded by the second cistron of an operon, so
we refer to the gene and protein as cotCB and CotCB, respec-
tively. CotE, based on its amino acid sequence, corresponded
to a novel bifunctional protein with amino-terminal peroxire-
doxin (1-Cys peroxiredoxin) and carboxy-terminal manganese
chitinase activities (Fig. S4). The predicted molecular mass of
this protein was 81 kDa, although the full-length protein was
not clearly discernible in our SDS-PAGE fractionations;
rather, a 20-kDa truncated species was found. CotE had
orthologues in a number of spore formers (Fig. S2). As a
single bifunctional protein, no orthologues were found for
other bacilli or clostridia, but matches were found with
either the peroxiredoxin or chitinase domain carried in
CotE. These included a putative peroxiredoxin, YkuU, in B.
subtilis (BS938810) and a number of putative chitinases
from exosporium-containing species, including Bacillus an-
thracis, B. cereus, Bacillus thuringiensis, Bacillus clausii, and
Bacillus halodurans (Fig. S2).
Immunoanalysis of spore coat proteins. Polyclonal antibod-
ies to recombinant Cot proteins were raised in mice. In the
case of CotE, we used the amino-terminal peroxiredoxin do-
main of CotE to generate antibodies. Using confocal imaging
of antibody-labeled C. difficile spores (purified after overnight
incubation at 4°C), we observed uniform surface decoration
using all antisera (Fig. 4), while naive serum gave no labeling
(not shown). Since, as mentioned above, these spores lacked
an exosporium, our data suggest that each of the five coat
proteins must be exposed on the outermost layers of the spore
and must be components of the spore coat rather than the
exosporium.
These antibodies were used in Western blot analyses to
probe spore coat protein extractions (Fig. 5A). CotA, CotB,
and CotD were present as single bands of 47, 40, and 23 kDa,
FIG. 1. Ultrastructure of C. difficile 630 spores. (A to C) Representative images of CD630 spores after 7 days of incubation on solid medium.
Panel B shows the basic structural features found in a mature endospore. CR, core; GCW, germ cell wall; CX, cortex; CT, coats. Panel C shows
a spore containing a partially attached exosporium (EX). (D and E) Seven-day-old spores subjected to 10 cycles of sonication. Panel E shows
angular projections found to be more abundant in sonicated samples.
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respectively, corresponding to the predicted molecular masses
of each of these proteins. CotE antisera identified two strongly
reacting bands of 81 and 40 kDa, but the 20-kDa species
(identified as a peptide fragment in Fig. 2) was not observed.
The most likely explanation is that this 20-kDa species is a
C-terminal fragment that is not recognized by the polyclonal
CotE antibodies that were raised against the N terminus of
CotE. For CotCB, when probed with anti-CotCB antibody, we
could sometimes discern two bands of 25 and 23 kDa, although
this is not apparent in Fig. 5A. Since CotCB and CotD were
homologous, we wondered whether these proteins shared re-
lated epitopes. Using recombinant proteins (recombinant
CotCB [rCotCB] and rCotD), we probed each one with anti-
CotCB and anti-CotD sera. As shown in Fig. 5B, CotD was
recognized by both anti-CotCB and anti-CotD sera. On the
other hand, CotCB was detectable by using anti-CotCB anti-
bodies but only very weakly by using anti-CotD antibody.
Using antisera raised against formalin-inactivated CD630
spores, we probed spore coat proteins extracted from CD630,
B. subtilis, and B. clausii (Fig. 5C). C. difficile serum showed no
cross-reaction against either B. subtilis or B. clausii spore coat
proteins, the latter of which carries an exosporium (7, 13).
Similarly, antiserum raised against formalin-inactivated B. sub-
tilis spores showed no reaction against CD630 spores but some
cross-reaction to B. clausii (Fig. 5D). These results support
results from previously reported bioinformatic analyses that
FIG. 2. Proteins extracted from CD630 spores. Proteins were ex-
tracted from CD630 spores (7-day-old cultures grown on solid me-
dium) by using a sodium borate-SDS-DTT extraction buffer. Proteins
were fractionated by SDS-PAGE (12.5% gel), and samples were
loaded as dilutions. Lane 1, no dilution; lane 2, 1/2 dilution; lane 3, 1/4
dilution; lane 4, 1/8 dilution. M, markers. Alongside the gel, the iden-
tities of the bands excised and analyzed by mass spectrometry are
shown. Partially truncated proteins (') are indicated.
TABLE 1. SDS-PAGE and MALDI peptide fingerprint analysis of C. difficile 630 spore coat proteins
Fragment
molecular
mass (kDa)
Protein descriptiona Codingsequenceb
Predicted
molecular
mass (kDa)
Assigned
gene
118 ND
47 Hypothetical protein CD1613 34 cotA
40 Hypothetical protein CD1511 35 cotB
37 Hypothetical protein CD1511 35 cotB
32 Proteinase K (contaminant from purification steps)
30 Hypothetical protein CD1613 34 cotA
25 Putative spore coat protein; manganese catalase; similar to CotJC of B. subtilis CD0598 21 cotCB
23 Putative spore coat protein; manganese catalase; similar to CotJC of B. subtilis CD2401 21 cotD
22 Putative spore coat protein; manganese catalase; similar to CotJC of B. subtilis CD0598 21 cotCB
20 Putative bifunctional protein, peroxiredoxin/chitinase CD1433 81 cotE
19 Proteinase K (contaminant from purification steps)
a Based on peptide mass fingerprinting of tryptic digestions. ND, no determination.
b Coding sequences are described in reference 30.
FIG. 3. Spore coat genes. The chromosomal positions of genes
referred to in this work are shown.
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have shown little conservation between C. difficile and Bacillus
spores (19, 30).
Effect of sonication on spore coat proteins. An exosporium
has been documented for C. difficile spores prepared in liquid
medium (19, 24). The exosporium remains the least-under-
stood component of the bacterial endospore (13), and harsh
physical methods, such as sonication and shear stress, have
been reported to remove the exosporial layer (27). Although
the majority of spores present in our preparations of CD630
did not appear to carry a recognizable exosporium, we sub-
jected CD630 spores to repeated cycles of sonication. Spore
pellets and supernatants were then separated. Pellets were
then extracted with Na borate-SDS-DTT buffer, and extracts
were run on 12.5% SDS-PAGE gels together with supernatant
fractions (Fig. 6A). Our results showed that as few as two
cycles of sonication were sufficient to remove almost the entire
FIG. 4. Surface display of CotA, CotB, CotC, CotD, and CotE using confocal imaging of suspensions of CD630 spores (7-day-old cultures
grown on solid medium) labeled with mouse serum (1:1,000 dilution) raised against each of the five Cot proteins. CD630 spores labeled with
preimmune serum served as a control and showed no labeling (not shown). Spores labeled with antispore serum are also shown (“Spores”). An
anti-mouse IgG-TRITC conjugate was used for secondary labeling. Images were taken by using a Nikon Eclipse fluorescence microscope equipped
with a Bio-Rad Radiance 2100 laser scanning system (image size, 37 by 37 #m). The top row shows the labeling of untreated spores, and the bottom
row shows the labeling of spores that had been sonicated 10 times.
FIG. 5. Immunoanalysis of spore coats. (A) Spore coats of CD630 were extracted, and separate lanes were probed with polyclonal (mouse)
antibodies to CotA to CotE. Molecular masses of the relevant bands are shown. For CotE, two principal bands of 81 and 40 kDa were found. Serum
from unimmunized mice did not react with C. difficile spore coat proteins. (B) Purified recombinant CotC and CotD proteins (2 #g) were
fractionated on SDS-PAGE gels and probed with either CotC or CotD antibodies at 1/1,500 and 1/3,000 dilutions, respectively. Positions of the
CotC (25 kDa) and CotD (23 kDa) bands are indicated. (C) Coat proteins extracted from spores of CD630, B. subtilis PY79, and B. clausii O/C
were fractionated and probed with antiserum to formalin-inactivated CD630 spores. Positions of CotA to CotE are shown. (D) Same as panel C
except that proteins were probed with antiserum to formalin-inactivated B. subtilis PY79 spores.
VOL. 193, 2011 C. DIFFICILE SPORES 6465
component of sodium borate-solubilized proteins, all of which
were found in the supernatant fraction. Examination of the
sonicated spores by phase-contrast microscopy revealed that
phase-bright spores remained intact, and analyses of CFU be-
fore and after sonication demonstrated no change in viability.
Analysis by TEM revealed no clear-cut differences between
sonicated spores (Fig. 1C) and unsonicated spores (Fig. 1D).
Although precise quantification was not possible, we observed
that in sonicated samples, many spores carried angular projec-
tions on the surface layers (shown in Fig. 1D). These crystal-
line-like structures might indicate an underlying layer of coat
resulting from sonication and the removal of one or more
layers of coat material.
Following sonication, the spore pellet and supernatant frac-
tions were probed with antiserum to CotA to CotE (Fig. 6B).
CotA, CotB, and CotCB were not detectable in the spore
pellets and were found only in the supernatant fractions. CotD
and CotE, although not visibly apparent in Coomassie-stained
gels, were present in both the spore pellet and supernatant
fractions by immunoanalysis. If CotD was still present in the
spore coat fraction, then why was it not detected by use of
anti-CotCB serum, since CotCB and CotD share related
epitopes? We reason that although the recombinant proteins,
at high concentrations, could be detected, this does not reflect
the composition and abundance of CotCB and CotD in the
spore coat but rather the different binding strengths and spec-
ificities of the respective antibodies. In the case of CotE, only
the 40-kDa CotE fragment was found in the spore pellet frac-
tion. We used confocal imaging to examine antibody-labeled
sonicated spores (Fig. 4). This analysis revealed that in each
case, following sonication, surface labeling was massively re-
duced. Labeling correlated well with the Western blotting data
(Fig. 6B), with CotA, CotB, and CotCB showing almost no
labeling and CotD and CotE weak labeling, suggesting that
some CotD and CotE remained in the sonicated spores. These
results then showed that all five Cot proteins are located on the
spore surface and can be liberated either by sonication or by
use of a sodium borate-SDS-DTT extraction buffer.
Enzymatic properties of spores. Based on the amino acid
sequences of CotC, CotD, and CotE and their surface location,
we predict that spores carry enzymatic activity, either latent or
active. Accordingly, we conducted a number of assays to mea-
sure catalase, peroxiredoxin, and chitinase activities. In each
case, we used suspensions of purified spores that had been
checked microscopically to confirm greater than 99.99% free
spores. Catalase activity was measured (Fig. 7A) by a photo-
metric assay of H2O2 breakdown using suspensions of CD630
spores and vegetative cells and, as useful comparators, B. sub-
tilis spores and vegetative cells. CD630 spores had noticeable
catalase activity, while vegetative cells were completely nega-
tive. In comparison, B. subtilis spores were catalase negative,
and vegetative cells were catalase positive. We next focused on
CD630 spores, and we heated the spores at different temper-
atures for 20 min, allowed the spore suspension to return to an
ambient temperature, and then conducted the catalase assay.
We found that heating at 50°C had no effect on enzyme activity
but that enzyme activity was reduced by 40% at 60°C and by
60% at 70°C, showing that although spores were heat stable,
the enzymatic activity was not.
The maturity of spores may affect spore-associated enzyme
activity, since in other spore formers, notably B. subtilis, the
spore coat physically changes over time, with the spore coat
shrinking and forming distinctive surface corrugations (6).
Spore suspensions were assessed for catalase activity at 1-day
intervals postpurification, and we observed a marked decline in
enzymatic activity after just 1 day of maturation (Fig. 7B).
FIG. 6. Removal of Cot proteins using sonication. (A) C. difficile spores were sonicated (30-s cycles) 2 times, 5 times, and 10 times, and pellets
and supernatants were separated. Pellets were treated with Na borate-SDS-DTT extraction buffer, and extracted proteins were mixed with
SDS-PAGE loading dye (4") and fractionated by SDS-PAGE (12.5%). Supernatants were mixed with loading dye and run directly. (B) Spores
were sonicated, and pellet and supernatant fractions (from panel A) were probed with antiserum to each of the five Cot proteins. Molecular masses
of Cot proteins are shown. UT, untreated spores; M, markers.
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Since the substrate for catalase activity, H2O2, was the same as
that used in the peroxiredoxin assay, we measured the effect of
sodium azide on catalase activity, since catalase is sensitive to
sodium azide, while peroxiredoxin activity is not (21). Using
increasing concentrations of sodium azide, the catalase activity
of CD630 spores was inhibited, demonstrating that we were
measuring spore-associated catalase and not that of peroxire-
doxin (Fig. 7C).
Peroxiredoxin activity was assessed by using CD630 spores
and vegetative cells together with a suspension of S. mutans
cells that are known to produce this enzyme (26). CD630
vegetative cells carried barely detectable levels of activity,
while spores clearly were positive and had levels of activity
equivalent to that of S. mutans (Fig. 7D). Peroxiredoxin
activity exhibited a marked decline (60%) when spores were
heated at above 60°C, and at 80°C, activity was abolished. The
effects of spore maturity were also assessed, with activity grad-
ually declining over time, with 7-day-old spores losing 48% of
FIG. 7. Enzymatic activities of C. difficile 630 spores. (A) Catalase activity in CD630 and B. subtilis spores or vegetative cells. (B) Catalase
activities of CD630 spores at different stages of maturation on solid agar. (C) Inhibition of catalase activity by sodium azide. (D) Peroxiredoxin
activity of CD630 spores and vegetative cells and S. mutans cells. (E) Peroxiredoxin activity of CD630 spores at different stages of maturation on
solid agar. (F) chitinase activity in CD630 spores and vegetative cells of CD630 and B. licheniformis. (G) Chitinase activity of CD630 spores at
different stages of maturation on solid agar. (H) Germination of CD630 spores in sodium taurocholate solutions. (I) Chitinase activity in response
to spore germination using 3% or 5% sodium taurocholate solutions. (J) Chitinase activity obtained in cell pellet and supernatant fractions of
CD630 spores following incubation with 0% and 3% sodium taurocholate for 30 min. (K) Chitinase activity of CD630 spores in response to
sonication (30-s cycles). (L) Chitinase activity obtained in cell pellet and supernatant fractions of CD630 spores following sonication (30-s cycles).
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the activity exhibited by 1-day-old preparations (Fig. 7E). The
peroxiredoxin activity of 1-day-old spores was measured in the
presence of 0.5, 1, and 2 mM sodium azide, and no decline in
activity was observed, indicating that the activity was that of
peroxiredoxin and was not due to catalase.
The chitinase activities of CD630 spores and vegetative cells
were assessed by using vegetative cells of chitinase-producing
cells of B. licheniformis as a positive control (34). CD630 cells
had no activity, but spores carried activity equivalent to that of
B. licheniformis (Fig. 7F). As with catalase and peroxiredoxin
activities, the age of the spores had a marked effect on spore-
associated activity, with 7-day-old spores carrying 20% of the
activity found for 2-day-old spores (Fig. 7G). Chitinase, as an
enzyme involved in macromolecular degradation, would serve
no obvious benefit to a dormant spore, but this would not be
the case for a germinating spore. The release and subsequent
activation of a latent enzyme could provide nutrients to an
outgrowing cell, so we asked whether chitinase activity might
be enhanced by the disruption of the spore coat and exospo-
rium. We measured activity first following spore germination,
which would rupture the spore coat, and second following the
sonication of spores, which, as shown above, would remove the
surface coat layers. The spore germination of 1-day-old spores
was evaluated by using different solutions of sodium tauro-
cholate as the germinant (38). By measuring the change in the
OD580 attributed to the phase darkening of spores, we identi-
fied 3% and 5% sodium taurocholate as being optimal for
spore germination, with a 38% reduction (at 3%) to a 50%
reduction (at 5%) in the OD580 in 30 min (Fig. 7H). Next, 30
min following germination using 3% and 5% sodium tauro-
cholate, we measured chitinase activity. We found that com-
pared to untreated spores, the germinant produced a marked
increase (21%) in chitinase activity with both 3% and 5%
solutions (Fig. 7I). Using commercially obtained chitinase (cat-
alog number C6242; Sigma) of the same type (family 18) as
that predicted for CotE, we determined that sodium tauro-
cholate had no effect on enzyme activity (data not shown). We
also found that the chitinase activity was released into the
medium following spore germination. Using 3% germinant,
activity was clearly detectable in the supernatant fraction fol-
lowing centrifugation, in contrast to spore samples that had not
been germinated (Fig. 7J). In support of this finding, we sub-
jected suspensions of 7-day-old spores to increasing cycles of
sonication. Seven 3-s bursts of sonication yielded more chiti-
nase activity than two bursts, which in turn yielded more ac-
tivity than untreated spores (Fig. 7K). As was the case during
spore germination, sonication was sufficient to release chiti-
nase activity into the medium (Fig. 7L). These results demon-
strate first that catalase, peroxiredoxin, and chitinase activities
are associated with spores and second that activity declines as
spores mature, demonstrating that the enzyme either is not
required or is rendered latent (dormant). Finally, for chitinase,
activity is enhanced if the spore coat is disrupted.
DISCUSSION
This study has provided an initial examination of the spore
coats of C. difficile spores with the identification of five proteins
that are exposed on the outermost layer of the spore coat. We
have named these proteins Cot and their genes cot, since our
study clearly shows that they are located in the outermost
layers of the spore coat. However, it should be noted that with
two distinct structures, the coat and exosporium, found on the
outermost layers of the spore, the assignment of names should
be approached with caution. With the exception of an uniden-
tified 118-kDa species, these five proteins represented the ma-
jor proteins extractable by using the procedures followed here.
We believe, however, that the coats of C. difficile are far more
complex and that these five proteins represent just a fraction of
the total protein content of the spore coat. We base this as-
sumption on existing bioinformatic analyses and the extraction
studies performed here. In B. subtilis, more than 70 proteins
are thought to be found in the coat layers (13), and 18 ortho-
logues have been identified in C. difficile (13, 19). Using anti-
CD630 serum, no cross-reaction was found with B. subtilis
spore coat proteins, suggesting that the functional composition
and organization of the coat may be very different in C. difficile.
Interestingly, recent spore proteome studies of CD630 (19)
identified five potential spore coat proteins, which included
CotCB and CotD but not CotA or CotB (CotE, as a chitinase,
was identified but not as a spore coat bifunctional protein).
Regarding the extraction procedures, our method was based
on the use of sodium borate, SDS, and DTT, used previously
for Clostridium perfringens (36) and shown here to efficiently
extract five proteins. However, the presence of a number of
truncated protein species suggests that this method may be
overly harsh (it should be noted that the inclusion of a protei-
nase K treatment step might contribute to this observed partial
degradation of some proteins). It is also possible that these
products arise from cleavage reactions occurring during spore
maturation. SDS-PAGE analysis revealed that the sonication
of spores was able to remove all five Cot proteins recovered by
extraction with buffer. Interestingly, though, residual spores,
which were still viable, released no additional protein when
extracted with borate-SDS-DTT buffer. Sonicated spores,
when examined by TEM, showed that the spore coat layers
were still essentially intact, suggesting that sonication removes
one component (possibly one or more layers of coat) of the
spore coat and that the remaining underlying coat is impervi-
ous to further extraction or sonication. We believe that the
deciphering of the inner layers of the spore coat will require
the development of new extraction procedures. One additional
structure of the spore is the exosporium, although note that
this should not be considered part of the spore coat per se. We
have shown here that C. difficile spores do carry an exosporium,
but at best, this is loosely attached to the spore, and it is
possible that the stability of the exosporium is linked to the
conditions required to prepare (e.g., solid versus liquid me-
dium) and/or store spores. In comparison, the exosporium of
B. anthracis spores is reasonably well characterized, yet there
are conflicting reports regarding how stable this structure is,
with recent studies suggesting that the exosporium is not easily
removed by either sonication or shear stress (35). If the C.
difficile exosporium is particularly fragile, then what, if any, is
the biological significance? Since our initial extraction and
identification of proteins were made with spores carrying some
exosporial material, we believe that one or more exosporial
proteins may have been recovered and perhaps were present in
low abundance in the protein extractions shown in Fig. 2. One
candidate could be the collagen-rich glycoprotein BclA1
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(CD0332), which has orthologues in a number of other spore
formers, including B. anthracis, where it forms filaments that
are attached to the exosporium and facilitates interactions with
host cells, including enhancing spore uptake by macrophages
(2). Interestingly, BclA is extracted from exosporium-contain-
ing Bacillus spores as a high-molecular-mass species, and its
identification using conventional proteomic tools is problem-
atic (5, 33). It will therefore be of interest to determine
whether the 118-kDa species is in fact BclA.
Some of the most interesting findings of this work are the
enzymatic properties of the spores and the identification of
three enzymatic coat proteins (CotCB, CotD, and CotE) that
most probably reside in the exosporium. Although absolute
confirmation will require the inactivation of the chromosomal
genes and, preferably, evidence of the enzyme activity of the
purified proteins, this assumption is supported by several lines
of evidence. First, vegetative cells were shown to exhibit no
enzyme activity, so this is unlikely to arise from any contami-
nating cells. Second, a previous analysis of the spore proteome
(19) revealed no additional genes that could encode these
enzyme activities, although it must be emphasized that the
spore proteome is incomplete.
What, then, are the functions of these putative spore-asso-
ciated enzymes? The catalase (CotCB and CotD) and perox-
iredoxin (CotE) activities are potential antioxidants, and at
first glance, all three would reduce the cellular toxicity of H2O2
by conversion to oxygen and water. In the case of C. difficile,
which is a strict anaerobe, the presence of oxygen would in turn
be harmful to the cell. Since the cell is irreversibly committed
to dormancy, it is conceivable that this is not actually harmful
and that C. difficile spores can be maintained in an oxic envi-
ronment. Presumably, though, there is a need to remove H2O2.
Previous studies of B. subtilis sporulation showed that H2O2
may play a key role in spore coat synthesis and could serve as
a substrate for the oxidative cross-linking of spore coat mono-
mers (12). Here, the enzyme superoxide dismutase (SodA) is
essential to the cross-linking of tyrosine-rich spore coat pro-
teins, and in CD630, a manganese-dependent SodA ortho-
logue has been identified in the spore proteome (CD1631).
CotE, as a 1-Cys-peroxiredoxin would be expected to have the
same enzymatic activity as that of a peroxidase and could
participate in the cross-linking of tyrosine-rich spore coat pro-
teins. None of the other coat proteins identified in this work
are tyrosine rich, but an examination of the C. difficile genome
has revealed at least one gene (CD0597) that would encode a
tyrosine-rich protein (10.34% tyrosines). This protein is ho-
mologous to CotJB of B. subtilis, and in C. difficile, its ORF lies
immediately upstream of cotC, which in turn encodes an or-
thologue of B. subtilis CotJC. The ORFs are separated by 61 bp
and probably lie within the same operon, so we propose to
name CD0597 cotCA and the downstream cistron cotCB
(Fig. 2B).
For chitinase activity, the presence of this enzyme in the
spore coat is intriguing, since it would be expected to be in-
volved in the breakdown of fungi and other biological matter
whether in the soil or in the intestine. However, spores are
dormant, so we speculate that chitinase activity may be re-
leased (or activated) during spore germination, enabling a po-
tential source of nutrients as the C. difficile cell emerges from
its coats. We have evidence to support this: the chitinase ac-
tivity decreased as spores matured but increased during both
spore germination and following sonication, with both of these
being events that would rupture the spore coat layers. Inter-
estingly, CotE (the putative chitinase) was detectable in the
supernatant fraction as either a full-length species (81 kDa) or
a single 40-kDa species following sonication, and we wonder
whether the smaller species is actually the active chitinase
enzyme. Another interesting aspect of CotE, based solely on its
sequence prediction, is its bifunctionality and its characteriza-
tion as one of a growing number of “moonlighting proteins”
(15) that carry multiple functions, including a mammalian pro-
tein, 1-Cys-peroxiredoxin, that carries peroxidase and phos-
pholipase activities (4). There is possibly a more important
consequence of a chitinase and a peroxiredoxin displayed on
the surface of C. difficile spores that should not be overlooked.
This relates to the potential link between peroxiredoxins, chiti-
nases, and inflammation. Peroxiredoxin 1 (a 2-Cys-peroxire-
doxin), secreted from tumor cells (22), was shown previously to
induce proinflammatory cytokines in macrophages via interac-
tions with Toll-like receptor 4 and to promote chronic inflam-
mation, which could support tumor growth (28). Regarding
chitinases, it is now clear that some inflammatory conditions of
the gastrointestinal (GI) tract (inflammatory bowel disease
[IBD] and ulcerative colitis [UC]) lead to the induction of host
cell chitinases by triggering the increased uptake of intracellu-
lar bacteria by colonic cells (16, 17) and in potentiating the
development of epithelial tumorigenesis (8). Considering that
some symptoms of CDAD resemble those of both IBD and
UC, C. difficile chitinase may play a direct role in infection and
not simply in macromolecular degradation.
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Immunization with Bacillus Spores Expressing Toxin A Peptide
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Clostridium difficile is a leading cause of nosocomial infection in the developed world. Two toxins, A and B,
produced by most strains of C. difficile are implicated as virulence factors, yet only recently has the requirement
of these for infection been investigated by genetic manipulation. Current vaccine strategies are focused mostly on
parenteral delivery of toxoids. In this work, we have used bacterial spores (Bacillus subtilis) as a delivery vehicle to
evaluate the carboxy-terminal repeat domains of toxins A and B as protective antigens. Our findings are important
and show that oral immunization of the repeat domain of toxin A is sufficient to confer protection in a hamster
model of infection designed to closely mimic the human course of infection. Importantly, neutralizing antibodies to
the toxin A repeat domain were shown to be cross-reactive with the analogous domain of toxin B and, being of high
avidity, provided protection against challenge with a C. difficile strain producing toxins A and B (A!B!). Thus,
although many strains produce both toxins, antibodies to only toxin A can mediate protection. Animals vaccinated
with recombinant spores were fully able to survive reinfection, a property that is particularly important for a disease
with which patients are prone to relapse. We show that mucosal immunization, not parenteral delivery, is required
to generate secretory IgA and that production of these neutralizing polymeric antibodies correlates with protection.
This work demonstrates that an effective vaccine against C. difficile can be designed around two attributes, mucosal
delivery and the repeat domain of toxin A.
Clostridium difficile is the most common cause of nosocomial
antibiotic-associated diarrhea in developed countries. Antibi-
otic therapy and disruption of the normal gastrointestinal (GI)
microflora are the primary causes of C. difficile-associated dis-
ease (CDAD), and the presence of one or both of these factors
is a prerequisite for colonization of the gut by this Gram-
positive bacterium. Morbidity and mortality rates have been
steadily increasing in recent years and probably result from the
emergence of more virulent strains of C. difficile as well as the
changing patterns of antibiotic usage. Recent estimates of
CDAD in the United States suggest as many as 500,000 cases
per year, with up to 20,000 deaths (32). CDAD is caused by the
secretion of two toxins, toxin A (TcdA) and toxin B (TcdB),
both of which are monoglucosyltransferases that are cytotoxic,
enterotoxic, and proinflammatory (5). CDAD is particularly
problematic to treat and contain because of the ability of the
bacterium to form robust endospores that can persist and be
easily transferred in a hospital environment. Currently, the
only treatment for CDAD is the use of antibiotics such as
vancomycin and metronidazole, possibly followed by surgery if
the disease is serious and refractory to antimicrobial treat-
ments. Recurrence of CDAD (i.e., diarrhea recurring within 30
days after the first treatment) is a particular challenge for
which there is no standard, uniformly effective treatment.
Although C. difficile can naturally cause disease without
toxin A, most clinically isolated C. difficile strains produce both
toxin A and toxin B (A!B!) (28). Therefore, an effective
vaccine to CDAD should target the two principal virulence
factors, toxin A and toxin B, since high titers of antibodies
against these toxins correlate well with protection in both ham-
sters and humans (1, 21, 26). Recent studies have shown that
both toxins are important for disease and that recombinant,
isogenic C. difficile strains that are A"B! or A!B" are able to
cause disease in the hamster model of infection (23). This work
seemingly contradicts an earlier study suggesting that only
toxin B is responsible for virulence (30) yet is supported by
numerous other studies implicating both toxin A and toxin B in
infection (7, 20, 29, 42). Both of the tcdA and tcdB genes, which
encode toxin A and toxin B, respectively, carry limited identity
at their C termini, where each carries an elaborate array of
repeated domains (40). The C-terminal domain of tcdA has
been shown to be involved in initial binding of the toxin to
sensitive cells prior to its translocation across the endosomal
membrane (17). Previous studies indicate that these repetitive
domains may be suitable as antigens against CDAD. Some
examples are, first, that toxin A cell binding repeats, and a
monoclonal antibody (MAb) directed against them, prevented
cytotoxicity (34). Second, a defined segment of repeats known
as 14CDTA expressed in a recombinant Salmonella vaccine
elicited local and systemic immunity and toxin A-neutralizing
activity (44). Finally, human monoclonal antibodies directed
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against toxins A and B prevent C. difficile-induced mortality in
hamsters (2) and reduced recurrence in humans (27).
The colon is the primary site of residency of germinated C.
difficile spores, and luminal epithelial cells are targeted by the
C-terminal regions of toxins A and B. High-avidity binding
facilitates the subsequent internalization of the toxins via re-
ceptor-mediated endocytosis in clathrin-coated pits (41). An-
tibodies to toxin A have been shown to confer protection
against C. difficile A!B! strains, whether delivered mucosally
(21) or parenterally (2, 20), although levels of protection are
more complete if antibodies to both toxins are used. Such
passive-immunization studies show that antibodies are the key
effector molecule, and in the GI tract, polymeric secretory IgA
(sIgA) may interfere with toxin binding. Despite this, current
vaccination strategies are based mostly on parenteral delivery
and inducing IgG, whose mechanistic action is far from clear
(9). Recombinant bacterial vaccines expressing the toxin A
binding domain have been shown to induce both mucosal-
sIgA- and serum IgG-neutralizing antibodies following oral
administration (43, 44), which prompted us to consider Bacillus
subtilis spores as a delivery vehicle for C. difficile antigens.
Recombinant, heat-stable spores of B. subtilis have been
used for mucosal delivery of heterologous antigens. In exper-
iments using spores expressing antigens on their surface coats,
they have been shown to protect mice immunized against tet-
anus toxin from Clostridium tetani (8) and Clostridium perfrin-
gens alpha toxin (13). In both cases, significant levels of local
immunity (sIgA) were induced. Interestingly, spores appear to
possess natural adjuvant properties, and coupled with their
heat stability and existing use as probiotics (14), they are at-
tractive vehicles with which to develop a vaccine to CDAD.
In the present study, B. subtilis spores expressing the cell-
binding domains of toxin A and toxin B were evaluated for
their ability to elicit neutralizing antibodies. Our findings show
that antibodies to the toxin A domain are cross-reactive to the
toxin B domain and can protect hamsters from challenge with
spores of a toxigenic strain of C. difficile. Our work shows that
oral immunization and the production of local immunity are
the key attributes required for vaccination against CDAD.
MATERIALS AND METHODS
General methods. Methods for work with B. subtilis are described elsewhere
(11). B. subtilis strain PY79 is a standard, prototrophic laboratory strain. C.
difficile spores of strain 630 (tcdA! tcdB!; lab stock) were prepared using an
anaerobic incubator (Don Whitley, United Kingdom) for all manipulations as
follows. A single colony was grown on BHIS (brain heart infusion supplemented
with 0.1% L-cysteine and 5 mg/ml yeast extract) agar overnight at 37°C. One fresh
single colony from the BHIS plate was inoculated in 10 ml of TGY medium (3%
tryptic soy broth, 2% glucose, 1% yeast extract, 0.1% L-cysteine) and incubated
at 37°C overnight. One milliliter of TGY culture was then subcultured into SMC
broth [90 g peptone, 5 g proteose peptone, 1 g (NH4)2SO4, 1.5 g Tris, 0.1%
L-cysteine], incubated overnight, and then plated onto SMC agar and incubated
for 7 days. Sporulation was confirmed by phase-contrast microscopy, and spore
crops were harvested and purified as described elsewhere (25).
Recombinant B. subtilis vaccine strains. Detailed strain constructions are
provided in the text in the supplemental material. B. subtilis merodiploid strains
contained chimeric genes of cotB and/or cotC fused at their 3# ends to the
C-terminal domains of toxin A (A26-39; codons for Ser2388 to Pro2706 [6]) or
toxin B (B15-24; codons for Glu2137 to Glu2366 [3]). The entire cotC gene was
used for fusion to the toxin domains, while for cotB, a 3# deletion was used so that
the encoded CotB segment was 33 kDa. Genes were integrated into the chro-
mosome by a stable double-crossover recombination and were placed in trans
into the indigenous cotB or cotC gene.
PP059 (thrC::cotB-A26-39) encodes a fusion of A26-39 to the C terminus of
CotB (predicted molecular mass, 69 kDa). The chimeric gene was carried at the
thrC locus of B. subtilis.
PP052 (amyE::cotC-A26-39) encodes a fusion of A26-39 to the C terminus of
the CotC (predicted molecular mass, 49 kDa). The chimeric gene was carried at
the amyE locus of B. subtilis.
PP108 (thrC::cotB-A26-39 amyE::cotC-A26-39) was created by transforming
competent cells of PP052 with chromosomal DNA of PP059, with selection for
Ermr, conferred by the thrC::cotB-A26-39 cassette.
PP132 (thrC::cotB-B15-24) encodes a fusion of B15-24 to the C terminus of
CotB (predicted molecular mass, 60 kDa).
PP142 (thrC::cotB-B15-24 amyE::cotC-A26-39) was created by transforming
competent cells of PP052 with chromosomal DNA of PP132 (thrC::cotB-B15-24),
with selection for Ermr, conferred by the thrC::cotB-B15-24 cassette.
Recombinant proteins. Recombinant A26-39 (36.6 kDa) and B15-24 (29.4
kDa) were produced in Escherichia coli BL21(DE3)(pLys) from a pET28b ex-
pression vector that separately carried the rA26-39 and rB15-24 open reading
frames (ORFs) fused to a C-terminal polyhistidine tag. High levels of expression
were obtained upon isopropyl-$-D-thiogalactopyranoside (IPTG) induction and
purification of rA26-39 and rB15-24 by passage of the cell lysate through a
HiTrap chelating high-performance (HP) column on a Pharmacia AKTA liquid
chromatography system.
Protein quantification. Coat proteins were extracted from purified spore sus-
pensions of PP108 and PP142 using two extraction procedures, SDS-dithiothre-
itol (DTT) and alkali extraction, as described elsewhere (8). SDS-DTT solubi-
lizes both CotB and CotC, while alkali extraction preferentially solubilizes CotC.
Quantification was made using a Bio-Rad Gel Doc imaging system.
Polyclonal antibodies. Polyclonal antibodies were raised in mice immunized by
the intraperitoneal (i.p.) route with 2 %g of purified protein on days 1, 14, and 28.
Dilutions used were 1:3,500 for anti-A26-39 and 1:1,500 for anti-B15-24.
Immunizations in mice. Animals used in this work were pathogen-free
BALB/c mice (Charles River) for antibody production and for analysis of im-
mune responses. In all cases, females, aged 6 to 8 weeks, were used. All animal
procedures were performed under the Home Office project license PPL 70/6126.
Mice were dosed orogastrically (o.g.) (0.2 ml) on days 0, 14, 35, and 57 with a
dose of 5& 1010 spores (PY79, PP108, or PP142). A naïve group of unimmunized
animals was included in all experiments, as well as a group receiving a mixture of
the rA29-36 (10 %g) and rB15-24 (10 %g) proteins. Intraperitoneal (i.p.) immu-
nizations consisted of doses on days 0, 7, and 28 with the rA26-29 and rB15-24
proteins (10 %g of each).
Determination of mouse antibody titers by indirect ELISA. For analysis of
responses, serum was taken on days "1, 34, and 56 (o.g. groups) or day 42 (i.p.
groups), and feces were collected on days 21, 42, and 67 and kept at "80°C.
Sample extractions were made at a one-fifth (wt/vol) dilution in extraction buffer
(2% fetal calf serum [FCS], Dulbecco’s modified Eagle’s medium [DMEM] plus
protease inhibitor cocktails, trypsin [0.1 mg/ml], leupeptin [1 %g/ml], benzamide
[1 %g/ml], aprotinin [10 %g/ml], phenylmethylsulfonyl fluoride [1 mM], and
EDTA [0.05 mg/ml]). Samples were gently shaken for 30 min at 4°C to disrupt
solid material and then centrifuged (13,000 rpm for 15 min). Supernatants were
filtered (0.45-%m pore size) before analysis. Antibodies from sera and feces were
determined by indirect enzyme-linked immunosorbent assay (ELISA). Greiner
96-well plates (MaxiSorp) were coated with purified recombinant A26-29 (rA26-
39) (10 %g/ml) or rB15-24 (50 %l/well) protein in phosphate-buffered saline
(PBS) overnight at room temperature (RT). After the plates were blocked for 1 h
at 30°C with 2% bovine serum albumin (BSA), 2-fold serially diluted samples
were added, starting at a dilution of 1/50 in diluent buffer (0.01 M PBS [pH 7.4],
0.5% [wt/vol] bovine serum albumin [BSA], 5% [vol/vol] fetal bovine serum
[FBS], 0.1% [vol/vol] Triton X-100, 0.5% [vol/vol] Tween 20). Replicate samples
were used together with a negative control (preimmune serum). Plates were
incubated for 2 h at RT before addition of appropriate horseradish peroxidase-
conjugated anti-mouse antibodies in conjugate buffer (5% FBS [vol/vol], 1%
BSA [wt/vol], 0.05% Tween 20 in 0.01 M PBS). Plates were incubated for 1 h at
RT and then developed using tetramethyl benzidine (TMB) substrate (0.1 mg/ml
3.3#,5.5#-tetramethylbenzidine in 0.1 M sodium acetate buffer [pH 5.5] in distilled
water). Reactions were stopped using 2 M H2SO4, and optical densities (ODs)
were read at 450 nm. Dilution curves were created for each sample, and endpoint
titers for each specific antibody were estimated at the maximum dilution of
serum giving an absorbance reading of 0.1 U over the ODs of naïve samples.
Neutralization assays. The ability of the antibody samples to neutralize C.
difficile toxins in vitro was determined as described recently (30), with some
modifications. HT29 and VERO cells were grown in McCoy’s 5A medium and
Dulbecco’s modified Eagle complete medium (10% [vol/vol] fetal calf serum and
1% [vol/vol] penicillin and streptomycin). Cells were cultured at 37°C with 5%
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(vol/vol) CO2 in air (100% humidity). HT29 and VERO cells were seeded in
96-well plates (0.5 & 104 cells/well and 2.5 & 104 cells/well, respectively). After
24 h, cells were washed twice in sterile PBS. Before the assay, toxins were
incubated with serially diluted pooled serum or fecal samples (1:1, vol/vol) in
medium containing 2% FCS and incubated for 1 h at 37°C before being added
to the prewashed cell monolayer. Cells were evaluated at 24 h (HT29) and 48 h
(VERO). Toxins used were toxins A and B obtained from the culture superna-
tant of strain 630 (toxin 630), which had been partially purified by ammonium
sulfate precipitation (60%). The presence of toxins A and B was confirmed in the
supernatant of 630 cultures by Western blotting (see Fig. S1 in the supplemental
material). Toxin A and toxin B had been purified from cell supernatants. Ap-
propriate toxin concentrations were determined by the highest dilutions causing
100% cytopathicity (i.e., cell rounding) (toxin 630 [120 ng/ml], toxin A [4.5
ng/ml], toxin B [6.2 pg/ml]). All assays were carried out in duplicate.
Hamster challenge. Groups of 6 to 10 female Golden Syrian hamsters (70 to
80 g; Charles River, United Kingdom), were immunized o.g. (0.2 ml) with either
(i) recombinant (PP108, PP142) and nonrecombinant PY79 spores (5 & 1010
spores/dose/hamster) or (ii) a mixture of the proteins rA26-39 (10 %g) and
rB15-24 (10 %g). One further group was dosed with the protein mixture delivered
by the i.p. route (0.2 ml). Hamsters were dosed o.g. on days 0, 14, 35, and 57 and
i.p. on days 0, 7, and 28. The challenges were performed as described by Gould-
ing et al. (10), with some minor modifications. In brief, 14 days after the last dose,
hamsters were transferred to individual sterile cages (including all food, bedding,
and water) and treated with clindamycin (30 mg/kg of body weight). Twelve
hours later, hamsters were o.g. infected with 100 C. difficile spores (strain 630).
Twenty-four hours after challenge and every 2 days thereafter, hamsters were
repeatedly transferred to new sterile cages. Hamsters were intensively monitored
38 to 60 h after challenge. Hamsters showing clear symptoms were killed and
considered unprotected.
Statistics. The unpaired t test was used to compare between groups. A P value
of '0.05 was considered nonsignificant.
RESULTS
Expression of the C-terminal domains of C. difficile toxin A
and toxin B on B. subtilis spores. B. subtilis was engineered to
express the A26-39 domain of toxin A (TcdA) and the B15-24
domain of toxin B (TcdB) on the outermost layer of the spore
coat. Both A26-39 and B15-24 lie within the C-terminal repeat
domains of each toxin and carry repetitive sequences (40) (Fig.
1A). Expression was achieved by fusing A26-39 and B15-24 to the
C termini of the outer spore coat proteins CotB (43 kDa) and
CotC (12 kDa), both of which have successfully been used for
surface display andmucosal delivery of heterologous antigens (16,
31) (in the case of CotB, fusions were made to a C-terminally
truncated version of CotB). Two different spore constructions
were made: PP108 (cotB-A26-39 cotC-A26-39), which expressed
A26-39 attached to both CotB and CotC, and PP142 (cotB-
B15-24 cotC-A26-39), which coexpressed two chimeras, CotB-
B15-24 and CotC-A26-39. Surface expression of A26-39 and B15-24
on PP142 spores and A26-39 on PP108 spores was confirmed by
confocal imaging of spores (Fig. 1B to D).
Antibodies to the C-terminal domain of toxin A cross-react
with the reciprocal domain of toxin B. The coat proteins of
PP108 and PP142 were extracted and probed with antibodies
to confirm expression of the chimeric CotB and CotC proteins
(Fig. 1E to F). PP108 spore coat protein extracts when probed
with anti-A26-39 antibodies revealed bands of 69 kDa (CotB-
FIG. 1. Recombinant spores expressing C. difficile toxin domains. (A) The functional domains of toxins A and B are shown, including the
glycosyltransferase (black), cysteine protease (gray), and translocation (white) domains and the repetitive sequences involved in cell binding
(stripes). The regions cloned and expressed in B. subtilis spores are indicated. These are the A26-39 domain (formerly known as 14CDTA), which
carries 14 repeat sequences and has been shown to be immunogenic and capable of inducing neutralizing antibodies in mice when delivered by
a mucosal route (43), and the B15-24 domain, which carries 10 repeats and shares homology with A26-39 (see Fig. S2 in the supplemental material).
(B to D) Surface display of A26-39 and B15-24, confirmed using confocal imaging of samples labeled with mouse anti-A26-39 or -B15-24 serum
followed by an anti-mouse IgG-tetramethyl rhodamine isocyanate (TRITC) conjugate. Spores of PP108 were labeled with anti-A26-39 (B), and
spores of PP142 were labeled with either anti-A26-39 (C) or anti-B15-24 (D). Nonrecombinant PY79 spores showed no labeling with either
antiserum. Images were taken using a Nikon Eclipse fluorescence microscope equipped with a Bio-Rad Radiance 2100 laser scanning system
(image size ( 37 by 37 %m). (E) Expression of A26-39 on spores of PP108 (CotB-A26-39 CotC-A26-39). Lane 4 shows PP108-extracted spore coat
proteins probed with antibodies to rA26-39. Lanes 1 to 3 were also probed with anti-A26-39. Lane 1, rA26-39 protein; lane 2, coat proteins from
PP052 (CotC-A26-39); lane 3, coat proteins from PP059 (CotB-A26-39). (F) Expression of A26-39 and B15-24 on spores of PP142 (CotB-B15-24
CotC-A26-39) probed with anti-A26-39 (lanes 1 to 5) and anti-B15-24 antibodies (lanes 6 to 10). Lanes 1 and 6, nonrecombinant PY79 spore coat
proteins; lane 2, rA26-39 protein (36.6 kDa); lanes 3 and 8, PP052 extracts (CotC-A26-39); lanes 4 and 9, PP132 extracts (CotB-B15-24); lanes 5 and
10, PP142 extracts; lane 7, rB15-24 protein (29.4 kDa). The positions of the 60-kDa CotB-B15-24 and 49-kDa CotC-A26-39 bands are shown.
(G) Purified rA26-39 (lanes 1 and 3) (36.6-kDa) and rB15-24 (lanes 2 and 4) (29.4-kDa) polypeptides were probed with anti-A26-39 or anti-B15-24.
Numbers at the left of the blots are molecular masses (in kilodaltons).
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A26-39) and 49 kDa (CotC-A26-39). Their molecular masses
were in agreement with the predicted sizes of the fusion pro-
teins (Fig. 1E) and corresponded in size to proteins in extracts
taken from spores carrying each chimera alone. Quantification
revealed that PP108 spores carried 2.2 & 10"4 pg/spore of
A26-39. When PP142 extracts were probed with anti-B15-24,
one principal band of 60 kDa was detectable (Fig. 1F, lane 6),
corresponding in size to CotB-B15-24. Using anti-A26-39,
CotC-A26-39 was observed as a 49-kDa species; a second band
of 60 kDa was also observed (Fig. 1F, lane 3). We predict that
this higher-molecular-mass species is CotB-B15-24 and could be
explained by the fact that the C-terminal cell-binding domains
of TcdA and TcdB share some sequence identity (30% iden-
tical residues [see Fig. S2 in the supplemental material]) and
may, as shown elsewhere, carry related epitopes (40). In support
of this, we demonstrated that anti-A26-39 antibodies could cross-
react with both the purified-rA26-39 (36.6-kDa) and -rB15-24
(29.4-kDa) polypeptides, yet anti-B15-24 antibodies reacted only
with rB15-24 (Fig. 1G). Protein expression was quantified, and
each spore of PP142 was shown to contain 2.45 & 10"5 pg of
B15-24 and 1.9 & 10"4 pg of A26-39. In additional work, we
verified, using anti-CotB and anti-CotC polyclonal antibodies, the
expected change in the molecular masses of the chimeric CotB
and CotC spore coat proteins in PP108 and PP142 spores (see
Fig. S3 in the supplemental material).
Oral delivery of the C-terminal domains of toxin A and toxin
B displayed on spores induces systemic and mucosal antibod-
ies. Immune responses were determined in mice dosed oro-
gastrically (o.g.) with PP108 or PP142 spores. Control groups
included naïve mice and groups dosed (o.g.) with nonrecom-
binant spores (PY79). In addition, we included one group
dosed (o.g.) with a mixture of the rA26-39 (10-%g/dose) and
rB15-24 (10-%g/dose) proteins using the same dosing regimen.
Ten micrograms was chosen for each protein since this equaled
or exceeded the dose of rA26-36 or rB15-24 delivered in one
o.g. dose of PP108 (11 %g of A26-39) or PP142 (9.5 %g of
A26-39 and 1.25 %g of B15-24) spores.
Specific antibodies (serum IgG and fecal IgA) against
A26-39 and B15-24 were measured by indirect ELISA. Com-
pared to control groups (naïve mice, mice dosed with PY79
spores, or mice receiving proteins alone), significant (P) 0.01)
levels of A26-39 and B15-24 (cross-reacting) IgG were de-
tected in the sera of animals dosed with PP108 (Fig. 2A and B).
In mice dosed with PP142 spores, anti-A26-39 IgG responses
were not significantly greater (P' 0.05) than in control groups,
while anti-B15-24 IgG responses were significantly greater
(P ) 0.01) (Fig. 2B) and showed seroconversion. IgG isotypes
were also determined (see Fig. S4 and S5 in the supplemental
material), and significant (P ) 0.01) levels of anti-A26-39 and
anti-B15-24 (cross-reacting) IgG1 and IgG2a were found in the
PP108 groups compared to the control groups. However, in the
PP142 groups, significant levels (P ) 0.01) of the IgG1 and
IgG2a isotypes were found only against B15-24. Analysis of the
IgG1/IgG2a ratios over time (see Fig. S6 in the supplemental
material) showed a clear increase (3-fold) after the third dose,
indicative of a Th2-biased immune response. Anti-spore IgG
responses were also measured and found to be markedly low,
with no responses substantially greater than those of the con-
trol groups (see Fig. S7 in the supplemental material). IgG
present in the sera of PP108-immunized mice was found to
bind in a Western blot to rA26-39 and rB15-24, while that
present in PP142-dosed mice bound only to rB15-24 (Fig. 2C).
Secretory IgA (sIgA) was measured in fecal samples (Fig. 3),
and anti-A26-39 responses were found to be particularly high
(Fig. 3A), with clear seroconversion in animals dosed with PP108
spores (P ) 0.001) but not with PP142 spores (P ' 0.05). Anti-
B15-24 sIgA responses were lower, but seroconversion was found
in animals dosed with both PP108 and PP142 (Fig. 3B) (P) 0.05).
The anti-B15-24 cross-reacting IgG and sIgA responses found in
animals dosed with PP108 spores expressing only the A26-39
FIG. 2. IgG responses after orogastric immunization of mice with recombinant spores. Anti-A26-39-specific IgG (A) and anti-B15-24 IgG
(B) responses are shown. Mice were immunized with spores of strain PP108 (CotB-A26-39 CotC-A26-39) (!), PP142 (CotB-B15-24 CotC-A26-39) (!),
nonrecombinant PY79 (!), a mixture of the rA26-39 and rB15-24 recombinant proteins (Œ) (10 %g of each) and naïve mice ("). (C) Western blots
containing pooled sera from naïve and PP108- and PP142-immunized groups were used to probe rA26-39 proteins and rB15-24.
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protein further support our finding that antibodies against the
A26-39 domains are cross-reactive to B15-24.
In vitro neutralization of cytotoxicity. Both toxin A and toxin
B exhibit cytotoxicity on cultured cells, with HT29 cells being
most sensitive to toxin A and VERO cells most sensitive to
toxin B (30, 38). Serum (IgG) and mucosal (fecal sIgA) anti-
bodies from mice were assessed for their ability to neutralize
toxin A- and toxin B-mediated cytotoxicity using either purified
toxins or partially purified supernatants from strain 630 (toxin
630) (Table 1). Cytotoxicity was confirmed by examination of
cells over a 24- to 48-h period, with susceptible cells showing a
rounded cell morphology (examples in Fig. S8 in the supple-
mental material).
Antibodies from PP108-immunized (o.g.) mice were found
to neutralize both toxin A and toxin B when either HT29 or
VERO cells were used, and higher titers were shown in HT29
cells (toxin A specific) than in VERO cells. In contrast, anti-
bodies produced by PP142-immunized (o.g.) animals neutral-
ized only toxin B. These results show, first, that in mice, o.g.
delivery of recombinant spores expressing A26-39 or B15-24
FIG. 3. Secretory IgA responses after orogastric immunization of mice with recombinant spores. Anti-A26-39-specific sIgA (A) and anti-B15-
24-specific sIgA (B) responses. Mice were immunized with spores of strain PP108 (CotB-A26-39 CotC-A26-39) (!), PP142 (CotB-B15-24 CotC-A26-39)
(!), nonrecombinant PY79 (!), and a mixture of the rA26-39 and rB15-24 recombinant proteins (Œ) (10 %g of each). ", naïve mice.
TABLE 1. Neutralization of in vitro cytotoxicity and protection
Group Route
Toxin neutralization titera Protection (%)b
Anti-toxin A Anti-toxin B Anti-toxinsA and Bc 1st 2nd
IgG sIgA IgG sIgA IgG sIgA
Naı¨ve " " " " " " 0
PY79 o.g. " " " " " " 0
rA26-39 ! rB15-24 o.g. " " " " " " 0
PP108 o.g. !! !!! ! ! !! !!! 75 100
PP142 o.g. " " ! ! " " 0
rA26-39 ! rB15-24 i.p. !!! " ! " !!! " 25 0
a Neutralization titers against toxin A or toxin B were measured on HT29 (anti-toxin A) or VERO (anti-toxin B) cells. Endpoint titers were determined as the highest
dilution of sample that prevented the cytopathic cell-rounding effect of the toxin in 100% of cells. Negative results are expressed as " when the endpoint titer dilution
was )1/10 for serum samples and )1/50 (wt/vol) for fecal samples. Representative neutralization data are shown in Fig. S8 in the supplemental material and
summarized as follows. For serum titers, ! indicates a titer of 10 to 20, !! indicates 40 to 80, and !!! indicates '160. For feces titers, ! indicates a titer of 50 to
100, !! indicates 100 to 200, and !!! indicates '200.
b Survival data are shown in Fig. 4. Animals surviving the first challenge were then rechallenged (2nd).
c Neutralization against toxins partially purified from C. difficile strain 630, measured using HT29 cells.
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can generate systemic and mucosal neutralizing antibodies.
Second, using PP108 spores expressing only A26-39, neutral-
izing antibodies to toxin A as well as toxin B could be elicited.
Protection in hamsters. The hamster model of C. difficile
infection most closely resembles the human disease and is the
best indicator of protective immunity (10, 33). We dosed ham-
sters o.g. with PP108 and PP142 spores, treated them with
clindamycin, and then challenged them with 100 spores of C.
difficile strain 630 (Fig. 4). Control groups included hamsters
dosed with nonrecombinant PY79 spores and animals dosed
with a mixture of the rA26-39 and rB15-24 proteins (10 %g of
each). Spores of C. difficile were used instead of live cells since,
as shown recently, they better mimic the natural infection
process (10) as well as minimize the difficulties of administer-
ing live anaerobic bacteria. All naïve animals (10/10) were
susceptible to C. difficile and showed symptoms of disease after
just 40 to 42 h, in close agreement with a previous study (10).
Interestingly, most of the animals dosed with PY79 spores showed
delayed symptoms, as did those dosed with a mixture of the
rA26-39 and rB15-24 proteins, but in both cases, all animals
succumbed. Hamsters dosed with PP142 spores showed no pro-
tection, with every animal displaying symptoms. PP108-immu-
nized animals, however, showed protection, with six out of eight
animals surviving the duration of the experiment.
Protection against reinfection. All surviving hamsters that
showed no symptoms of C. difficile infection were then rechal-
lenged 16 days after the first challenge using clindamycin to
induce C. difficile colonization. Control groups included unim-
munized (naïve) hamsters and animals dosed o.g. with nonre-
combinant PY79 spores. We found that only PP108 hamsters
were 100% protected to C. difficile challenge and showed no
symptoms of infection (Fig. 5). These results show that o.g.
immunization of hamsters with the A26-39 domain of toxin A
displayed on the surfaces of B. subtilis spores is sufficient to
confer protection against a strain of C. difficile that produces
both toxin A and toxin B. Moreover, protected animals were
fully resistant to reinfection.
Parenteral immunization of the cell-binding domains of
toxin A and toxin B. As a comparator of oral-versus-parenteral
delivery, mice were dosed (intraperitoneally [i.p.]) with a mix-
ture of rA26-39 (10 %g/dose) and rB15-24 (10 %g/dose). High
ELISA titers of IgG antibodies specific to A26-39 (34,161 *
9,838) and B15-24 (21,475 * 7,152) were found 2 weeks after
the last dose (day 45), significantly greater than titers in naïve
animals (P ) 0.001) and higher than in serum samples from
PP108-immunized mice (P ) 0.001). In contrast, no significant
(P ' 0.05) levels of sIgA were detectable in feces. Serum
antibodies were shown to be able to neutralize the cytotoxic
effects of both toxin A and toxin B (Table 1). In the hamsters
dosed i.p. with the recombinant proteins, 25% protection was
achieved (Fig. 4), but animals failed to survive reinfection with
C. difficile (Fig. 5).
DISCUSSION
Our use of B. subtilis spores as a vehicle for C. difficile
vaccination demonstrated a number of important findings that
will be invaluable to the design of an effective C. difficile vac-
cine: first, that only toxin A antibodies are required for pro-
tection, second, that mucosal immunity is very important, and,
finally, that vaccination provides protection against relapse.
We discuss each of these in turn.
(i) Toxin A antibodies and protection. Expression of the
toxin A (A26-39) and toxin B (B15-24) C-terminal domains on
B. subtilis spores was shown to generate high titers of specific
IgG and sIgA antibodies. Using spores (PP108) displaying only
the toxin A domain, A26-39, serum and fecal antibodies were
FIG. 4. Protection in Golden Syrian hamsters. Hamsters were
given four o.g. doses (days 0, 14, 35, and 57) of recombinant spores
(PP108 or PP142) and then challenged with C. difficile 630 (A!B!).
Control groups included naïve animals, a group dosed with nonrecom-
binant PY79 spores, and, finally, a group receiving a mixture of the
rA26-39 and rB14-24 proteins (10 %g each). Further groups were
hamsters dosed parenterally (i.p.) with rA26-39 plus rB14-24 (10 %g
each). Colonization of hamsters is presented as time from inoculation
to signs of first symptoms, when animals were killed. Animals showing
no symptoms after 14 days were considered protected (i.e., the PP108
group). For animals showing signs of infection, the mean times (*stan-
dard deviations) to visible symptoms were, for naïve hamsters, 40.9 h
(*1.7 h), for PY79 hamsters, 53.2 h (*2.3 h), for PP108 hamsters,
55.6 h (*1.7 h), for PP142 hamsters, 50.9 h (*0.9 h), and for hamsters
dosed o.g. with the protein mixture and for hamsters in the i.p. group,
51.8 h (*2.4 h) and 48.6 h (* 2.3), respectively.
FIG. 5. Protection against reinfection. Hamsters immunized orally
with PP108 spores or parenterally with recombinant proteins that had
survived challenge with C. difficile 630 (as shown in Fig. 4) were then
rechallenged with C. difficile 630 spores 16 days after the end of the
first challenge. Kaplan-Meier survival estimates are shown. Results are
also shown for control groups of naïve hamsters and animals dosed
with nonrecombinant PY79 spores (dosed on days 0, 14, 35, and 57).
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found to be cross-reactive to B15-24. Moreover, they neutral-
ized both toxin A and toxin B in vitro, and hamsters immunized
with A26-39 were protected against C. difficile disease. Further
evidence of the cross-reactivity of toxin A antibodies came
from Western blotting, which showed that anti-A26-39 anti-
bodies could recognize B15-24. The repeat domains of both
toxins share limited sequence identity, which could explain this
cross-reactivity. In particular, the sequences YFAPANT, MQ
IGVF, AAT, and YYF are conserved between the toxin A and
B repeat used here, and together they may contain epitopes
responsible for the observed cross-reactivity.
We infer that antibodies to A26-39 are of higher avidity than
those to B15-24, since in mice, ELISA antibody titers to
A26-39 and B15-24 were equivalent. PP142 spores present
both toxin A and toxin B antigens, so why do these spores not
provide protection against disease after administration? Al-
though B15-24-neutralizing antibodies were produced, no neu-
tralizing antibodies to A26-39 were detected. This implies that,
for protection, antibodies to toxin A are of greater importance
than those to toxin B. PP142 spores do express the A26-39
domain, yet no neutralization of toxin A was observed. To
account for this, we predict that insufficient A26-29 was ex-
pressed, since PP142 spores carried nine times less A26-39
than PP108 spores. Of course, we cannot completely rule out
the potential contribution of anti-B15-24 antibodies in protec-
tion; rather, our work shows that anti-A26-39 responses are
sufficient. It is possible that our prototype vaccines simply do
not elicit sufficiently high toxin B-neutralizing titers, possibly
due to B15-24 being displayed in a partially denatured form
that impairs the generation of appropriate neutralizing anti-
bodies. This may reflect the action of its fusion partner, the
spore coat protein CotB, although this has been used success-
fully previously (8, 13). Full protection to challenge using
PP108 spores might be achieved either by changing the dosing
regimen or by increasing the dose of heterologous protein
expression (whether of A26-39 and/or of B15-24).
This work agrees with a number of studies linking protection
against C. difficile infection with toxin A, for example, a passive
immunization study using oral delivery of anti-toxin A antibod-
ies (21) and studies showing that there is strong association
between serum antibody responses to toxin A and protection
against C. difficile in humans (1, 22, 24). Of particular note is
the study of Kim et al. (20), where hamsters immunized (sub-
cutaneously) with C. difficile toxoid A were fully (100%) pro-
tected but hamsters immunized with toxoid B demonstrated no
protection. Our work does show, however, that a vaccine ex-
pressing only A26-39 should be protective to all known natu-
rally virulent strains of C. difficile (A!B! and A"B!). How-
ever, a challenge experiment using an A"B! strain is required
for confirmation; this finding is important for the design of
future C. difficile vaccines.
(ii) Mucosal immunity. Considerable effort has been di-
rected toward parenteral vaccines to C. difficile and the gener-
ation of systemic responses. However, far less attention has
been spent on examining the role of local immunity, despite a
number of reports demonstrating the importance of sIgA.
First, a correlation between neutralizing sIgA and protection
in hamsters has been reported using mucosal delivery of tox-
oids, with 100% protection by intranasal delivery and 40%
protection by o.g. delivery (39). Second, and most importantly,
several studies demonstrate unequivocally that sIgA both is
capable of neutralizing toxin A and is superior to IgG and
monomeric serum, IgA (19, 35).
Oral delivery of A26-39 using PP108 spores promoted high
titers of fecal sIgA, with levels of toxin A- and toxin B (cross-
reacting)-neutralizing sIgA correlating with protection. In con-
trast, i.p. delivery of both the rA26-39 and rB15-24 proteins
produced high titers of serum-neutralizing IgG to toxin A and
toxin B, no localized immune responses (sIgA), and lower
levels of protection. In another study, however, Torres et al.
(39) used parenteral delivery (including i.p.) of toxoids A and
B and demonstrated 100% protection in hamsters. A number
of factors might account for why we did not observe complete
protection when using the recombinant proteins. For example,
in the Torres et al. study, the complete toxoids were adminis-
tered together with an adjuvant and a different virulent strain
of C. difficile was used for challenge (39).
(iii) Relapse. PP108-immunized hamsters that survived C.
difficile challenge were fully protected against rechallenge, a
phenomenon particularly important for treatment of CDAD
when patients succumb to relapse. Up to 20% of patients with
CDAD 2 to 8 weeks after discontinuation of antibiotic therapy
(metronidazole or vancomycin) relapse, and a further 30% of
these patients may do so again after a second course of therapy
(4, 18). Antibiotic treatment may disrupt the normal human
microflora and lead to overgrowth of toxigenic strains of C.
difficile, a condition favoring relapse. Vaccination then may
provide the only rational treatment to control CDAD, so it is
encouraging that we found no symptoms of disease in rechal-
lenged animals. This is consistent with an earlier study that has
shown that antibodies to toxins A and B, administered orally,
can prevent relapse (21) and also with a study in which 75%
protection against relapse was found after mucosal and paren-
teral delivery of toxoids A and B (39). In our studies, protec-
tion against relapse was found only in hamsters dosed with
PP108 spores and not in animals that had been vaccinated with
the recombinant proteins by a parenteral-dosing regimen. In-
terestingly, animals dosed parenterally all failed to generate
significant sIgA responses, and it is possible that production of
mucosal antibodies is important for protection from reinfection.
Some probiotic formulations have been shown to significantly
reduce the occurrence of relapses in double-blind controlled trials
(12, 36). Potentially, live spores may share some attributes with
these “probiotic” bacteria, and it is notable that B. subtilis is itself
used extensively as a probiotic (14). B. subtilis spores can germi-
nate and resporulate in the GI tract and possibly even transiently
colonize (37). PP108 spores may therefore be able to promote a
more extensive production of anti-A26-39 sIgA, sufficient to pro-
tect against reinfection. With regard to their potential probiotic
attributes, it is noteworthy that even nonrecombinant PY79
spores, when they were administered orally to hamsters, provided
a noticeable delay in the onset of symptoms, and it is possible that
this phenomenon may reflect involvement of an innate immune
response, such as interaction with Toll-like receptors. Alterna-
tively, although the suggestion is highly speculative, we cannot
rule out the possibility of sequestration of the toxin in an animal’s
GI tract, since Bacillus spores have been shown to be able to
adsorb C. difficile toxin in vitro (15).
Finally, we have used C. difficile spores, in contrast to vege-
tative cells or toxins, as our challenge in the vaccine protection
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experiments, which, as has been shown recently, best mimics
the natural course of infection in humans (10). Our study
confirms that in the hamster model of infection, there is a
correlation between neutralizing antibodies and protection in
hamsters, with HT29 cells providing a more precise in vitro
indicator of protection.
We show that oral delivery of B. subtilis spores displaying
high levels of toxin A repeats can confer to hamsters immu-
nological protection from a lethal dose of C. difficile spores.
The basis of the vaccination strategy is induction of secretory
IgA, which shows cross-reactivity to toxin B. Such a vaccine
would be particularly attractive to the end user, as it can be
delivered orally, it is heat stable, and the vehicle is currently
used as a probiotic.
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Bacillus subtilis is a Gram-positive spore forming bacterium 
that has been extensively studied as a model for unicellular 
microbial development. Bacterial spores are of importance 
in the food industry where some species are involved in 
food-borne disease, for example, Bacillus cereus which is 
one of the most common causes of foodborne diarrhoea 
in developed countries. Bacillus spores are also being 
used extensively as probiotic food supplements where 
they are used in humans as dietary supplements and in 
feed for livestock and aquaculture as growth promoters 
and competitive exclusion agents (for reviews see Bader 
et al., 2012; Cutting, 2011; Hong et al., 2005; Leonel 
Ochoa-Solano and Olmos-Soto, 2006; Sanders et al., 2003; 
Shivaramaiah et al., 2011). In Europe B. subtilis has been 
granted QPS (qualified presumption of safety) status by 
the European Food Safety Authority (EFSA, 2008) and its 
use as a probiotic is likely to increase. How Bacillus spores 
exert their beneficial effects is less clear but most probably 
involves the induction of non-specific immune responses 
that prime the host against infection by bacterial or viral 
pathogens. Evidence showing immune stimulation in mice 
dosed orally with spores has been documented (Huang 
et al., 2008) and studies in poultry and mice have shown 
that oral dosing with spores of B. subtilis can suppress 
infection against Escherichia coli 070:K80, Salmonella 
enterica, Clostridium perfringens and Citrobacter rodentium 
(D’Arienzo et al., 2006; La Ragione and Woodward, 2003; 
La Ragione et al., 2001).
B. subtilis has long been considered a soil organism since 
this is where it can be found in abundance. However, its 
presence is mostly as the dormant spore and a compelling 
case now exists that spores can inhabit the intestinal tract 
of humans and animals (Hong et al., 2009b). In the gastro-
intestinal (GI)-tract spores have been shown to germinate in 
the intestine, proliferate and then resporulate before being 
shed in the faeces (Casula and Cutting, 2002; Tam et al., 
2006). This intestinal residency is intriguing and implies 
that spore formers could actually be gut commensals and 
thus their use as probiotic supplements could be based on 
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Spores of Bacillus subtilis including one strain used commercially were evaluated for their potential value as a 
probiotic and as potential food additives. Two isolates of B. subtilis examined here were HU58, a human isolate 
and PXN21, a strain used in an existing commercial product. Compared to a domesticated laboratory strain of B. 
subtilis both isolates carried traits that could prove advantageous in the human gastro-intestinal tract. This included 
full resistance to gastric fluids, rapid sporulation and the formation of robust biofilms. We also showed that PXN21 
spores when administered weekly to mice conferred non-specific cellular immune responses, indicative signs of 
the stimulation of innate immunity. Spores mixed in wholemeal biscuits were found to survive baking at 235 °C for 
8 minutes with only a 1-log reduction in viability. That spores can survive the baking process offers the possibility 
of using spores as probiotic supplements in a range of novel food products.
Keywords: Bacillus subtilis, spores, food supplements, probiotics
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a more scientifically rational basis. This is supported by 
studies that show that B. subtilis spores play an important 
role in the development of the gut-associated lymphoid 
tissue (GALT) in infant rabbits (Rhee et al., 2004).
From a commercial perspective a probiotic supplement that 
can be stored at room temperature in a desiccated form is 
attractive and alleviates the necessity for freeze or spray-
drying as well complicated encapsulation methods (Bader 
et al., 2012; Ding and Shah, 2009; Franks, 1998). Further, 
the resistance properties of spores raises the possibility that 
they can be incorporated in a number of food products 
(e.g. beverages, chocolate, etc.). In the USA Bacillus 
coagulans spores are being incorporated in a number of 
foods including baked cakes and muffins (Cutting, 2011).
Two strains of B. subtilis were evaluated in this study, HU58 
a human isolate (Hong et al., 2009a) and PXN21 that is 
used in a commercial product Biokult (Protexin Ltd., Lopen 
Head, UK) available in the UK. The purpose of this study 
was threefold: first, to determine by comparison with a 
known natural human isolate of B. subtilis (strain HU58) 
whether PXN21 was similar to other natural isolates of B. 
subtilis and shared traits that might favour residency in 
the GI-tract. Second, to demonstrate that PXN21 could 
stimulate innate immunity. Finally, to determine whether B. 
subtilis (strains PXN21 and HU58) could be incorporated 
into a baked foodstuff.
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PY79 and HU58 have been described previously and are 
laboratory stocks (Hong et al., 2009a; Youngman et al., 
1984). PXN21 was obtained from NCIMB Ltd. (Aberdeen, 
UK) as strain NCIMB 30223.
=6%6'/0#;6&5()2
Sporulation was made in liquid Difco sporulation medium 
(DSM) by the exhaustion method (Nicholson and Setlow, 
1990). Spore counts were determined by heating cultures 
at 65 °C for 45 min (to kill any vegetative cells) followed 
by serial dilution and plating out on DSM solid agar. Pure 
suspensions of spores were prepared by the exhaustion 
method using lysozyme treatment to remove vegetative cells 
as described (Nicholson and Setlow, 1990). Procedures for 
measurement of spore survival in simulated gastric fluid 
(SGF) were performed as described by Le Duc et al. (2003).
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Surfactin was evaluated using the oil-displacement 
method (Youssef et al., 2004). Evaluation of swarming and 
dendritic growth using CM, CMK and MSgg media have 
been described elsewhere (Fakhry et al., 2009; Hong et al., 
2009a). Adhesion to mucin was determined as described 
previously (Sanchez et al., 2010) by binding 1 mg of mucin 
(in phosphate buffered saline (PBS) at 10 mg/ml) to each 
well of a 96-well microtitre plate. Following the steps 
outlined for this assay ~109 cells were incubated per well 
for 1 h at 37 °C. Unbound cells were removed by washing 
and Triton-X-100 treatment used to detach bound bacteria 
followed by serial dilution and determination of cfu/well. 
The experiment was repeated two times.
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All experiments used Balb/c inbred mice (female, 6 weeks 
old). For analysis of persistence the procedure was that 
described previously (Barbosa et al., 2005; Tam et al., 2006). 
In brief, groups of 6 mice were each administered a single 
intra-gastric dose of 1×109 spores (0.2 ml in PBS). At time 
points thereafter fresh faecal pellets were recovered from 
individual mice and the number of heat-resistant spores 
(per g) determined by heat treatment (45 min at 65 °C) of 
homogenised faecal material followed by serial dilution 
and plating on DSM agar plates.
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For analysis of immune stimulation groups of mice (n=5) 
were each given weekly doses (intra-gastric) of 1×109 
spores for 10 weeks (10 doses). Mice were killed 24 h after 
the last dose of spores. Splenocytes were recovered from 
spleen tissue of immunised mice and 5×105 splenocytes 
were seeded per well (using 96-well plates) and stimulated 
with the following antigens: Clostridium difficile toxoid 
A (CDTA; 5 µg/well; ÄKTA purified) protein, E. coli 
lipopolysaccharide (LPS; 1 µg/well; Sigma, St. Louis, 
MO, USA), gluteraldehyde-inactivated spores of C. 
difficile (1×106 spores/well) and finally two spore coat 
proteins, CotC and CotD that are found on the coats of 
C. difficile spores (P. Permpoonpattana et al., 2011). C. 
difficile spores were inactivated by overnight incubation 
in 2% gluteraldehyde at 4 °C. After 4 days of incubation 
supernatants were analysed for IFN-γ by ELISA as described 
previously (Huang et al., 2008).
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Lyophilised spores of HU58 and PXN21 were mixed 
with 1 kg of a commercial biscuit dough using facilities 
at United Biscuits (High Wycombe, UK) to give a final 
bacterial count of ~1×109 spores/g of mix. The dough 
mixture consisted of flour (58.6%), fat (18%), sugars (13.6%), 
salt (0.7%), sodium bicarbonate (1.1%), malic acid (0.4%), 
ammonium bicarbonate (0.2%) and water (7.4%). The dough 
was mixed using a Hobart planetary mixer (Troy, OH, USA) 
in two stages. Dough was covered and allowed to rest for 
25 minutes before being formed into 19 g dough pieces 
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using a bench scale rotary moulder. Dough pieces were 
baked on a 5×5 oven band at 235 °C in a static deck oven 
for 8 minutes and then stored in heat-sealed foil bags until 
analysis. The initial dough mixture had a moisture content 
of 14% which, after baking, was reduced to 2%. For analysis 
individual biscuits were homogenised in sterile PBS buffer, 
serially diluted and plated for cfu count on DSM agar plates. 
Three independent counts were made per time point.
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Sporulation of PXN21 and HU58 was made in parallel with a 
domesticated laboratory strain known as PY79 (Youngman 
et al., 1984). Using the exhaustion method we induced 
sporulation of all three strains and examined heat-resistant 
(spore) counts. As shown in Figure 1 PXN21 most closely 
resembled HU58 in its kinetics of spore formation with 
the first detectable levels of heat resistant spores appearing 
2-3 h post-induction and maximal counts at 8 h. By contrast 
PY79 reached maximal levels of sporulation 24 h after the 
initiation of development while the first detectable heat-
resistant spores were found after 5-6 h. The fast and slow 
sporulation characteristics of HU58 and PY79 have been 
determined previously (Tam et al., 2006) and are repeated 
here. Compared to PY79 it is clear that PXN21 and HU58 
are fast sporulators and most closely resemble other natural 
isolates of B. subtilis (Hong et al., 2009a). Although the 
mechanism for how this occurs is unclear, rapid sporulation 
is a characteristic of many natural isolates of B. subtilis and 
may reflect the necessity to adapt rapidly to movement 
through the GI-tract (Hong et al., 2009a; Tam et al., 2006).
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Many B. subtilis strains are known to form structured 
multicellular biofilms in the form of pellicle-like surface 
colonies on semi-solid media where different phases of 
colonisation can be observed (Branda et al., 2001; Hong 
et al., 2009a). Biofilm formation may enable bacteria to 
persist longer in the GI-tract and is a feature thought to be 
required for residency (Tam et al., 2006). In the first phase, 
cells spread, or swarm, over the agar surface as dendritic 
branching colonies (e.g. using growth on CM agarose). 
If sufficient potassium ions are present, the cells enter a 
second rapid and profuse growth phase in which the colony 
can spread over the entire surface as a pellicle-like film (e.g. 
using CMK agarose). Dendritic growth, i.e. the first phase 
of colonisation, is generally considered an indication of the 
ability of bacteria to form surface biofilms.
Using growth on MSgg medium (Fakhry et al., 2009) we 
found that both HU58 and PXN21 were able to form robust 
biofilms (Figure 2). We also examined PXN21, HU58 and 
PY79 on CM and CMK media (Table 1 and Appendix A) 
and found that on CM agar only HU58 was able to form 
swarming (dendritic) colonies. On CMK agarose both HU58 
and PXN21, but not PY79, produced a profuse surface 
colony formation. This rapid surface motility has been 
explained earlier by a lubricating model where growth is 
partly due to the secretion of biosurfactants (Kinsinger et 
al., 2003). Surprisingly, for PXN21, in contrast to PY79, 
we were unable to detect any significant level of surfactin 
(a well characterised Bacillus biosurfactant; Nagal et al., 
1996) using a simple oil-displacement method (Youssef et 
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al., 2004). This does not exclude the possibility that PXN21 
does not produce surfactin, but if it does, it must be at levels 
that we cannot detect.
We also examined the ability of all three strains to adhere 
to mucin, a feature which may be beneficial to intestinal 
bacteria enabling them to obtain nutrients and more 
efficiently colonise the mucosal epithelial layers (Fakhry 
et al., 2009; Ruas-Madiedo et al., 2008; Sanchez et al., 2010). 
Bacillus species have been shown to adhere and degrade 
mucin and presumably do so by the action of a number 
of hydrolytic enzymes such as glycosidases, proteases, 
peptidases and sulfatases, all of which are required for the 
complete breakdown of mucin (Macfarlane et al., 2005). 
Our analysis (Table 1) revealed that all three strains could 
adhere to mucin. Using strains of Bacillus firmus (GB1) 
and Bacillus indicus (HU36) previously characterised using 
the mucin-adhesion assay (Manzo et al., 2011) we obtained 
similar binding efficiencies which in turn demonstrated that 
adhesion of HU58 and PXN21 was significantly higher by 
one (HU58) to two (PXN21)-logs, respectively, than PY79, 
GB1 or HU36.
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B. subtilis spores have been shown to be resistant to 
intestinal fluids, specifically gastric and bile salts (Barbosa 
et al., 2005; Le Duc et al., 2003). Passage through the 
stomach dictates that the spore must survive intact if it is 
to have any effect on immune stimulation or gut health. 
We evaluated the resistance of spores (PXN21, HU58 
and PY79) in SGF at pH 2, pH 3 and pH 4. As shown in 
Table 2 spores exhibited almost no loss in viability after 
1 h of incubation. By contrast vegetative cells were labile 
at pH 2 showing a 4-5 log reduction in cfu count after 1 
h incubation. Interestingly, we found that at pH 4, most 
closely resembling the gastric pH after a full meal, vegetative 
cells of all three strains showed no sensitivity to SGF and 
total cfu count was unaffected. This implies that if live B. 
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subtilis vegetative cells are consumed after a full meal, the 
majority of bacilli should pass through the gastric barrier 
unscathed.
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The passage of spores through the murine GI-tract can 
provide a useful insight into the intestinal residency of 
B. subtilis. Studies have shown that following a single 
inoculum of B. subtilis spores the first detectable counts 
of spores in the faeces are found after 3 h. This indicates 
that the minimum time taken to transit the murine gut is 
3 h (Hoa et al., 2001). Despite this, following a single large 
inoculum (~109 spore cfu) spores are still being shed from 
the gut 7-21 days post-dosing (Barbosa et al., 2005; Tam 
et al., 2006). This suggests that spores must be residing in 
the GI-tract either by adhering to the gut mucosa or by 
germinating and establishing biofilms. Interestingly, B. 
subtilis shows low levels of adhesion to intestinal cells and 
it is probable that the formation of biofilms may play an 
important role in maintaining gut residency (Hong et al., 
2009a). Molecular studies have shown that spores, orally 
administered to mice can germinate, proliferate and then 
re-sporulate as they pass through the GI-tract (Casula 
and Cutting, 2002; Tam et al., 2006). In poultry evidence 
for mass germination of spores has also been observed 
(Cartman et al., 2008). This implies that spores adapt to 
entry into the GI-tract and, by germinating, outgrowing and 
establishing themselves in the gut are able to reside, albeit 
transiently. Spore counts are eventually reduced suggesting 
that a natural process of competition with other members 
of the microflora maintains a stable population of bacilli 
in the gut. In humans, the resident population of Bacilli is 
approximately 104 spores/g of faeces (Hong et al., 2009b). 
One interesting observation that has been made is that the 
transit period for B. subtilis varies considerably between 
different strains. For example, with PY79, a laboratory 
strain, following a dose of 108 spores no significant counts 
are detected after 7 days, while for natural isolates such 
as HU58 counts are still detectable 18-21 days post-
dosing. This extended transit time may reflect inherent 
characteristics of natural strains of B. subtilis enabling 
them to maintain a gut residency, for example, the ability 
to adhere and/or to establish robust biofilms. We therefore 
evaluated PXN21, HU58 and PY79 in parallel experiments 
using groups of inbred mice (Figure 3). Following a single 
oral dose of 1×109 spores PXN21 was found to exhibit a 
profile of shedding similar to HU58 with spores still present 
in the faeces 18 days post-dosing. By contrast, PY79 spores 
were cleared after just 7 days. We interpret this as evidence 
that PXN21, like HU58, is better adapted to gut residency 
than laboratory strains and this correlates with the ability 
of both strains to produce biofilms.
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A principal mechanism for how probiotic bacteria might 
produce a beneficial effect is immune stimulation. This 
would be the innate immune system (which is not a 
memorised response) and, although short-lived, repeated 
dosing with probiotic bacteria could stimulate the 
immune system enabling protective immune responses. 
This assumption is supported by studies which show that 
innate immunity can provide protection against a number 
of important pathogens (Korbel et al., 2008; Trinchieri and 
Sher, 2007). Strikingly, evidence is now emerging that innate 
immunity can carry some memory perhaps as long as six 
months (Gillard et al., 2011). The ingestion of probiotic 
bacteria could lead to their interaction with certain types 
of immune cells such as macrophages and dendritic cells 
lying in the lymphoid tissues of the GALT. Phagocytosis 
then leads, in turn, to a number of signals that sensitise 
the immune system, for example, cytokine secretion (e.g. 
IFN-γ), activation of the complement cascade and certain 
lymphocytes such as natural killer (NK) cells. Innate 
immunity also serves to prime the adaptive (memorised) 
immune response. Bacterial spores of PY79 and HU58 
have been shown to stimulate the expression of Toll-like 
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receptors TLR2 and TLR4 and this is a key step in signalling 
the innate immune response (Huang et al., 2008; Trinchieri 
and Sher, 2007). We next set out to establish whether PY79 
and PXN21 spores, delivered orally, could stimulate non-
specific innate immune responses using a dosing regimen 
that would resemble that of probiotic usage in humans. 
HU58 was not examined here since its ability to stimulate 
innate immunity has been described previously (Huang et 
al., 2008). Groups of inbred mice were dosed orally with 
1×109 spores of PY79 or PXN21 every 7 days for 10 weeks. 
At the end of the dosing regimen splenocytes were cultured 
and stimulated with a variety of exogenous antigens: E. coli 
LPS, CDTA of C. difficile (Dove et al., 1990), gluteraldehyde-
inactivated C. difficile 630 spores, as well as two C. difficile 
spore coat proteins, CotC and CotD. Measurement of IFN-γ 
in stimulated splenocytes showed clear differences between 
PY79 and PXN21 spores (Figure 4). IFN-γ was abundantly 
produced in splenocytes from PXN21-immunised mice 
showing that PXN21 must sensitise spleen cells such 
that stimulation with an exogenous antigen leads to 
production of IFN-γ, the primary cytokine involved in 
macrophage activation and mediating the host’s defences 
to bacterial and viral pathogens. By contrast, splenocytes 
from PY79-dosed mice produced little to no detectable 
levels of IFN-γ when stimulated with CDTA or LPS and 
a low level of IFN-γ (approximately 10-times less than in 
PXN21 dosed mice) when stimulated with inactivated C. 
difficile spores. These results demonstrate the ability of 
PXN21 spores to stimulate non-specific (innate) immunity 
and the differences in magnitude between mice dosed 
with a domesticated strain of B. subtilis and PXN21 are 
both intriguing and unexpected. The low levels of IFN-γ 
produced by splenocytes from PY79-dosed mice, when 
stimulated with C. difficile spores, may reflect shared 
antigens between spores of B. subtilis and C. difficile spores 
and thus could imply an adaptive immune response. This 
study suggests that non-specific immune responses induced 
by B. subtilis should be assessed on a strain-by-strain basis 
and any conclusions regarding immune modulation cannot 
be considered universally to apply to all members of the 
taxonomic group.
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Bacterial spores typically are resistant to maximum 
temperatures of 60-85 °C. Prolonged exposure to 
temperatures above these limits results in loss in viability 
although this is not immediate and for a population of 
spores there is steady decline in viability. Spores of 
B. coagulans are being incorporated commercially in 
baked foods, e.g. cakes and muffins (Cutting, 2011) and 
presumably the temperatures used in baking do not 
inactivate spores. We designed an experiment to assess 
whether B. subtilis spores could survive the temperatures 
used in baking biscuits. Our analysis revealed that baking 
at 235 °C for 8 min reduced the count of live spores by just 
over 1 log (Figure 5). After this, counts remained stable for 
a period of three months demonstrating that live spores of 
B. subtilis can be incorporated into baked foods. The initial 
reduction in spore counts is most likely due to those spores 
that are present on the surface layers of the biscuit where 
temperatures were highest or alternatively some spores 
may have germinated during the initial preparation of the 
biscuit dough. The biscuit mix is presumably able to shield 
spores from the extremes of temperature. Untreated biscuits 
were found to contain a basal level of heat resistant spores 
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(~102/g). We conducted preliminary characterisation of 
these bacteria and found all to contain spores, they grew 
aerobically and were not strains of B. cereus, a Bacillus 
species commonly found in wheat-based products. Since 
the biscuit mix was not sterilised we assume this basal level 
of spores originates from one or more of the ingredients 
(e.g. wholemeal flour).
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This work shows that bacterial spores can be incorporated 
into baked food products and can survive baking for 8 
minutes at 235 °C with no more than a 1-log reduction 
in viability. This demonstrates that Bacillus spores can 
have applications as probiotic additives into a number 
of food products (e.g. chocolate, cakes, etc.) that could 
not be considered for the more common lactobacilli and 
bifidobacteria probiotics. We have also demonstrated that 
PXN21, a B. subtilis strain found in a commercial product 
carries a number of attributes common in human isolates of 
B. subtilis that support its use as a probiotic. This includes 
prolonged persistence in the GI-tract, the formation of 
robust biofilms, rapid sporulation and the stimulation of 
innate immune responses. B. subtilis currently carries QPS 
status in Europe and there is likely to be increased interest 
in using this heat-stable bacterium as a food ingredient.
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